<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Votubia-II-61 EN PI clean</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:BISansCond;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;}
@font-face
	{font-family:"Bahnschrift Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Bahnschrift;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight SemiConde";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold SemiConden";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Candara Light";
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"Corbel Light";
	panose-1:2 11 3 3 2 2 4 2 2 4;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;}
@font-face
	{font-family:"Ink Free";
	panose-1:3 8 4 2 0 5 0 0 0 0;}
@font-face
	{font-family:"Javanese Text";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Leelawadee UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Leelawadee UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;}
@font-face
	{font-family:"\@Malgun Gothic";}
@font-face
	{font-family:"Malgun Gothic Semilight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Malgun Gothic Semilight";}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei";}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";}
@font-face
	{font-family:"Microsoft JhengHei Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei Light";}
@font-face
	{font-family:"Microsoft JhengHei UI Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI Light";}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei";}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei UI";}
@font-face
	{font-family:"Microsoft YaHei Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei Light";}
@font-face
	{font-family:"Microsoft YaHei UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei UI Light";}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS UI Gothic";}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;}
@font-face
	{font-family:"Myanmar Text";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:3 11 5 4 2 0 0 0 0 3;}
@font-face
	{font-family:"Segoe UI Black";
	panose-1:2 11 10 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Historic";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;}
@font-face
	{font-family:"\@NSimSun";}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;}
@font-face
	{font-family:"\@SimSun-ExtB";}
@font-face
	{font-family:"Sitka Small";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Text";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Subheading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Heading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Display";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Banner";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Yu Gothic UI";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI";}
@font-face
	{font-family:"Yu Gothic UI Semibold";
	panose-1:2 11 7 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semibold";}
@font-face
	{font-family:"Yu Gothic Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Light";}
@font-face
	{font-family:"Yu Gothic UI Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Light";}
@font-face
	{font-family:"Yu Gothic Medium";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Medium";}
@font-face
	{font-family:"Yu Gothic UI Semilight";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semilight";}
@font-face
	{font-family:"HoloLens MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;}
@font-face
	{font-family:Dubai;
	panose-1:2 11 5 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Light";
	panose-1:2 11 3 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Medium";
	panose-1:2 11 6 3 3 4 3 3 2 4;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;}
@font-face
	{font-family:AngsanaUPC;}
@font-face
	{font-family:CordiaUPC;}
@font-face
	{font-family:Abadi;}
@font-face
	{font-family:"Abadi Extra Light";}
@font-face
	{font-family:Aharoni;}
@font-face
	{font-family:Aldhabi;}
@font-face
	{font-family:Aparajita;}
@font-face
	{font-family:"Arabic Typesetting";}
@font-face
	{font-family:"Arial Nova";}
@font-face
	{font-family:"Arial Nova Cond";}
@font-face
	{font-family:"Arial Nova Cond Light";}
@font-face
	{font-family:"Arial Nova Light";}
@font-face
	{font-family:"Avenir Next LT Pro";}
@font-face
	{font-family:"Avenir Next LT Pro Light";}
@font-face
	{font-family:BatangChe;}
@font-face
	{font-family:Bembo;}
@font-face
	{font-family:Biome;}
@font-face
	{font-family:"Biome Light";}
@font-face
	{font-family:"Browallia New";}
@font-face
	{font-family:BrowalliaUPC;}
@font-face
	{font-family:Cavolini;}
@font-face
	{font-family:Dante;}
@font-face
	{font-family:DaunPenh;}
@font-face
	{font-family:David;}
@font-face
	{font-family:Daytona;}
@font-face
	{font-family:"Daytona Condensed";}
@font-face
	{font-family:"Daytona Condensed Light";}
@font-face
	{font-family:"Daytona Light";}
@font-face
	{font-family:"DengXian Light";}
@font-face
	{font-family:DilleniaUPC;}
@font-face
	{font-family:DokChampa;}
@font-face
	{font-family:DotumChe;}
@font-face
	{font-family:"Elephant Pro";}
@font-face
	{font-family:EucrosiaUPC;}
@font-face
	{font-family:Euphemia;}
@font-face
	{font-family:FangSong;}
@font-face
	{font-family:FrankRuehl;}
@font-face
	{font-family:FreesiaUPC;}
@font-face
	{font-family:"Georgia Pro";}
@font-face
	{font-family:"Georgia Pro Black";}
@font-face
	{font-family:"Georgia Pro Cond";}
@font-face
	{font-family:"Georgia Pro Cond Black";}
@font-face
	{font-family:"Georgia Pro Cond Light";}
@font-face
	{font-family:"Georgia Pro Cond Semibold";}
@font-face
	{font-family:"Georgia Pro Light";}
@font-face
	{font-family:"Georgia Pro Semibold";}
@font-face
	{font-family:"Gill Sans Nova";}
@font-face
	{font-family:"Gill Sans Nova Cond";}
@font-face
	{font-family:"Gill Sans Nova Cond Lt";}
@font-face
	{font-family:"Gill Sans Nova Cond Ultra Bold";}
@font-face
	{font-family:"Gill Sans Nova Cond XBd";}
@font-face
	{font-family:"Gill Sans Nova Light";}
@font-face
	{font-family:"Gill Sans Nova Ultra Bold";}
@font-face
	{font-family:Gisha;}
@font-face
	{font-family:Grotesque;}
@font-face
	{font-family:"Grotesque Light";}
@font-face
	{font-family:GulimChe;}
@font-face
	{font-family:Gungsuh;}
@font-face
	{font-family:GungsuhChe;}
@font-face
	{font-family:"Hadassah Friedlaender";}
@font-face
	{font-family:HGGothicE;}
@font-face
	{font-family:HGMaruGothicMPRO;}
@font-face
	{font-family:HGMinchoE;}
@font-face
	{font-family:HGPGothicE;}
@font-face
	{font-family:HGPMinchoE;}
@font-face
	{font-family:HGPSoeiKakugothicUB;}
@font-face
	{font-family:HGSGothicE;}
@font-face
	{font-family:HGSMinchoE;}
@font-face
	{font-family:HGSoeiKakugothicUB;}
@font-face
	{font-family:HGSSoeiKakugothicUB;}
@font-face
	{font-family:IrisUPC;}
@font-face
	{font-family:"Iskoola Pota";}
@font-face
	{font-family:JasmineUPC;}
@font-face
	{font-family:KaiTi;}
@font-face
	{font-family:Kalinga;}
@font-face
	{font-family:Kartika;}
@font-face
	{font-family:"Khmer UI";}
@font-face
	{font-family:Kigelia;}
@font-face
	{font-family:"Kigelia Arabic";}
@font-face
	{font-family:"Kigelia Arabic Light";}
@font-face
	{font-family:"Kigelia Light";}
@font-face
	{font-family:KodchiangUPC;}
@font-face
	{font-family:Kokila;}
@font-face
	{font-family:"Lao UI";}
@font-face
	{font-family:Leelawadee;}
@font-face
	{font-family:"Levenim MT";}
@font-face
	{font-family:LilyUPC;}
@font-face
	{font-family:"Mangal Pro";}
@font-face
	{font-family:Meiryo;}
@font-face
	{font-family:"Meiryo UI";}
@font-face
	{font-family:"Microsoft GothicNeo";}
@font-face
	{font-family:"Microsoft GothicNeo Light";}
@font-face
	{font-family:"Microsoft Uighur";}
@font-face
	{font-family:MingLiU_HKSCS;}
@font-face
	{font-family:Miriam;}
@font-face
	{font-family:"Miriam Fixed";}
@font-face
	{font-family:"Modern Love";}
@font-face
	{font-family:"Modern Love Caps";}
@font-face
	{font-family:"Modern Love Grunge";}
@font-face
	{font-family:MoolBoran;}
@font-face
	{font-family:"MS PMincho";}
@font-face
	{font-family:"MT Extra";}
@font-face
	{font-family:Narkisim;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";}
@font-face
	{font-family:"News Gothic MT";}
@font-face
	{font-family:Nyala;}
@font-face
	{font-family:OCRB;}
@font-face
	{font-family:"Plantagenet Cherokee";}
@font-face
	{font-family:Posterama;}
@font-face
	{font-family:"Quire Sans";}
@font-face
	{font-family:"Quire Sans Light";}
@font-face
	{font-family:"Quire Sans Pro Light";}
@font-face
	{font-family:"Rockwell Light";}
@font-face
	{font-family:"Rockwell Nova";}
@font-face
	{font-family:"Rockwell Nova Cond";}
@font-face
	{font-family:"Rockwell Nova Cond Light";}
@font-face
	{font-family:"Rockwell Nova Extra Bold";}
@font-face
	{font-family:"Rockwell Nova Light";}
@font-face
	{font-family:Rod;}
@font-face
	{font-family:"Sabon Next LT";}
@font-face
	{font-family:"Sagona Book";}
@font-face
	{font-family:"Sagona ExtraLight";}
@font-face
	{font-family:"Sakkal Majalla";}
@font-face
	{font-family:"Sanskrit Text";}
@font-face
	{font-family:Selawik;}
@font-face
	{font-family:"Selawik Light";}
@font-face
	{font-family:"Selawik Semibold";}
@font-face
	{font-family:"Shonar Bangla";}
@font-face
	{font-family:"Simplified Arabic";}
@font-face
	{font-family:"Simplified Arabic Fixed";}
@font-face
	{font-family:"Sitka Banner Semibold";}
@font-face
	{font-family:"Sitka Display Semibold";}
@font-face
	{font-family:"Sitka Heading Semibold";}
@font-face
	{font-family:"Sitka Small Semibold";}
@font-face
	{font-family:"Sitka Subheading Semibold";}
@font-face
	{font-family:"Sitka Text Semibold";}
@font-face
	{font-family:"Source Sans Pro";}
@font-face
	{font-family:"Source Sans Pro Black";}
@font-face
	{font-family:"Source Sans Pro ExtraLight";}
@font-face
	{font-family:"Source Sans Pro Light";}
@font-face
	{font-family:"Source Sans Pro SemiBold";}
@font-face
	{font-family:"Speak Pro";}
@font-face
	{font-family:"Speak Pro Light";}
@font-face
	{font-family:STCaiyun;}
@font-face
	{font-family:STFangsong;}
@font-face
	{font-family:STHupo;}
@font-face
	{font-family:STKaiti;}
@font-face
	{font-family:STXihei;}
@font-face
	{font-family:STXingkai;}
@font-face
	{font-family:STXinwei;}
@font-face
	{font-family:STZhongsong;}
@font-face
	{font-family:"TH SarabunPSK";}
@font-face
	{font-family:"The Hand";}
@font-face
	{font-family:"The Hand Black";}
@font-face
	{font-family:"The Hand Extrablack";}
@font-face
	{font-family:"The Hand Light";}
@font-face
	{font-family:"The Serif Hand";}
@font-face
	{font-family:"The Serif Hand Black";}
@font-face
	{font-family:"The Serif Hand Extrablack";}
@font-face
	{font-family:"The Serif Hand Light";}
@font-face
	{font-family:"Tisa Offc Serif Pro";}
@font-face
	{font-family:"Tisa Offc Serif Pro Thin";}
@font-face
	{font-family:"Trade Gothic Next";}
@font-face
	{font-family:"Trade Gothic Next Cond";}
@font-face
	{font-family:"Trade Gothic Next Cond Hv";}
@font-face
	{font-family:"Trade Gothic Next Heavy";}
@font-face
	{font-family:"Trade Gothic Next Light";}
@font-face
	{font-family:"Traditional Arabic";}
@font-face
	{font-family:"UD Digi Kyokasho N-B";}
@font-face
	{font-family:"UD Digi Kyokasho N-R";}
@font-face
	{font-family:"UD Digi Kyokasho NK-B";}
@font-face
	{font-family:"UD Digi Kyokasho NK-R";}
@font-face
	{font-family:"UD Digi Kyokasho NP-B";}
@font-face
	{font-family:"UD Digi Kyokasho NP-R";}
@font-face
	{font-family:Univers;}
@font-face
	{font-family:"Univers Condensed";}
@font-face
	{font-family:"Univers Condensed Light";}
@font-face
	{font-family:"Univers Light";}
@font-face
	{font-family:"Urdu Typesetting";}
@font-face
	{font-family:Utsaah;}
@font-face
	{font-family:Vani;}
@font-face
	{font-family:"Verdana Pro";}
@font-face
	{font-family:"Verdana Pro Black";}
@font-face
	{font-family:"Verdana Pro Cond";}
@font-face
	{font-family:"Verdana Pro Cond Black";}
@font-face
	{font-family:"Verdana Pro Cond Light";}
@font-face
	{font-family:"Verdana Pro Cond SemiBold";}
@font-face
	{font-family:"Verdana Pro Light";}
@font-face
	{font-family:"Verdana Pro SemiBold";}
@font-face
	{font-family:Vijaya;}
@font-face
	{font-family:"Walbaum Display";}
@font-face
	{font-family:"Walbaum Display Heavy";}
@font-face
	{font-family:"Walbaum Display Light";}
@font-face
	{font-family:"Walbaum Display SemiBold";}
@font-face
	{font-family:"Walbaum Heading";}
@font-face
	{font-family:"Walbaum Text";}
@font-face
	{font-family:"Yu Mincho";}
@font-face
	{font-family:"Yu Mincho Demibold";}
@font-face
	{font-family:"Yu Mincho Light";}
@font-face
	{font-family:"TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:2 2 8 3 7 5 5 2 3 4;}
@font-face
	{font-family:PraxisCom-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EUAlbertina;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"\@TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@Batang";
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@BatangChe";}
@font-face
	{font-family:"\@Gungsuh";}
@font-face
	{font-family:"\@GungsuhChe";}
@font-face
	{font-family:"\@DengXian Light";}
@font-face
	{font-family:"\@Gulim";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@GulimChe";}
@font-face
	{font-family:"\@Dotum";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@DotumChe";}
@font-face
	{font-family:"\@Meiryo";}
@font-face
	{font-family:"\@Meiryo UI";}
@font-face
	{font-family:"\@MingLiU";
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:"\@PMingLiU";
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"\@MingLiU_HKSCS";}
@font-face
	{font-family:"\@MS PMincho";}
@font-face
	{font-family:"\@STXingkai";}
@font-face
	{font-family:"\@STZhongsong";}
@font-face
	{font-family:"\@Yu Mincho";}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Times-Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:CourierNewPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"SAS Monospace";}
@font-face
	{font-family:"Bookshelf Symbol 3";}
@font-face
	{font-family:Goudy;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Garamond-Italic;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:DIN-Bold;}
@font-face
	{font-family:"CG Times \(W1\)";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"HelveticaNeue Condensed";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@HGMaruGothicMPRO";}
@font-face
	{font-family:CourierStd;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EFPPNA+TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@TimesNewRoman";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRomanPSMT\,Times New Rom";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,Times New Roman";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"CG Times";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Minion;}
@font-face
	{font-family:CourierNew;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Noto Sans Symbols";}
@font-face
	{font-family:LZLLQG+TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPS;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:HelveticaNeueLTStd-Cn;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@HelveticaNeueLTStd-Cn";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Wingdings-Regular";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Geneva;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,BoldItalic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:ArialMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:ZapfDingbats;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\(Utiliser une police de caractè";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:+mn-ea;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:inherit;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:DIN-Black;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:17.85pt;
	text-indent:-17.85pt;
	line-height:13.0pt;
	font-size:13.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
h2
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Helvetica",sans-serif;
	font-weight:bold;
	font-style:italic;}
h3
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h4
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h5
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;}
h6
	{margin:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-align:justify;
	text-indent:-28.35pt;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-name:"Comment Text\,Annotationtext\,Comment Text Char Char Char\,Comment Text Char1\,Comment Text Char1 Char";
	mso-style-link:"Comment Text Char\,Annotationtext Char\,Comment Text Char Char Char Char\,Comment Text Char1 Char1\,Comment Text Char1 Char Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	font-size:10.0pt;
	font-family:"Helvetica",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	font-size:8.0pt;
	font-family:"Helvetica",sans-serif;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	line-height:13.0pt;
	font-size:16.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-align:justify;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoDate, li.MsoDate, div.MsoDate
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	text-autospace:none;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;
	font-weight:bold;
	text-decoration:underline;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{margin:0in;
	text-align:justify;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-align:justify;
	line-height:13.0pt;
	text-autospace:none;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;
	font-weight:bold;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:31.65pt;
	text-align:justify;
	line-height:13.0pt;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	line-height:13.0pt;
	background:navy;
	font-size:11.0pt;
	font-family:"Tahoma",sans-serif;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.AHeader1, li.AHeader1, div.AHeader1
	{mso-style-name:"AHeader 1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.2pt;
	text-indent:-14.2pt;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader2, li.AHeader2, div.AHeader2
	{mso-style-name:"AHeader 2";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:35.45pt;
	text-indent:-21.25pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader3, li.AHeader3, div.AHeader3
	{mso-style-name:"AHeader 3";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:63.8pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader2abc, li.AHeader2abc, div.AHeader2abc
	{mso-style-name:"AHeader 2 abc";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:63.8pt;
	text-align:justify;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.AHeader3abc, li.AHeader3abc, div.AHeader3abc
	{mso-style-name:"AHeader 3 abc";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:85.05pt;
	text-align:justify;
	text-indent:-21.25pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.Text, li.Text, div.Text
	{mso-style-name:"Text\,Graphic";
	mso-style-link:"Text Char3";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.TextChar3
	{mso-style-name:"Text Char3";
	mso-style-link:"Text\,Graphic";
	font-family:"MS Mincho";}
span.TextChar
	{mso-style-name:"Text Char";
	font-family:"MS Mincho";}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.Style, li.Style, div.Style
	{mso-style-name:Style;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:12.0pt;
	font-size:10.0pt;
	font-family:"Verdana",sans-serif;}
p.knZulassung01, li.knZulassung01, div.knZulassung01
	{mso-style-name:knZulassung01;
	margin-top:0in;
	margin-right:14.2pt;
	margin-bottom:0in;
	margin-left:92.15pt;
	text-indent:-92.15pt;
	text-autospace:none;
	font-size:12.0pt;
	font-family:Courier;}
p.Tegn, li.Tegn, div.Tegn
	{mso-style-name:Tegn;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:12.0pt;
	font-size:10.0pt;
	font-family:"Verdana",sans-serif;}
p.CharCharCharCharCharCharCharCharChar, li.CharCharCharCharCharCharCharCharChar, div.CharCharCharCharCharCharCharCharChar
	{mso-style-name:"Char Char Char Char Char Char Char Char Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:12.0pt;
	font-size:10.0pt;
	font-family:"Verdana",sans-serif;}
p.Nottoc-headings, li.Nottoc-headings, div.Nottoc-headings
	{mso-style-name:"Not toc-headings";
	mso-style-link:"Not toc-headings Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:85.05pt;
	text-indent:-85.05pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.Nottoc-headingsChar
	{mso-style-name:"Not toc-headings Char";
	mso-style-link:"Not toc-headings";
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.TableChar
	{mso-style-name:"Table Char\,10 pt  Bold Char\,10 pt Char\,9 Char\,9 pt Char\,9pt Char";
	mso-style-link:"Table\,\(Complex\) Arial\,10 pt\,10 pt  Bold\,9\,9 pt\,9 pt Char Char\,9pt\,Bold\,Normal + \(Latin\) Arial\,table text 10 pt + Arial";
	font-family:"Arial",sans-serif;}
p.Table, li.Table, div.Table
	{mso-style-name:"Table\,\(Complex\) Arial\,10 pt\,10 pt  Bold\,9\,9 pt\,9 pt Char Char\,9pt\,Bold\,Normal + \(Latin\) Arial\,table text 10 pt + Arial";
	mso-style-link:"Table Char\,10 pt  Bold Char\,10 pt Char\,9 Char\,9 pt Char\,9pt Char";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:1.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.Listlevel1, li.Listlevel1, div.Listlevel1
	{mso-style-name:"List level 1";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:1.0pt;
	margin-left:21.25pt;
	text-indent:-21.25pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Authors, li.Authors, div.Authors
	{mso-style-name:Authors;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.Legend, li.Legend, div.Legend
	{mso-style-name:Legend;
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:1.0pt;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.No-numheading3Agency, li.No-numheading3Agency, div.No-numheading3Agency
	{mso-style-name:"No-num heading 3 \(Agency\)";
	mso-style-link:"No-num heading 3 \(Agency\) Char";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.TableheadingrowsAgency, li.TableheadingrowsAgency, div.TableheadingrowsAgency
	{mso-style-name:"Table heading rows \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	margin:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.No-numheading3AgencyChar
	{mso-style-name:"No-num heading 3 \(Agency\) Char";
	mso-style-link:"No-num heading 3 \(Agency\)";
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char\,Annotationtext Char\,Comment Text Char Char Char Char\,Comment Text Char1 Char1\,Comment Text Char1 Char Char";
	mso-style-link:"Comment Text\,Annotationtext\,Comment Text Char Char Char\,Comment Text Char1\,Comment Text Char1 Char";}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:teal;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:red;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX I</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia
2.5&nbsp;mg tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>Votubia
5&nbsp;mg tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>Votubia
10&nbsp;mg tablets</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=FR-CH>2.       QUALITATIVE AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Votubia 2.5&nbsp;mg tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each tablet
contains 2.5&nbsp;mg everolimus.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Excipient with known effect</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each tablet
contains 74&nbsp;mg lactose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Votubia 5&nbsp;mg tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each tablet
contains 5&nbsp;mg everolimus.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Excipient with known effect</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each tablet
contains 149&nbsp;mg lactose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Votubia 10&nbsp;mg tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each tablet
contains 10&nbsp;mg everolimus.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Excipient with known effect</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each tablet
contains 297&nbsp;mg lactose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the full
list of excipients, see section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>3.       PHARMACEUTICAL FORM</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tablet.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Votubia 2.5&nbsp;mg tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>White to
slightly yellow, elongated tablets of approximately 10.1&nbsp;x&nbsp;4.1&nbsp;mm,
with a bevelled edge and no score, engraved with LCL on one side and NVR on
the other.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Votubia 5&nbsp;mg tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>White to
slightly yellow, elongated tablets of approximately 12.1&nbsp;x&nbsp;4.9&nbsp;mm,
with a bevelled edge and no score, engraved with 5 on one side and NVR on
the other.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Votubia 10&nbsp;mg tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>White to
slightly yellow, elongated tablets of approximately 15.1&nbsp;x&nbsp;6.0&nbsp;mm,
with a bevelled edge and no score, engraved with UHE on one side and NVR on
the other.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB style='text-transform:uppercase'>4.       Clinical particulars</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.1     Therapeutic indications</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Renal angiomyolipoma associated with tuberous sclerosis complex
(TSC)</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia is
indicated for the treatment of adult patients with renal angiomyolipoma
associated with tuberous sclerosis complex (TSC) who are at risk of
complications (based on factors such as tumour size or presence of aneurysm, or
presence of multiple or bilateral tumours) but who do not require immediate
surgery.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The evidence is
based on analysis of change in sum of angiomyolipoma volume.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Subependymal giant cell astrocytoma (SEGA) associated with tuberous
sclerosis complex (TSC)</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia is
indicated for the </span><span lang=EN-GB>treatment of adult and paediatric patients
with subependymal giant cell astrocytoma (SEGA) associated with tuberous
sclerosis complex (TSC) who require therapeutic intervention but are not
amenable to surgery.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The evidence is
based on analysis of change in SEGA volume. Further clinical benefit, such as improvement
in disease&#8209;related symptoms, has not been demonstrated.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.2     Posology and method
of administration</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment with
Votubia should be initiated by a physician experienced in the treatment of
patients with TSC and therapeutic drug monitoring.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Renal angiomyolipoma associated with TSC</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The recommended
dose is 10&nbsp;mg of everolimus once daily. Treatment should continue as long
as clinical benefit is observed or until unacceptable toxicity occurs.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If a dose is
missed, the patient should not take an additional dose, but take the usual
prescribed next dose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>SEGA associated with TSC</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Careful
titration may be required to obtain the optimal therapeutic effect. Doses that
will be tolerated and effective vary between patients. Concomitant
antiepileptic therapy may affect the metabolism of everolimus and may
contribute to this variance (see section&nbsp;4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Dosing is individualised based on Body Surface Area (BSA) using the
Dubois formula, where weight (W) is in kilograms and height (H) is in
centimetres:</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
page-break-after:avoid'><span lang=EN-GB>BSA = (W<sup>0.425 </sup>x H<sup>0.725</sup>)
x 0.007184</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The recommended
starting dose for Votubia for the treatment of patients with SEGA is
4.5&nbsp;mg/m<sup>2</sup>. A higher starting dose of 7&nbsp;mg/m<sup>2</sup> is
recommended for patients 1 to less than 3&nbsp;years of age based on
pharmacokinetic simulations (see section&nbsp;5.2). Different strengths of
Votubia tablets can be combined to attain the desired dose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Everolimus whole
blood trough concentrations should be assessed at least 1&nbsp;week after
commencing treatment. Dosing should be titrated to attain trough concentrations
of 5 to 15&nbsp;ng/ml. </span>The dose may be increased to attain a higher
trough concentration within the target range to obtain optimal efficacy, subject
to tolerability.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Individualised dosing should be titrated by increasing the dose by
increments of 2.5&nbsp;mg to attain the target trough concentration for optimal
clinical response. Efficacy, safety, concomitant therapy, and the current
trough concentration should be considered when planning for dose titration. Individualised
dose titration can be based on simple proportion:</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>New
everolimus dose = current dose x (target concentration / current concentration)</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For example, a
patients current dose based on BSA is 2.5&nbsp;mg with a steady state
concentration of 4&nbsp;ng/ml. In order to achieve a target concentration above
the lower C<sub>min</sub> limit of 5&nbsp;ng/ml, e.g. 8&nbsp;ng/ml, the new
everolimus dose would be 5&nbsp;mg (an increase of 2.5&nbsp;mg from the current
daily dose). In cases where the revised dose is not a multiple of 2.5&nbsp;mg, it
should be rounded to the next available tablet strength.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Dosing
recommendations for paediatric patients with SEGA are consistent with those for
the adult SEGA population, except for patients in the range from 1&nbsp;year to
less than 3&nbsp;years of age, and those with hepatic impairment (see section&nbsp;Hepatic
impairment below and section&nbsp;5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>SEGA volume
should be evaluated approximately 3&nbsp;months after commencing Votubia
therapy, with subsequent dose adjustments taking changes in SEGA volume,
corresponding trough concentration, and tolerability into consideration.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Once a stable
dose is attained, trough concentrations should be monitored every 3 to 6&nbsp;months
in patients with changing body surface area, or every 6 to 12&nbsp;months in
patients with stable body surface area, for the duration of treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment should
continue as long as clinical benefit is observed or until unacceptable toxicity
occurs.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If a dose is
missed, the patient should not take an additional dose, but take the usual
prescribed next dose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Dose adjustments due to adverse reactions</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Management of severe and/or intolerable suspected adverse reactions
may require dose reduction and/or temporary interruption of Votubia therapy. <span
style='color:black'>For adverse reactions of Grade&nbsp;1, dose adjustment is
usually not required.</span> If dose reduction is required, the recommended
dose is </span><span lang=EN-GB>approximately 50% lower than the daily dose
previously administered</span><span lang=EN-GB>. For dose reductions below the
lowest available strength, alternate day dosing should be considered.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
style='color:black'>Table&nbsp;1 summarises dose adjustment recommendations for
specific adverse reactions (see also section&nbsp;4.4).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><b><span lang=EN-GB>Table&nbsp;1       Votubia</span></b><b>
dose adjustment recommendations</b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>&nbsp;</p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=639
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Adverse reaction</span></b></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Severity<sup>1</sup></span></b></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Votubia dose
  adjustment</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Non&#8209;infectious pneumonitis</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;2</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Consider interruption of therapy until symptoms
  improve to Grade&nbsp;</span><span style='font-size:11.0pt;font-family:Symbol'>£</span><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>1.</span></p>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Re&#8209;initiate Votubia at approximately 50% lower
  than the daily dose previously administered.</span></p>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Discontinue treatment if failure to recover within </span><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>4</span><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;weeks.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;3</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Interrupt Votubia until symptoms resolve to
  Grade&nbsp;</span><span style='font-size:11.0pt;font-family:Symbol'>£</span><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>1.</span></p>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Consider re&#8209;initiating Votubia at
  approximately 50% lower than the daily dose previously administered. If
  toxicity recurs at Grade&nbsp;3, consider discontinuation.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;4</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.35pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Discontinue Votubia.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Stomatitis</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;2</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Temporary dose interruption until recovery to
  Grade&nbsp;</span><span style='font-size:11.0pt;font-family:Symbol'>£</span><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>1.</span></p>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Re&#8209;initiate Votubia at same dose.</span></p>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>If stomatitis recurs at Grade&nbsp;2, interrupt dose
  until recovery to Grade&nbsp;</span><span style='font-size:11.0pt;font-family:
  Symbol'>£</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>1.
  Re&#8209;initiate Votubia at approximately 50% lower than the daily dose
  previously administered.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;3</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Temporary dose interruption until recovery to Grade&nbsp;</span><span
  style='font-size:11.0pt;font-family:Symbol'>£</span><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>1.</span></p>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Re&#8209;initiate Votubia </span><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>at </span><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>approximately
  50% lower than the daily dose previously administered.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;4</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.35pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Discontinue Votubia.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Other non&#8209;haematological toxicities</span></p>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>(excluding metabolic events)</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;2</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>If toxicity is tolerable, no dose adjustment
  required.</span></p>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>If toxicity becomes intolerable, temporary dose
  interruption until recovery to Grade&nbsp;</span><span style='font-size:11.0pt;
  font-family:Symbol'>£</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>1.
  Re&#8209;initiate Votubia at same dose.</span></p>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>If toxicity recurs at Grade&nbsp;2, interrupt Votubia
  until recovery to Grade&nbsp;</span><span style='font-size:11.0pt;font-family:
  Symbol'>£</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>1.
  Re&#8209;initiate Votubia at approximately 50% lower than the daily dose
  previously administered.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;3</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Temporary dose interruption until recovery to
  Grade&nbsp;</span><span style='font-size:11.0pt;font-family:Symbol'>£</span><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>1.</span></p>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Consider re&#8209;initiating Votubia at
  approximately 50% lower than the daily dose previously administered. If
  toxicity recurs at Grade&nbsp;3, consider discontinuation.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;4</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.35pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Discontinue Votubia.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Metabolic events</span></p>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>(e.g. hyperglycaemia,
  dyslipidaemia)</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;2</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>No dose
  adjustment required.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=139 colspan=3 valign=top style='width:104.5pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;3</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.7pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Temporary dose
  interruption.</span></p>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Re&#8209;initiate
  Votubia at approximately 50% lower than the daily dose previously
  administered.</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=7><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;4</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.35pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Discontinue Votubia.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Thrombocytopenia</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;2</span></p>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>(&lt;75,
  &#8805;50x10<sup>9</sup>/l)</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Temporary dose interruption until recovery to
  Grade&nbsp;</span><span style='font-size:11.0pt;font-family:Symbol'>£</span><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>1 (&#8805;75x10<sup>9</sup>/l).
  Re&#8209;initiate Votubia at same</span><span lang=EN-GB style='font-size:
  11.0pt;font-family:"Times New Roman",serif'> dose.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;3
  &amp; 4</span></p>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>(&lt;50x10<sup>9</sup>/l)</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.35pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Temporary dose interruption until recovery to
  Grade&nbsp;</span><span style='font-size:11.0pt;font-family:Symbol'>£</span><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>1 (&#8805;75x10<sup>9</sup>/l).
  Re&#8209;initiate Votubia at approximately 50% lower than the daily dose
  previously administered.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Neutropenia</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;2</span></p>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>(&#8805;1x10<sup>9</sup>/l)</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>No dose adjustment required</span><span lang=DE-CH
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;3</span></p>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>(&lt;1,
  &#8805;0.5x10<sup>9</sup>/l)</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Temporary dose interruption until recovery to
  Grade&nbsp;</span><span style='font-size:11.0pt;font-family:Symbol'>£</span><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>2 (&#8805;1x10<sup>9</sup>/l).
  Re&#8209;initiate Votubia at same dose.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;border-bottom:solid windowtext 1.0pt' width=9
  colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;4</span></p>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>(&lt;0.5x10<sup>9</sup>/l)</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.35pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Temporary dose interruption until recovery to
  Grade&nbsp;</span><span style='font-size:11.0pt;font-family:Symbol'>£</span><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>2 (&#8805;1x10<sup>9</sup>/l).
  Re&#8209;initiate Votubia at approximately 50% lower than the daily dose
  previously administered.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Febrile neutropenia</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>Grade&nbsp;3</p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.4pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Temporary dose
  interruption until recovery to Grade&nbsp;</span><span style='font-size:11.0pt;
  font-family:Symbol'>£</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>2
  (&#8805;1.25x10<sup>9</sup>/l) and no fever.</span></p>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Re&#8209;initiate
  Votubia at approximately 50% lower than the daily dose previously
  administered.</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;4</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.4pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=DE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Discontinue </span><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Votubia</span><span
  lang=DE style='font-size:11.0pt;font-family:"Times New Roman",serif'>.</span></p>
  </td>
  <td style='border:none;border-bottom:solid windowtext 1.0pt' width=9
  colspan=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=630 colspan=9 valign=top style='width:472.5pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin-left:28.1pt;text-indent:-28.1pt'><sup><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>1</span></sup><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>        Grading
  based on National Cancer Institute (NCI) Common Terminology Criteria for
  Adverse Events (CTCAE) v3.0</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=2 style='border:none'></td>
  <td width=8 style='border:none'></td>
  <td width=130 style='border:none'></td>
  <td width=1 style='border:none'></td>
  <td width=8 style='border:none'></td>
  <td width=107 style='border:none'></td>
  <td width=1 style='border:none'></td>
  <td width=8 style='border:none'></td>
  <td width=365 style='border:none'></td>
  <td width=2 style='border:none'></td>
  <td width=7 style='border:none'></td>
 </tr>
</table>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Therapeutic drug monitoring</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Therapeutic drug
monitoring of everolimus blood concentrations, using a validated assay, is <b>required</b>
for patients treated for SEGA. Trough concentrations should be assessed at
least 1&nbsp;week after the initial dose, after any change in dose or pharmaceutical
form, after initiation of or change in co&#8209;administration of CYP3A4
inhibitors (see sections&nbsp;4.4 and 4.5) or after any change in hepatic
status (Child&#8209;Pugh) (see section&nbsp;Hepatic impairment below and section&nbsp;5.2).
Trough concentrations should be assessed 2 to 4&nbsp;weeks after initiation of
or change in co-administration of CYP3A4 inducers (see sections&nbsp;4.4 and
4.5) since the natural degradation time of the induced enzymes has to be taken
into account.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Therapeutic drug
monitoring of everolimus blood concentrations, using a validated assay, is an <b>option</b>
to be considered for patients treated for renal angiomyolipoma associated with
TSC (see section&nbsp;5.1) after initiation of or change in co&#8209;administration
of CYP3A4 inducers or inhibitors (see sections&nbsp;4.4 and 4.5) or after any
change in hepatic status (Child&#8209;Pugh) (see section&nbsp;Hepatic
impairment below and section&nbsp;5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>When possible,
the same assay and laboratory for therapeutic drug monitoring should be used
throughout the treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Switching pharmaceutical forms</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia is
available in two pharmaceutical forms: tablets and dispersible tablets. Votubia
tablets and Votubia dispersible tablets are <b>not</b> to be used
interchangeably. The two pharmaceutical forms must not be combined to achieve
the desired dose. The same pharmaceutical form must be used consistently, as
appropriate for the indication being treated.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>When switching
pharmaceutical forms, the dose should be adjusted to the closest milligram
strength of the new pharmaceutical form and the everolimus trough concentration
should be assessed at least 1&nbsp;week later (see section&nbsp;Therapeutic
drug monitoring above).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Special populations</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Elderly</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No dose
adjustment is required (see section&nbsp;5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Renal impairment</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No dose
adjustment is required (see section&nbsp;5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Hepatic impairment</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Patients with renal angiomyolipoma associated with TSC:</span></p>

<p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Mild hepatic impairment
(Child&#8209;Pugh A): The recommended dose is 7.5&nbsp;mg daily.</span></p>

<p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Moderate hepatic
impairment (Child&#8209;Pugh B): The recommended dose is 5&nbsp;mg daily.</span></p>

<p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt'><span
style='font-size:11.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Severe hepatic
impairment (Child&#8209;Pugh C):</span><span style='font-size:11.0pt'> Votubia
is only recommended if the desired benefit outweighs the risk. In this case, a
dose of 2.5&nbsp;mg daily must not be exceeded </span><span lang=EN-GB
style='font-size:11.0pt'>(see sections&nbsp;4.4 and 5.2)</span><span
style='font-size:11.0pt'>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Dose adjustments
should be made if a patients hepatic (Child&#8209;Pugh) status changes during
treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Patients with SEGA associated with TSC:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Patients &lt;18&nbsp;years of age:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia is not
recommended for patients &lt;18&nbsp;years of age with SEGA and hepatic
impairment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Patients &#8805;18&nbsp;years of age:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Mild hepatic impairment (Child&#8209;Pugh A):
75% of the recommended starting dose calculated based on BSA (rounded to the
nearest strength)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Moderate hepatic impairment (Child&#8209;Pugh B):
50% of the recommended starting dose calculated based on BSA (rounded to the
nearest strength)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Severe hepatic impairment (Child&#8209;Pugh C): </span><span
lang=EN-GB>Votubia is only recommended if the desired benefit outweighs the
risk. In this case,</span><span lang=EN-GB> 25% of the dose calculated based on
BSA (rounded to the nearest strength) must not be exceeded.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Everolimus whole
blood trough concentrations should be assessed at least 1&nbsp;week after any
change in hepatic status (Child&#8209;Pugh).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Paediatric population</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The safety and
efficacy of Votubia in children aged 0 to 18&nbsp;years with renal
angiomyolipoma </span><span lang=EN-GB>associated with TSC </span><span
lang=EN-GB>in the absence of SEGA have not been established. No data are
available.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The safety,
efficacy and pharmacokinetic profile of Votubia in children below the age of 1&nbsp;year
with TSC who have SEGA have not been established. No data are available (see
sections 5.1 and 5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Clinical study
results did not show an impact of Votubia on growth and pubertal development.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Method of administration</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia must be
administered orally once daily at the same time every day, consistently either
with or without food (see section&nbsp;5.2). Votubia tablets are to be
swallowed whole with a glass of water. The tablets must not be chewed or
crushed. </span><span lang=EN-GB>For patients with TSC who have SEGA and are
unable to swallow tablets, Votubia tablet(s) can be dispersed completely in a
glass with approximately 30&nbsp;ml of water by gently stirring until the
tablet(s) is(are) fully disintegrated (approximately 7&nbsp;minutes),
immediately prior to drinking. After the dispersion has been swallowed, any
residue must be re&#8209;dispersed in the same volume of water and swallowed (see
section&nbsp;5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.3     Contraindications</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypersensitivity
to the active substance, to other rapamycin derivatives or to any of the
excipients listed in section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.4     Special warnings and precautions for use</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Non&#8209;infectious pneumonitis</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Non&#8209;infectious
pneumonitis is a class effect of rapamycin derivatives, including everolimus.
Non&#8209;infectious pneumonitis (including interstitial lung disease) was
described very commonly in patients taking everolimus in the advanced renal
cell carcinoma (RCC) setting (see section&nbsp;4.8). Some cases were severe and
on rare occasions, a fatal outcome was observed. A diagnosis of non&#8209;infectious
pneumonitis should be considered in patients presenting with non&#8209;specific
respiratory signs and symptoms such as hypoxia, pleural effusion, cough or
dyspnoea, and in whom infectious, neoplastic and other non&#8209;medicinal
causes have been excluded by means of appropriate investigations. </span>Opportunistic
infections such as pneumocystis jirovecii (carinii) pneumonia (PJP, PCP) should
be ruled out in the differential diagnosis of non-infectious pneumonitis (see section<span
lang=EN-GB>&nbsp;</span>Infections below). <span lang=EN-GB>Patients should
be advised to report promptly any new or worsening respiratory symptoms.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients who
develop radiological changes suggestive of non&#8209;infectious pneumonitis and
have few or no symptoms may continue Votubia therapy without dose adjustments.
If symptoms are moderate, consideration should be given to interruption of
therapy until symptoms improve. The use of corticosteroids may be indicated. </span><span
lang=EN-GB>Votubia may be reinitiated at a daily dose approximately 50% lower
than the dose previously administered.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For cases where
symptoms of non&#8209;infectious pneumonitis are severe, Votubia therapy should
be discontinued and the use of corticosteroids may be indicated until clinical
symptoms resolve. </span><span lang=EN-GB>Votubia may be reinitiated at a daily
dose approximately 50% lower than the dose previously administered depending on
the individual clinical circumstances.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>For patients who require use of
corticosteroids for treatment of non-infectious pneumonitis, prophylaxis for
pneumocystis jirovecii (carinii) pneumonia (PJP, PCP) may be considered.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Infections</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Everolimus has
immunosuppressive properties and may predispose patients to </span><span
lang=EN-GB>bacterial, fungal, viral or protozoal</span><span lang=EN-GB>
infections, including infections with opportunistic pathogens (see section&nbsp;4.8).
Localised and systemic infections, including pneumonia, other bacterial infections,
invasive fungal infections such as aspergillosis, candidiasis </span><span
lang=EN-GB>or pneumocystis jirovecii (carinii) pneumonia (PJP, PCP) and viral
infections including reactivation of hepatitis&nbsp;B virus</span><span
lang=EN-GB>, have been described in patients taking everolimus. Some of these
infections have been severe (e.g. leading to sepsis [including septic shock], respiratory
or hepatic failure) and occasionally fatal in adult and paediatric patients
(see section&nbsp;4.8).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Physicians and
patients should be aware of the increased risk of infection with Votubia. Pre&#8209;existing
infections should be treated appropriately and should have resolved fully
before starting treatment with Votubia. While taking Votubia, be vigilant for
symptoms and signs of infection; </span><span lang=EN-GB style='color:black'>if
a diagnosis of infection is made,</span><span lang=EN-GB> institute appropriate
treatment promptly </span><span lang=EN-GB>and consider interruption or
discontinuation of Votubia</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span class=TextChar><span
lang=EN-GB style='font-family:"Times New Roman",serif'>If a diagnosis of
invasive systemic fungal infection is made, Votubia treatment should be
promptly and permanently discontinued and the patient treated with appropriate
antifungal therapy.</span></span></p>

<p class=MsoNormal style='line-height:normal'><span class=TextChar><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></span></p>

<p class=MsoNormal style='line-height:normal'>Cases of pneumocystis jirovecii (carinii)
pneumonia (PJP, PCP), some with fatal outcome, have been reported in patients
who received everolimus. PJP/PCP may be associated with concomitant use of
corticosteroids or other immunosuppressive agents. Prophylaxis for PJP/PCP
should be considered when concomitant use of corticosteroids or other
immunosuppressive agents are required.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Hypersensitivity reactions</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypersensitivity
reactions manifested by symptoms including, but not limited to, anaphylaxis,
dyspnoea, flushing, chest pain or angioedema (e.g. swelling of the airways or
tongue, with or without respiratory impairment) have been observed with
everolimus (see section&nbsp;4.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u>Concomitant
use of angiotensin-converting enzyme (ACE) inhibitors</u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>Patients taking concomitant ACE
inhibitor (e.g. ramipril) therapy may be at increased risk for angioedema (e.g.
swelling of the airways or tongue, with or without respiratory impairment) (see
section&nbsp;4.5).</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Stomatitis</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Stomatitis,
including mouth ulcerations and oral mucositis, is the most commonly reported
adverse reaction in patients treated with Votubia (see section&nbsp;4.8).
Stomatitis mostly occurs within the first 8&nbsp;weeks of treatment. A
single-arm study in postmenopausal breast cancer patients treated with Afinitor
(everolimus) plus exemestane suggested that an alcohol-free corticosteroid oral
solution, administered as a mouthwash during the initial 8&nbsp;weeks of
treatment, may decrease the incidence and severity of stomatitis (see
section&nbsp;5.1). Management of stomatitis may therefore include prophylactic
(in adults) and/or therapeutic use of topical treatments, such as an
alcohol-free corticosteroid oral solution as a mouthwash. However products
containing alcohol, hydrogen peroxide, iodine and thyme derivatives should be
avoided as they may exacerbate the condition. Monitoring for and treatment of
fungal infection is recommended, especially in patients being treated with
steroid-based medicinal products. Antifungal agents should not be used unless
fungal infection has been diagnosed (see section&nbsp;4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Haemorrhage</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p style='margin:0in'><span style='font-size:11.0pt'>Serious cases of
haemorrhage, some with a fatal outcome, have been reported in patients treated
with everolimus</span><span lang=EN-GB style='font-size:11.0pt'> in the
oncology setting. No serious cases of renal haemorrhage were reported in the
TSC setting.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Caution is
advised in patients taking Votubia, particularly during concomitant use with
active substances known to affect platelet function or that can increase the
risk of haemorrhage as well as in patients with a history of bleeding
disorders. Healthcare professionals and patients should be vigilant for signs
and symptoms of bleeding throughout the treatment period, especially if risk factors
for haemorrhage are combined.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Renal failure events</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cases of renal
failure (including acute renal failure), some with a fatal outcome, have been
observed in patients treated with Votubia (see section 4.8). Renal function of
patients should be monitored particularly where patients have additional risk
factors that may further impair renal function.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Laboratory tests and monitoring</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Renal function</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Elevations of
serum creatinine, usually mild, and proteinuria have been reported in patients
treated with Votubia (see section&nbsp;4.8). Monitoring of renal function,
including measurement of blood urea nitrogen (BUN), urinary protein or serum
creatinine, is recommended prior to the start of Votubia therapy and
periodically thereafter.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Blood glucose</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hyperglycaemia
has been reported in patients taking Votubia (see section&nbsp;4.8). Monitoring
of fasting serum glucose is recommended prior to the start of Votubia therapy
and periodically thereafter. More frequent monitoring is recommended when
Votubia is co-administered with other medicinal products that may induce
hyperglycaemia. When possible optimal glycaemic control should be achieved
before starting a patient on Votubia.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Blood </span></u></i><i><u><span lang=EN-GB>lipids</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Dyslipidaemia
(including hypercholesterolaemia and hypertriglyceridaemia) has been reported
in patients taking Votubia. Monitoring of blood cholesterol and triglycerides
prior to the start of Votubia therapy and periodically thereafter, as well as
management with appropriate medical therapy, is also recommended.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Haematological parameters</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Decreased
haemoglobin, lymphocytes, neutrophils and platelets have been reported in patients
treated with Votubia (see section&nbsp;4.8). Monitoring of complete blood count
is recommended prior to the start of Votubia therapy and periodically
thereafter.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Interactions</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Co&#8209;administration
with inhibitors and inducers of CYP3A4 and/or the multidrug efflux pump P&#8209;glycoprotein
(PgP) should be avoided. If </span><span lang=EN-GB>co&#8209;administration of
a <b><i>moderate</i></b> CYP3A4 and/or PgP inhibitor or inducer cannot be
avoided, dose adjustments of Votubia may be required (see section&nbsp;4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant
treatment with <b><i>potent</i></b> CYP3A4 inhibitors result in dramatically
increased blood concentrations of everolimus (see section&nbsp;4.5). There are
currently not sufficient data to allow dosing recommendations in this
situation. Hence, concomitant treatment of Votubia and <b><i>potent</i></b>
inhibitors is not recommended.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>Caution should be exercised when
Votubia is taken in combination with orally administered CYP3A4 substrates with
a narrow therapeutic index due to the potential for drug interactions. If
Votubia is taken with orally administered CYP3A4 substrates with a narrow
therapeutic index (e.g. pimozide, terfenadine, astemizole, cisapride, quinidine,
ergot alkaloid derivatives or carbamazepine), the patient should be monitored
for undesirable effects described in the product information of the orally
administered CYP3A4 substrate (see section&nbsp;4.5).</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Hepatic
impairment</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Votubia is
not recommended for use in patients:</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&#8805;</span></b><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>18&nbsp;years of age </span></b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>and concomitant severe
hepatic impairment (Child&#8209;Pugh C) unless the potential benefit outweighs
the risk (see sections&nbsp;4.2 and 5.2).</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&lt;18&nbsp;years
of age with SEGA</span></b><span lang=EN-GB style='font-family:"Times New Roman",serif'>
and concomitant hepatic impairment (Child&#8209;Pugh A, B and C) (see
sections&nbsp;4.2 and 5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Vaccinations</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The use of live
vaccines should be avoided during treatment with Votubia (see section&nbsp;4.5).
For paediatric patients with SEGA who do not require immediate treatment, completion
of the recommended childhood series of live virus vaccinations is advised prior
to the start of therapy according to local treatment guidelines.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Wound healing complications</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Impaired wound
healing is a class effect of rapamycin derivatives, including Votubia. Caution
should therefore be exercised with the use of Votubia in the peri&#8209;surgical
period.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Lactose</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients with
rare hereditary problems of galactose intolerance, total lactase deficiency or
glucose&#8209;galactose malabsorption should not take this medicinal product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.5     Interaction with other medicinal products and other forms of
interaction</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Everolimus is a
substrate of CYP3A4, and also a substrate and moderate inhibitor of PgP.
Therefore, absorption and subsequent elimination of everolimus may be influenced
by products that affect CYP3A4 and/or PgP. <i>In vitro</i>, everolimus is a
competitive inhibitor of CYP3A4 and a mixed inhibitor of CYP2D6.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Known and
theoretical interactions with selected inhibitors and inducers of CYP3A4 and
PgP are listed in Table&nbsp;2 below.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>CYP3A4 and PgP inhibitors increasing everolimus concentrations</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Substances that
are inhibitors of CYP3A4 or PgP may increase everolimus blood concentrations by
decreasing metabolism or the efflux of everolimus from intestinal cells.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>CYP3A4 and PgP inducers decreasing everolimus concentrations</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Substances that
are inducers of CYP3A4 or PgP may decrease everolimus blood concentrations by
increasing metabolism or the efflux of everolimus from intestinal cells.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Table&nbsp;2       Effects of other active substances on everolimus</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="101%"
 style='width:101.9%;border-collapse:collapse;border:none'>
 <tr>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Active substance by interaction</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width="34%" colspan=2 valign=top style='width:34.24%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Interaction  Change in Everolimus AUC/C<sub>max</sub></span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Geometric mean ratio (observed range)</span></b></p>
  </td>
  <td width="38%" valign=top style='width:38.0%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Recommendations concerning co&#8209;administration</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=4 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><i><span
  lang=EN-GB>Potent</span></i></b><b><span lang=EN-GB> CYP3A4/PgP inhibitors</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Ketoconazole</span></b></p>
  </td>
  <td width="34%" colspan=2 valign=top style='width:34.24%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>AUC
  &#8593;15.3&#8209;fold</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(range 11.2&#8209;22.5)</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>C<sub>max</sub>
  &#8593;4.1&#8209;fold</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(range 2.6&#8209;7.0)</span></p>
  </td>
  <td width="38%" rowspan=5 valign=top style='width:38.0%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant
  treatment of Votubia and potent inhibitors is not recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Itraconazole,
  posaconazole, voriconazole</span></b></p>
  </td>
  <td width="34%" colspan=2 rowspan=4 valign=top style='width:34.24%;
  border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not studied.
  Large increase in everolimus concentration is expected.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Telithromycin,
  clarithromycin</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Nefazodone</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR-CH>Ritonavir,
  atazanavir, saquinavir, darunavir, indinavir, nelfinavir</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=4 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><i><span
  lang=EN-GB>Moderate</span></i></b><b><span lang=EN-GB> CYP3A4/PgP inhibitors</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Erythromycin</span></b></p>
  </td>
  <td width="34%" colspan=2 valign=top style='width:34.24%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>AUC &#8593;4.4&#8209;fold</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(range 2.0&#8209;12.6)</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>C<sub>max</sub>
  &#8593;2.0&#8209;fold</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(range 0.9&#8209;3.5)</span></p>
  </td>
  <td width="38%" rowspan=8 valign=top style='width:38.0%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use caution
  when co&#8209;administration of moderate CYP3A4 inhibitors or PgP inhibitors
  cannot be avoided.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>For
  patients with renal angiomyolipoma associated with TSC:</span></i></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If patients
  require co&#8209;administration of a moderate CYP3A4 or PgP inhibitor, dose
  reduction to 5&nbsp;mg or 2.5&nbsp;mg daily may be considered. However, there
  are no clinical data with this dose adjustment. Due to between subject
  variability the recommended dose adjustments may not be optimal in all
  individuals, therefore close monitoring of side effects is recommended. If the
  moderate inhibitor is discontinued, consider a washout period of at least 2
  to 3&nbsp;days (average elimination time for most commonly used moderate
  inhibitors) before the Votubia dose is returned to the dose used prior to
  initiation of the co-administration (see also Therapeutic drug monitoring in
  section&nbsp;4.2).</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>For
  patients with SEGA associated with TSC:</span></i></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If patients
  require co&#8209;administration of a moderate CYP3A4 or PgP inhibitor, reduce
  the daily dose by approximately 50%. Further dose reduction may be required
  to manage adverse reactions (see sections&nbsp;4.2 and 4.4). Everolimus
  trough concentrations should be assessed at least 1&nbsp;week after the
  addition of a moderate CYP3A4 or PgP inhibitor. If the moderate inhibitor is
  discontinued, consider a washout period of at least 2 to 3&nbsp;days (average
  elimination time for most commonly used moderate inhibitors) before the Votubia
  dose is returned to the dose used prior to initiation of the co-administration.
  The everolimus trough concentration should be assessed at least 1&nbsp;week later
  (see sections&nbsp;4.2 and 4.4).</span></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Imatinib</span></b></p>
  </td>
  <td width="34%" colspan=2 valign=top style='width:34.24%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>AUC </span><span
  lang=EN-GB style='font-family:"Arial",sans-serif;color:black'>&#8593; </span><span
  lang=EN-GB style='color:black'>3.7&#8209;fold</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>C<sub>max</sub> </span><span lang=EN-GB style='font-family:
  "Arial",sans-serif;color:black'>&#8593; </span><span lang=EN-GB
  style='color:black'>2.2&#8209;fold</span></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Verapamil</span></b></p>
  </td>
  <td width="34%" colspan=2 valign=top style='width:34.24%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>AUC &#8593;3.5&#8209;fold</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(range 2.2&#8209;6.3)</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>C<sub>max</sub>
  &#8593;2.3&#8209;fold</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(range1.3&#8209;3.8)</span></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Ciclosporin
  oral</span></b></p>
  </td>
  <td width="34%" colspan=2 valign=top style='width:34.24%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>AUC &#8593;2.7&#8209;fold</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(range 1.5&#8209;4.7)</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>C<sub>max</sub>
  &#8593;1.8&#8209;fold</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(range 1.3&#8209;2.6)</span></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Fluconazole</span></b></p>
  </td>
  <td width="34%" colspan=2 rowspan=2 valign=top style='width:34.24%;
  border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Not studied. Increased exposure expected.</span></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Diltiazem</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Dronedarone</span></b></p>
  </td>
  <td width="34%" colspan=2 valign=top style='width:34.24%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not studied.
  Increased exposure expected.</span></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Amprenavir,
  fosamprenavir</span></b></p>
  </td>
  <td width="34%" colspan=2 valign=top style='width:34.24%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not studied.
  Increased exposure expected.</span></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Grapefruit
  juice or other food affecting CYP3A4/PgP</span></b></p>
  </td>
  <td width="34%" colspan=2 valign=top style='width:34.24%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not studied.
  Increased exposure expected (the effect varies widely).</span></p>
  </td>
  <td width="38%" valign=top style='width:38.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Combination
  should be avoided.</span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=4 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><i><span
  lang=EN-GB>Potent</span></i></b><b><span lang=EN-GB> <i>and moderate</i> CYP3A4
  inducers</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="29%" colspan=2 valign=top style='width:29.62%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Rifampicin</span></b></p>
  </td>
  <td width="32%" valign=top style='width:32.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>AUC &#8595;63%</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(range 0&#8209;80%)</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>C<sub>max</sub>
  &#8595;58%</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(range 10&#8209;70%)</span></p>
  </td>
  <td width="38%" rowspan=4 valign=top style='width:38.0%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Avoid the use
  of concomitant potent CYP3A4 inducers.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>For
  patients with renal angiomyolipoma associated with TSC:</span></i></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If patients
  require co&#8209;administration of a potent CYP3A4 inducer, a Votubia dose
  increase from 10&nbsp;mg daily up to 20&nbsp;mg daily should be considered
  using 5&nbsp;mg increments or less applied on Day&nbsp;4 and 8 following
  start of the inducer. This dose of Votubia is predicted to adjust the AUC to
  the range observed without inducers. However, there are no clinical data with
  this dose adjustment. If treatment with the inducer is discontinued, consider
  a washout period of at least 3 to 5&nbsp;days (reasonable time for
  significant enzyme de-induction) before the Votubia dose is returned to the
  dose used prior to initiation of the co&#8209;administration (see also
  Therapeutic drug monitoring in section&nbsp;4.2).</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>For
  patients with SEGA associated with TSC:</span></i></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients
  receiving concomitant potent CYP3A4 inducers may require an increased Votubia
  dose to achieve the same exposure as patients not taking potent inducers.
  Dosing should be titrated to attain trough concentrations of 5 to
  15&nbsp;ng/ml. If concentrations are below 5&nbsp;ng/ml, the daily dose may
  be increased by 2.5&nbsp;mg every 2&nbsp;weeks, checking the trough level and
  assessing tolerability before increasing the dose.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'>The addition of another
  concomitant strong CYP3A4 inducer may not require additional dose adjustment.
  Assess the everolimus trough level 2&nbsp;weeks after initiating the
  additional inducer. Adjust the dose by increments of 2.5&nbsp;mg as necessary
  to maintain the target trough concentration.</p>
  <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Discontinuation
  of one of multiple strong CYP3A4 inducers may not require additional dose
  adjustment. Assess the everolimus trough level 2&nbsp;weeks after
  discontinuation of one of multiple strong CYP3A4 inducers. If all potent
  inducers are discontinued, consider a washout period of at least 3 to
  5&nbsp;days (reasonable time for significant enzyme de-induction) before the
  Votubia dose is returned to the dose used prior to initiation of the co&#8209;administration.
  The everolimus trough concentrations should be assessed 2&nbsp;to 4 weeks later
  since the natural degradation time of the induced enzymes has to be taken
  into account (see sections&nbsp;4.2 and 4.4).</span></p>
  </td>
 </tr>
 <tr>
  <td width="29%" colspan=2 valign=top style='width:29.62%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=IT>Dexamethasone</span></b></p>
  </td>
  <td width="32%" valign=top style='width:32.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not studied.
  Decreased exposure expected.</span></p>
  </td>
 </tr>
 <tr>
  <td width="29%" colspan=2 valign=top style='width:29.62%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Antiepileptics
  (e.g. carbamazepine, phenobarbital, phenytoin)</span></b></p>
  </td>
  <td width="32%" valign=top style='width:32.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not studied.
  Decreased exposure expected.</span></p>
  </td>
 </tr>
 <tr>
  <td width="29%" colspan=2 valign=top style='width:29.62%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Efavirenz,
  nevirapine</span></b></p>
  </td>
  <td width="32%" valign=top style='width:32.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not studied.
  Decreased exposure expected.</span></p>
  </td>
 </tr>
 <tr>
  <td width="29%" colspan=2 valign=top style='width:29.62%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>St Johns
  Wort (<i>Hypericum perforatum</i>)</span></b></p>
  </td>
  <td width="32%" valign=top style='width:32.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not studied.
  Large decrease in exposure expected.</span></p>
  </td>
  <td width="38%" valign=top style='width:38.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Preparations
  containing St Johns Wort should not be used during treatment with everolimus</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=200 style='border:none'></td>
  <td width=13 style='border:none'></td>
  <td width=233 style='border:none'></td>
  <td width=274 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Agents whose plasma concentration may be altered by everolimus</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Based on <i>in
vitro</i> results, the systemic concentrations obtained after oral daily doses
of 10&nbsp;mg make inhibition of PgP, CYP3A4 and CYP2D6 unlikely. However,
inhibition of CYP3A4 and PgP in the gut cannot be excluded. </span>An
interaction study in healthy subjects demonstrated that co&#8209;administration
of an oral dose of midazolam, a sensitive CYP3A substrate probe, with
everolimus resulted in a 25% increase in midazolam C<sub>max</sub> and a 30%
increase in midazolam AUC<sub>(0-inf)</sub>. The effect is likely to be due to
inhibition of intestinal CYP3A4 by everolimus.<span lang=EN-GB> Hence
everolimus may affect the bioavailability of orally co&#8209;administered
CYP3A4 substrates. However, a clinically relevant effect on the exposure of
systemically administered CYP3A4 substrates is not expected (see
section&nbsp;4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In EXIST-3
(Study CRAD001M2304), everolimus increased pre&#8209;dose concentrations of the
antiepileptics carbamazepine, clobazam, and the clobazam metabolite N&#8209;desmethylclobazam
by about 10%. The increase in the pre&#8209;dose concentrations of these antiepileptics
may not be clinically significant but dose adjustments for antiepileptics with
a narrow therapeutic index, e.g carbamazepine, may be considered</span><span
lang=EN-GB>. Everolimus had no impact on pre&#8209;dose concentrations of </span><span
lang=EN-GB>antiepileptics</span><span lang=EN-GB> that are substrates of CYP3A4
(clonazepam, diazepam, felbamate and zonisamide).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u>Concomitant
use of angiotensin-converting enzyme (ACE) inhibitors</u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>Patients taking concomitant ACE
inhibitor (e.g. ramipril) therapy may be at increased risk for angioedema (see
section&nbsp;4.4).</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Vaccinations</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The immune response
to vaccination may be affected and, therefore, vaccination may be less
effective during treatment with Votubia. The use of live vaccines should be
avoided during treatment with Votubia. Examples of live vaccines are:
intranasal influenza, measles, mumps, rubella, oral polio, BCG (Bacillus
Calmette&#8209;Guérin), yellow fever, varicella, and TY21a typhoid vaccines.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.6     Fertility, pregnancy and lactation</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Women of childbearing potential/Contraception in males and females</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Women of
childbearing potential must use a highly effective method of contraception (e.g.
oral, injected, or implanted non&#8209;oestrogen&#8209;containing hormonal
method of birth control, progesterone&#8209;based contraceptives, hysterectomy,
tubal ligation, complete abstinence, barrier methods, intrauterine device [IUD],
and/or female/male sterilisation) while receiving everolimus, and for up to 8&nbsp;weeks
after ending treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Male patients
should not be prohibited from attempting to father children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There are no adequate
data from the use of everolimus in pregnant women. Studies in animals have
shown reproductive toxicity effects including embryotoxicity and foetotoxicity (see
section&nbsp;5.3). The potential risk for humans is unknown.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Everolimus is
not recommended during pregnancy and in women of childbearing potential not
using contraception.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Breast&#8209;feeding</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is not known
whether everolimus is excreted in human breast milk. However, in rats,
everolimus and/or its metabolites readily pass into the milk (see
section&nbsp;5.3). Therefore, women taking everolimus should not breast&#8209;feed
during treatment and for 2&nbsp;weeks after the last dose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The potential
for everolimus to cause infertility in male and female patients is unknown,
however secondary amenorrhoea and associated luteinising hormone (LH)/follicle
stimulating hormone (FSH) imbalance has been observed in female patients (see also
section&nbsp;5.3 for preclinical observations on the male and female
reproductive systems).</span><span lang=EN-GB> Based on non&#8209;clinical
findings, male and female fertility may be compromised by treatment with
everolimus (see section&nbsp;5.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.7     Effects on ability to drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia may have
a minor or moderate influence on the ability to drive and use machines. Patients
should be advised to be cautious when driving or using machines if they
experience fatigue during treatment with Votubia.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.8     Undesirable effects</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Summary of the safety profile</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Three randomised, double&#8209;blind, placebo&#8209;controlled
pivotal phase III studies, including double-blind and open label treatment
periods, and a non-randomised, open-label, single-arm phase II study contribute
to the safety profile of Votubia (n=612, including 409&nbsp;patients &lt;18&nbsp;years
of age; median duration of exposure 36.8&nbsp;months [range 0.5 to 83.2]).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>EXIST-3 (CRAD001M2304): This
was a randomised, double-blind, controlled, phase III trial comparing
adjunctive treatment of low and high everolimus exposure (low trough [LT] range
of 3&#8209;7&nbsp;ng/ml [n=117] and high trough [HT] range of 9&#8209;15&nbsp;ng/ml
[n=130]) versus placebo (n=119), in patients with TSC and refractory partial-onset
seizures receiving 1 to 3&nbsp;antiepileptics. The median duration of the
double-blind period was 18&nbsp;weeks. The cumulative median duration exposure
to Votubia (361&nbsp;patients who took at least one dose of everolimus) was 30.4&nbsp;months
(range 0.5 to 48.8).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>EXIST&#8209;2 (CRAD001M2302): This was a </span><span
lang=EN-GB>randomised, double&#8209;blind, controlled, phase III trial of
everolimus (n=79) versus placebo (n=39) in patients with either TSC plus renal angiomyolipoma
(n=113) or sporadic lymphangioleiomyomatosis (LAM) plus renal angiomyolipoma
(n=5)</span><span lang=EN-GB>. </span><span lang=EN-GB>The median duration of
blinded study treatment was 48.1&nbsp;weeks (range 2 to 115) for patients
receiving Votubia and 45.0&nbsp;weeks (range 9 to 115) for those receiving <span
style='color:black'>placebo. The cumulative median duration of exposure to
Votubia (112&nbsp;patients who took at least one dose of everolimus) was 46.9&nbsp;months
(range 0.5 to 63.9).</span></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>EXIST&#8209;1
(CRAD001M2301): This was a </span><span lang=EN-GB style='color:black'>randomised,
double&#8209;blind, controlled, phase III trial of everolimus (n=78) versus
placebo (n=39) in patients with TSC who have SEGA, irrespective of age. The
median duration of blinded study treatment was 52.2&nbsp;weeks (range 24 to 89)
for patients receiving Votubia and 46.6&nbsp;weeks (range 14 to 88) for those
receiving placebo. The cumulative median duration of exposure to Votubia (111&nbsp;patients
who took at least one dose of everolimus) was 47.1&nbsp;months (range 1.9 to 58.3).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>CRAD001C2485: This was a
prospective, open&#8209;label, single&#8209;arm phase II study of everolimus in
patients with SEGA (n=28). The median duration of exposure was 67.8&nbsp;months
(range 4.7 to 83.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>The adverse events considered to be associated with the use
of Votubia (adverse reactions), based upon the review and medical assessment of
all adverse events reported in the above studies, are described below.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>The most frequent adverse reactions (incidence &#8805;1/10)
from the pooled safety data are (in decreasing order): stomatitis, pyrexia, nasopharyngitis,
diarrhoea, upper respiratory tract infection, vomiting, cough, rash, headache, amenorrhoea,
acne, pneumonia, urinary tract infection, sinusitis, menstruation irregular, pharyngitis,
decreased appetite, fatigue, hypercholesterolaemia, and hypertension.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>The most frequent grade&nbsp;3&#8209;4 adverse reactions
(incidence &#8805;1%) were pneumonia, stomatitis, amenorrhoea, neutropenia,
pyrexia, menstruation irregular, hypophosphataemia, diarrhoea, and cellulitis. The
grades follow CTCAE Version&nbsp;3.0 and 4.03.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB style='color:black'>Tabulated list of adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Table&nbsp;3 shows the incidence of adverse reactions based
on pooled data of patients receiving everolimus in the three TSC studies
(including both the double&#8209;blind and open&#8209;label extension phase,
where applicable). Adverse reactions are listed according to MedDRA system organ
class. Frequency categories are defined using the following convention: very
common (&#8805;1/10); common (&#8805;1/100 to &lt;1/10); uncommon
(&#8805;1/1,000 to &lt;1/100); rare (&#8805;1/10,000 to &lt;1/1,000); very rare
(&lt;1/10,000); not known (cannot be estimated from the available data).</span><span
lang=EN-GB style='color:black'> </span><span lang=EN-GB style='color:black'>Within
each frequency grouping, adverse reactions are presented in order of decreasing
seriousness.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB style='color:black'>Table&nbsp;3       Adverse
reactions reported in TSC studies</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=612
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=612 colspan=3 valign=top style='width:459.0pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Infections and infestations</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:none;
  border-left:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Very common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Nasopharyngitis, upper respiratory tract infection</span><span
  lang=EN-GB style='color:black'>, pneumonia</span><sup><span lang=EN-GB>&nbsp;a</span></sup><span
  lang=EN-GB style='color:black'>, urinary tract infection, sinusitis,
  pharyngitis</span></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:none;
  border-left:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Otitis media, cellulitis, pharyngitis streptococcal,
  gastroenteritis viral, gingivitis</span></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:none;
  border-left:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Uncommon</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Herpes zoster,
  sepsis, bronchitis viral</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=3 valign=top style='width:459.0pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Blood and lymphatic system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Common</span></p>
  </td>
  <td width=510 colspan=2 valign=top style='width:382.7pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=IT style='color:black'>Anaemia, neutropenia,
  leucopenia, thrombocytopenia, lymphopenia</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=3 valign=top style='width:459.0pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Immune system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Common</span></p>
  </td>
  <td width=510 colspan=2 valign=top style='width:382.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Hypersensitivity</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=3 valign=top style='width:459.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Metabolism and nutrition disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:none;
  border-left:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Very common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Decreased appetite, hypercholesterolaemia</span></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:none;
  border-left:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Hypertriglyceridaemia,
  hyperlipidaemia, hypophosphataemia, hyperglycaemia</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=3 valign=top style='width:459.0pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Psychiatric disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:none;
  border-left:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Insomnia, aggression,
  irritability</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=3 valign=top style='width:459.0pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Nervous system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:none;
  border-left:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Very common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Headache</span></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:none;
  border-left:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Uncommon</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Dysgeusia</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=3 valign=top style='width:459.0pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Vascular disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:none;
  border-left:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Very common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Hypertension</span></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:none;
  border-left:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Lymphoedema</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=3 valign=top style='width:459.0pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Respiratory, thoracic and mediastinal disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:none;
  border-left:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Very common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Cough</span></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:none;
  border-left:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Epistaxis,
  pneumonitis</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=3 valign=top style='width:459.0pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Gastrointestinal disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:none;
  border-left:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Very common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Stomatitis</span><sup><span lang=EN-GB>&nbsp;<span
  style='color:black'>b</span></span></sup><span lang=EN-GB style='color:black'>,
  diarrhoea, vomiting</span></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Constipation, nausea,
  abdominal pain, flatulence, oral pain, gastritis</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=3 valign=top style='width:459.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Skin and subcutaneous tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:none;
  border-left:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Very common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Rash</span><sup><span lang=EN-GB>&nbsp;<span
  style='color:black'>c</span></span></sup><span lang=EN-GB style='color:black'>,
  acne</span></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:none;
  border-left:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Dry skin, acneiform dermatitis, pruritus, alopecia</span></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Uncommon</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Angioedema</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=3 valign=top style='width:459.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Musculoskeletal and connective tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Uncommon</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Rhabdomyolysis</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=3 valign=top style='width:459.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Renal and urinary disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Proteinuria</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=3 valign=top style='width:459.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB style='color:black'>Reproductive system and breast disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:none;
  border-left:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Very common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=ES style='color:
  black'>Amenorrhoea</span><sup><span lang=ES>&nbsp;<span style='color:black'>d</span></span></sup><span
  lang=ES style='color:black'>, menstruation irregular</span><sup><span
  lang=ES>&nbsp;<span style='color:black'>d</span></span></sup></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:none;
  border-left:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Menorrhagia, ovarian cyst, vaginal haemorrhage</span></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:none;
  border-left:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Uncommon</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Menstruation delayed</span><sup><span lang=EN-GB>&nbsp;</span><span
  lang=EN-GB style='color:black'>d</span></sup></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=3 valign=top style='width:459.0pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>General disorders and administration site conditions</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:none;
  border-left:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Very common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Pyrexia, fatigue</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=3 valign=top style='width:459.0pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Investigations</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:none;
  border-left:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Blood lactate
  dehydrogenase increased, blood luteinising hormone increased, weight
  decreased</span></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Uncommon</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Blood follicle
  stimulating hormone increased</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=3 valign=top style='width:459.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><sup><span lang=EN-GB>a                 </span></sup><span
  lang=EN-GB>Includes </span>pneumocystis jirovecii (carinii) pneumonia (PJP,
  PCP)</p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><sup><span lang=EN-GB
  style='color:black'>b</span></sup><span lang=EN-GB style='color:black'>        Includes
  (very common) stomatitis, mouth ulceration, aphthous ulcer; (common) tongue
  ulceration, lip ulceration and (uncommon) gingival pain, glossitis</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><sup><span lang=EN-GB style='color:black'>c</span></sup><span
  lang=EN-GB style='color:black'>         Includes (very common) rash; (common)
  rash erythematous, erythema and (uncommon) rash generalised, rash maculo&#8209;papular,
  rash macular</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><sup><span lang=EN-GB style='color:black'>d                 </span></sup><span
  lang=EN-GB style='color:black'>F</span><span style='color:black'>requenc</span><span
  style='color:black'>y based upon number of women from 10 to 55&nbsp;years of
  age while on treatment in the pooled data</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=102 style='border:none'></td>
  <td width=2 style='border:none'></td>
  <td width=509 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB style='color:black'>Description of selected adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>In clinical studies, everolimus has been associated with
serious cases of hepatitis&nbsp;B reactivation, including fatal outcome.
Reactivation of infection is an expected reaction during periods of
immunosuppression.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>In clinical studies and
post&#8209;marketing spontaneous reports, everolimus has been associated with
renal failure events (including fatal outcome), proteinuria and increased serum
creatinine. Monitoring of renal function is recommended (see section&nbsp;4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>In clinical studies,
everolimus has been associated with haemorrhage events. On rare occasions,
fatal outcomes were observed in the oncology setting (see section&nbsp;4.4). No
serious cases of renal haemorrhage were reported in the TSC setting.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>In clinical studies and post&#8209;marketing spontaneous
reports, everolimus has been associated with cases of pneumocystis jirovecii
(carinii) pneumonia (PJP, PCP), some with fatal outcome (see section&nbsp;4.4).</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Additional adverse reactions of relevance observed in
oncology clinical studies and post&#8209;marketing spontaneous reports, were
cardiac failure, pulmonary embolism, deep vein thrombosis, impaired wound
healing and hyperglycaemia.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>In clinical trials and post-marketing spontaneous reports,
angioedema has been reported with and without concomitant use of ACE inhibitors
(see section&nbsp;</span><span lang=EN-GB style='color:black'>4.4</span><span
lang=EN-GB style='color:black'>).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='color:black'>Paediatric population</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>In the pivotal phase II
study, 22 of the 28 SEGA patients studied were below the age of 18&nbsp;years
and in the pivotal phase III study, 101 of the 117 SEGA patients studied were
below the age of 18&nbsp;years. In the pivotal phase III study in patients with
TSC and refractory seizures, 299 of the 366&nbsp;patients studied were below
the age of 18&nbsp;years. The overall type, frequency and severity of adverse
reactions observed in children and adolescents have been generally consistent
with those observed in adults, with the exception of infections which were
reported at a higher frequency and severity in children below the age of 6&nbsp;years.
A total of 49 out of 137&nbsp;patients (36%) aged &lt;6&nbsp;years had
Grade&nbsp;3/4 infections, compared to 53 out of 272&nbsp;patients (19%) aged 6
to &lt;18&nbsp;years and 27 out of 203&nbsp;patients (13%) aged
&#8805;18&nbsp;years. Two fatal cases due to infection were reported in
409&nbsp;patients aged &lt;18&nbsp;years receiving everolimus.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='color:black'>Elderly</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>In the oncology safety
pooling, 37% of the patients treated with everolimus were &#8805;65&nbsp;years
of age. The number of oncology patients with an adverse reaction leading to
discontinuation of everolimus was higher in patients &#8805;65&nbsp;years of
age (20% versus 13%). The most common adverse reactions leading to
discontinuation were pneumonitis (including interstitial lung disease),
fatigue, dyspnoea, and stomatitis.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB style='color:black'>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Reporting suspected
adverse reactions after authorisation of the medicinal product is important. It
allows continued monitoring of the benefit/risk balance of the medicinal
product. Healthcare professionals are asked to report any suspected adverse
reactions via <span style='background:#D9D9D9'>the national reporting system
listed in </span></span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:black;background:#D9D9D9'>Appendix V</span></a></span><span
lang=EN-GB style='color:black'>.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB style='color:black'>4.9     Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Reported experience with overdose in humans is very limited</span><span
lang=EN-GB>. Single doses of up to 70&nbsp;mg have been given with acceptable
acute tolerability in the adult population.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is essential
to assess everolimus blood levels in cases of suspected overdose. General
supportive measures should be initiated in all cases of overdose. Everolimus is
not considered dialysable to any relevant degree (less than 10% was removed
within 6&nbsp;hours of haemodialysis).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A limited number
of paediatric patients have been exposed to doses higher than 10&nbsp;mg/m<sup>2</sup>/day.
No signs of acute toxicity have been reported in these cases.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>5.       PHARMACOLOGICAL PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>5.1     Pharmacodynamic properties</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>Pharmacotherapeutic group: Antin<span style='color:black'>eoplastic
agents, other antineoplastic agents, protein </span>kinase inhibitors, ATC
code: <span style='color:black'>L01XE10</span></span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Mechanism of action</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Everolimus is a
selective mTOR (mammalian target of rapamycin) inhibitor. mTOR is a key serine&#8209;threonine
kinase, the activity of which is known to be upregulated in a number of human
cancers. Everolimus binds to the intracellular protein FKBP&#8209;12, forming a
complex that inhibits mTOR complex&#8209;1 (mTORC1) activity.</span><b><i><span
lang=EN-GB> </span></i></b><span lang=EN-GB>Inhibition of the mTORC1 signalling
pathway interferes with the translation and synthesis of proteins by reducing
the activity of S6 ribosomal protein kinase (S6K1) and eukaryotic elongation
factor 4E&#8209;binding protein (4EBP&#8209;1) that regulate proteins involved
in the cell cycle, angiogenesis and glycolysis. Everolimus can reduce levels of
vascular endothelial growth factor (VEGF). In patients with TSC, treatment with
everolimus increases VEGF&#8209;A and decreases VEGF&#8209;D levels. Everolimus
is a potent inhibitor of the growth and proliferation of tumour cells,
endothelial cells, fibroblasts and blood&#8209;vessel&#8209;associated smooth
muscle cells and has been shown to reduce glycolysis in solid tumours <i>in
vitro</i> and <i>in vivo</i>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Two primary
regulators of mTORC1 signalling are the oncogene suppressors tuberin&#8209;sclerosis
complexes&nbsp;1 &amp; 2 (TSC1, TSC2). Loss of either TSC1 or TSC2 leads to
elevated rheb&#8209;GTP levels, a ras family GTPase, which interacts with the
mTORC1 complex to cause its activation. mTORC1 activation leads to a downstream
kinase signalling cascade, including activation of the S6 kinases. In tuberous
sclerosis complex syndrome, inactivating mutations in the TSC1 or the TSC2 gene
lead to hamartoma formation throughout the body.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Clinical efficacy and safety</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Renal angiomyolipoma associated with TSC</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><a
name="_316155941Figure_114529Waterfall_p"></a><a
name="_315155941Figure_114529Waterfall_p"></a><a
name="_314155941Figure_114529Waterfall_p"></a><a
name="_319155941Figure_114529Waterfall_p"></a><a
name="_320155941Figure_114529Waterfall_p"></a><span lang=EN-GB>EXIST&#8209;2
(study CRAD001M2302), a randomised, controlled phase III study was conducted to
evaluate the efficacy and safety of Votubia in patients with TSC plus renal angiomyolipoma.
Presence of at least one angiomyolipoma &#8805;3&nbsp;cm in longest diameter
using CT/MRI (based on local radiology assessment) was required for entry.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The primary
efficacy endpoint was angiomyolipoma response rate based on independent central
radiology review. The analysis was stratified by use of enzyme&#8209;inducing
antiepileptics at randomisation (yes/no).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Key secondary
endpoints included time to angiomyolipoma progression and skin lesion response
rate.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A total of
118&nbsp;patients were randomised, 79 to Votubia 10&nbsp;mg daily and 39 to
placebo. Median age was 31&nbsp;years (range: 18 to 61&nbsp;years; 46.6% were
&lt;30&nbsp;years at enrolment), 33.9% were male, and 89.0% were Caucasian. Of
the enrolled patients, 83.1% had angiomyolipomas &#8805;4&nbsp;cm (28.8%
&#8805;8&nbsp;cm), 78.0% had bilateral angiomyolipomas, and 39.0% had undergone
prior renal embolisation/nephrectomy; 96.6% had skin lesions at baseline and
44.1% had target SEGAs (at least one SEGA &#8805;1&nbsp;cm in longest
diameter).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Results showed
that the primary objective related to best overall angiomyolipoma response was
met with best overall response rates of 41.8% (95% CI: 30.8, 53.4) for the
Votubia arm compared with 0% (95% CI: 0.0, 9.0) for the placebo arm (p&lt;0.0001)
(Table&nbsp;4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients
initially treated with placebo were allowed to cross over to everolimus at the
time of angiomyolipoma progression and upon recognition that treatment with
everolimus was superior to treatment with placebo. At the time of the final
analysis (4&nbsp;years following the last patient randomisation), the median
duration of exposure to everolimus was 204.1&nbsp;weeks (range 2 to 278). The
angiomyolipoma best overall response rate had increased to 58.0% (95% CI: 48.3,
67.3), with a rate of stable disease of 30.4% (Table&nbsp;4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Among patients
treated with everolimus during the study, no cases of angiomyolipoma-related
nephrectomy and only one case of renal embolisation were reported.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><a
name="_Toc303330260"></a><a name="_Toc58831468"></a><a name="_Toc94946163"><b><span
lang=EN-GB>Table</span></b></a><b><span lang=EN-GB>&nbsp;4       EXIST&#8209;2
- Angiomyolipoma response</span></b><a name="_4926571Table_54519Best_overall_an"></a></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid;height:14.35pt'>
  <td width=274 valign=top style='width:2.85in;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=255 colspan=3 valign=top style='width:191.35pt;border:none;
  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal align=center style='margin-right:-6.45pt;text-align:center;
  text-indent:-5.4pt;line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Primary analysis<sup>3</sup></span></b></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal align=center style='margin-right:-6.45pt;text-align:center;
  text-indent:-5.4pt;line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Final analysis<sup>4</sup></span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:14.35pt'>
  <td width=274 valign=top style='width:2.85in;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal align=center style='margin-right:-4.45pt;text-align:center;
  text-indent:-5.4pt;line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Votubia</span></b></p>
  </td>
  <td width=85 valign=top style='width:63.75pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>Placebo</span></b></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal align=center style='margin-right:-6.45pt;text-align:center;
  text-indent:-5.4pt;line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>p&#8209;value</span></b></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal align=center style='margin-right:-6.45pt;text-align:center;
  text-indent:-5.4pt;line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Votubia</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:14.35pt'>
  <td width=274 valign=top style='width:2.85in;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>n=79</span></b></p>
  </td>
  <td width=85 valign=top style='width:63.75pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>n=39</span></b></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>n=112</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:14.35pt'>
  <td width=529 colspan=4 valign=top style='width:396.55pt;border:none;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Primary analysis</span></b></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:14.35pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:14.35pt'>
  <td width=274 valign=top style='width:2.85in;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:14.35pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>     Angiomyolipoma response rate<sup>1,2</sup>  %</span></b></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>41.8</span></p>
  </td>
  <td width=85 valign=top style='width:63.75pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>0</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&lt;0.0001</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>58.0</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:14.35pt'>
  <td width=274 valign=top style='width:2.85in;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:14.35pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>     95% CI</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>30.8, 53.4</span></p>
  </td>
  <td width=85 valign=top style='width:63.75pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>0.0, 9.0</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>48.3, 67.3</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:14.35pt'>
  <td width=529 colspan=4 valign=top style='width:396.55pt;border:none;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Best overall angiomyolipoma response  %</span></b></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:14.35pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:14.35pt'>
  <td width=274 valign=top style='width:2.85in;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:14.35pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>     Response</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>41.8</span></p>
  </td>
  <td width=85 valign=top style='width:63.75pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>0</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:14.35pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:14.35pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>58.0</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:11.0pt'>
  <td width=274 valign=top style='width:2.85in;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:11.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>     Stable disease</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:11.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>40.5</span></p>
  </td>
  <td width=85 valign=top style='width:63.75pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:11.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>79.5</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:11.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:11.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>30.4</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:14.35pt'>
  <td width=274 valign=top style='width:2.85in;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:14.35pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>     Progression</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>1.3</span></p>
  </td>
  <td width=85 valign=top style='width:63.75pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>5.1</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:14.35pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:14.35pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>0.9</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:14.35pt'>
  <td width=274 valign=top style='width:2.85in;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:14.35pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>     Not evaluable</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>16.5</span></p>
  </td>
  <td width=85 valign=top style='width:63.75pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>15.4</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:14.35pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:14.35pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>10.7</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:54.85pt'>
  <td width=604 colspan=5 valign=top style='width:453.25pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt;height:54.85pt'>
  <p class=MsoNormal style='margin-left:28.55pt;text-indent:-28.55pt;
  line-height:normal;page-break-after:avoid'><sup><span lang=EN-GB>1</span></sup><span
  lang=EN-GB>        According to independent central radiology review</span></p>
  <p class=MsoNormal style='margin-left:28.55pt;text-indent:-28.55pt;
  line-height:normal;page-break-after:avoid'><sup><span lang=EN-GB>2</span></sup><span
  lang=EN-GB>        Angiomyolipoma responses were confirmed with a repeat
  scan. Response was defined as: &#8805;50% reduction in the sum of
  angiomyolipoma volume relative to baseline, plus absence of new
  angiomyolipoma &#8805;1.0&nbsp;cm in longest diameter, plus no increase in
  renal volume &gt;20% from nadir, plus absence of grade &#8805;2
  angiomyolipoma&#8209;related bleeding.</span></p>
  <p class=MsoNormal style='margin-left:28.55pt;text-indent:-28.55pt;
  line-height:normal;page-break-after:avoid'><sup><span lang=EN-GB>3                 </span></sup><span
  lang=EN-GB>Primary analysis for double blind period</span></p>
  <p class=MsoNormal style='margin-left:28.55pt;text-indent:-28.55pt;
  line-height:normal;page-break-after:avoid'><sup><span lang=EN-GB>4</span></sup><span
  lang=EN-GB>        Final analysis includes patients who crossed over from the
  placebo group; median duration of exposure to everolimus of 204.1&nbsp;weeks</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Consistent treatment effects on
angiomyolipoma response rate were observed across all subgroups evaluated (i.e.
enzyme&#8209;inducing antiepileptic use versus enzyme&#8209;inducing
antiepileptic non&#8209;use, sex, age and race) at the primary efficacy
analysis.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the final analysis, reduction in
angiomyolipoma volume improved with longer term treatment with Votubia. At
weeks&nbsp;12, 96 and 192, &#8805; 30% reductions in volume were observed in
75.0%, 80.6%, and 85.2% of the treated patients, respectively. Similarly, at the
same timepoints, &#8805;50% reductions in volume were observed in 44.2%, 63.3%,
and 68.9% of the treated patients, respectively.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Median time to angiomyolipoma progression
was 11.4&nbsp;months in the placebo arm and was not reached in the everolimus
arm (HR&nbsp;0.08; 95% CI: 0.02, 0.37; p&lt;0.0001). Progressions were observed
in 3.8% of patients in the everolimus arm compared with 20.5% in the placebo
arm. Estimated progression&#8209;free rates at 6&nbsp;months were 98.4% for the
everolimus arm and 83.4% for the placebo arm. At the final analysis, median
time to angiomyolipoma progression was not reached. Angiomyolipoma progressions
were observed in 14.3% of the patients. The estimated angiomyolipoma
progression-free rates at 24&nbsp;months and 48&nbsp;months were 91.6% and
83.1%, respectively.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>At the primary analysis, skin lesion
response rates of 26.0% (95% CI: 16.6, 37.2) for the Votubia arm and 0% (95%
CI: 0.0, 9.5) for the placebo arm were observed (p=0.0002). At the final
analysis, the skin lesion response rate had increased to 68.2% (95% CI: 58.5,
76.9), with one patient reporting a confirmed complete clinical skin lesion
response and no patients experiencing progressive disease as their best
response.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In an exploratory analysis of patients with
TSC with angiomyolipoma who also had SEGA, the SEGA response rate (proportion
of patients with &#8805;50% reduction from baseline in target lesion volumes in
the absence of progression) was 10.3% in the everolimus arm in the primary
analysis (versus no responses reported in the 13&nbsp;patients randomised to
placebo with a SEGA lesion at baseline) and increased to 48.0% in the final
analysis.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Post&#8209;hoc sub&#8209;group analysis of
EXIST&#8209;2 (study CRAD001M2302) carried out at time of primary analysis demonstrated
that angiomyolipoma response rate is reduced below the threshold of 5&nbsp;ng/ml
(Table&nbsp;5).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>Table&nbsp;5       EXIST&#8209;2
- Angiomyolipoma response rates by time&#8209;averaged C<sub>min</sub> category,
at primary analysis</span></b></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=168 valign=top style='width:125.9pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=X-NONE>Time</span></b><b>&#8209;</b><b><span
  lang=X-NONE>averaged C<sub>min</sub> category</span></b></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=X-NONE>Number of patients</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=X-NONE>Response rate</span></b></p>
  </td>
  <td width=198 valign=top style='width:148.8pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=X-NONE>95% confidence interval</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=168 valign=top style='width:125.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=X-NONE>&#8804;5</span><span lang=DE-CH>&nbsp;</span><span
  lang=X-NONE>ng/m</span><span lang=DE-CH>l</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=X-NONE>20</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=X-NONE>0.300</span></p>
  </td>
  <td width=198 valign=top style='width:148.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=X-NONE>0.099, 0.501</span></p>
  </td>
 </tr>
 <tr>
  <td width=168 valign=top style='width:125.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=X-NONE>&gt;5</span><span lang=DE-CH>&nbsp;</span><span
  lang=X-NONE>ng/m</span><span lang=DE-CH>l</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=X-NONE>42</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=X-NONE>0.524</span></p>
  </td>
  <td width=198 valign=top style='width:148.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=X-NONE>0.373, 0.675</span></p>
  </td>
 </tr>
 <tr>
  <td width=168 valign=top style='width:125.9pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=X-NONE>Difference<sup>1</sup></span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=X-NONE>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:normal;
  page-break-after:avoid'>&#8209;<span lang=X-NONE>0.224</span></p>
  </td>
  <td width=198 valign=top style='width:148.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:normal;
  page-break-after:avoid'>&#8209;<span lang=X-NONE>0.475, 0.027</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=4 valign=top style='width:459.0pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0in;margin-bottom:
  1.0pt;margin-left:0in;line-height:normal;page-break-after:avoid'><sup><span
  lang=X-NONE>1</span></sup><span lang=X-NONE> Difference is &#8804;5</span>&nbsp;<span
  lang=X-NONE>ng/m</span>l<span lang=X-NONE> minus &gt;5</span>&nbsp;<span
  lang=X-NONE>ng/m</span>l<span lang=X-NONE></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>SEGA associated with TSC</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Phase III study in SEGA patients</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXIST&#8209;1
(Study CRAD001M2301), a randomised, double&#8209;blind, multicentre phase III study
of Votubia versus placebo, was conducted in patients with SEGA, irrespective of
age. Patients were randomised in a 2:1&nbsp;ratio to receive either Votubia or
matching placebo. Presence of at least one SEGA lesion &#8805;1.0&nbsp;cm in
longest diameter using MRI (based on local radiology assessment) was required
for entry. In addition, serial radiological evidence of SEGA growth, presence
of a new SEGA lesion &#8805;1&nbsp;cm in longest diameter, or new or worsening
hydrocephalus was required for entry.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The primary
efficacy endpoint was SEGA response rate based on independent central radiology
review. The analysis was stratified by use of enzyme&#8209;inducing
antiepileptics at randomisation (yes/no).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Key secondary
endpoints in hierarchal order of testing included the absolute change in
frequency of total seizure events per 24&#8209;hour EEG from baseline to
week&nbsp;24, time to SEGA progression, and skin lesion response rate.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A total of
117&nbsp;patients were randomised, 78 to Votubia and 39 to placebo. The two
treatment arms were generally well balanced with respect to demographic and
baseline disease characteristics and history of prior anti&#8209;SEGA
therapies. In the total population, 57.3% of patients were male and 93.2% were
Caucasian. The median age for the total population was 9.5&nbsp;years (age range
for the Votubia arm: 1.0 to 23.9; age range for the placebo arm: 0.8 to 26.6),
69.2% of the patients were aged 3 to &lt;18&nbsp;years and 17.1% were
&lt;3&nbsp;years at enrolment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Of the enrolled
patients, 79.5% had bilateral SEGAs, 42.7% had &#8805;2&nbsp;target SEGA
lesions, 25.6% had inferior growth, 9.4% had evidence of deep parenchymal
invasion, 6.8% had radiographic evidence of hydrocephalus, and 6.8% had
undergone prior SEGA&#8209;related surgery. 94.0% had skin lesions at baseline
and 37.6% had target renal angiomyolipoma lesions (at least one angiomyolipoma
&#8805;1&nbsp;cm in longest diameter).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The median
duration of blinded study treatment was 9.6&nbsp;months (range: 5.5 to 18.1)
for patients receiving Votubia and 8.3&nbsp;months (range: 3.2 to 18.3) for
those receiving placebo.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Results showed
that Votubia was superior to placebo for the primary endpoint of best overall
SEGA response (p&lt;0.0001). Response rates were 34.6% (95% CI: 24.2, 46.2) for
the Votubia arm compared with 0% (95% CI: 0.0, 9.0) for the placebo arm
(Table&nbsp;6). In addition, all 8&nbsp;patients on the Votubia arm who had
radiographic evidence of hydrocephalus at baseline had a decrease in
ventricular volume.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients
initially treated with placebo were allowed to cross over to everolimus at the
time of SEGA progression and upon recognition that treatment with everolimus
was superior to treatment with placebo. All patients receiving at least one
dose of everolimus were followed until drug discontinuation or study
completion. At the time of the final analysis, the median duration of exposure
among all such patients was 204.9&nbsp;weeks (range: 8.1 to 253.7). The best
overall SEGA response rate had increased to 57.7% (95% CI: 47.9, 67.0) at the
final analysis.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No patient
required surgical intervention for SEGA during the entire course of the study.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Table&nbsp;6       EXIST&#8209;1  SEGA response</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=618
 style='border-collapse:collapse'>
 <thead>
  <tr style='page-break-inside:avoid;height:11.5pt'>
   <td width=297 valign=top style='width:222.75pt;border:none;border-top:solid black 1.0pt;
   background:white;padding:0in 3.0pt 0in 3.0pt;height:11.5pt'>
   <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
   avoid'><b>&nbsp;</b></p>
   </td>
   <td width=151 colspan=2 valign=top style='width:113.4pt;border:none;
   border-top:solid black 1.0pt;background:white;padding:0in 3.0pt 0in 3.0pt;
   height:11.5pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span style='color:black'>Primary analysis<sup>3</sup></span></b></p>
   </td>
   <td width=66 valign=top style='width:49.6pt;border-top:solid black 1.0pt;
   border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 3.0pt 0in 3.0pt;height:11.5pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b>&nbsp;</b></p>
   </td>
   <td width=104 valign=top style='width:77.95pt;border:none;border-top:solid black 1.0pt;
   background:white;padding:0in 3.0pt 0in 3.0pt;height:11.5pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span style='color:black'>Final analysis<sup>4</sup></span></b></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid;height:11.5pt'>
   <td width=297 valign=top style='width:222.75pt;border:none;border-top:solid black 1.0pt;
   background:white;padding:0in 3.0pt 0in 3.0pt;height:11.5pt'>
   <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
   avoid'><b>&nbsp;</b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border:none;border-top:solid black 1.0pt;
   background:white;padding:0in 3.0pt 0in 3.0pt;height:11.5pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span style='color:black'>Votubia</span></b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border:none;border-top:solid black 1.0pt;
   background:white;padding:0in 3.0pt 0in 3.0pt;height:11.5pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span style='color:black'>Placebo</span></b></p>
   </td>
   <td width=66 valign=top style='width:49.6pt;border-top:solid black 1.0pt;
   border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 3.0pt 0in 3.0pt;height:11.5pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span style='color:black'>p&#8209;value</span></b></p>
   </td>
   <td width=104 valign=top style='width:77.95pt;border:none;border-top:solid black 1.0pt;
   background:white;padding:0in 3.0pt 0in 3.0pt;height:11.5pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span style='color:black'>Votubia</span></b></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=297 valign=bottom style='width:222.75pt;background:white;
   padding:0in 3.0pt 0in 3.0pt'>
   <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
   avoid'><b>&nbsp;</b></p>
   </td>
   <td width=76 valign=bottom style='width:56.7pt;background:white;padding:
   0in 3.0pt 0in 3.0pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span style='color:black'>N=78</span></b></p>
   </td>
   <td width=76 valign=bottom style='width:56.7pt;background:white;padding:
   0in 3.0pt 0in 3.0pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span style='color:black'>N=39</span></b></p>
   </td>
   <td width=66 valign=bottom style='width:49.6pt;border:none;border-right:
   solid windowtext 1.0pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b>&nbsp;</b></p>
   </td>
   <td width=104 valign=top style='width:77.95pt;border:none;background:white;
   padding:0in 3.0pt 0in 3.0pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span style='color:black'>N=111</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width=297 valign=top style='width:222.75pt;border:none;border-top:solid windowtext 1.0pt;
  background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span style='color:black'>          SEGA response rate<sup>1,2</sup> -
  (%)</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-top:solid windowtext 1.0pt;
  background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>34.6</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-top:solid windowtext 1.0pt;
  background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>0</span></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>&lt;0.0001</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border:none;border-top:solid windowtext 1.0pt;
  background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>57.7</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=297 valign=top style='width:222.75pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span style='color:black'>          95% CI</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>24.2, 46.2</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>0.0, 9.0</span></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border:none;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border:none;background:white;
  padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>47.9, 67.0</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=297 valign=top style='width:222.75pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><b><span style='color:black'>Best overall SEGA response - (%)</span></b></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b>&nbsp;</b></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b>&nbsp;</b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border:none;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b>&nbsp;</b></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border:none;background:white;
  padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b>&nbsp;</b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=297 valign=top style='width:222.75pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span style='color:black'>          Response</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>34.6</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>0</span></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border:none;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border:none;background:white;
  padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>57.7</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=297 valign=top style='width:222.75pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span style='color:black'>          Stable disease</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>62.8</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>92.3</span></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border:none;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border:none;background:white;
  padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>39.6</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=297 valign=top style='width:222.75pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span style='color:black'>          Progression</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>0</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>7.7</span></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border:none;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border:none;background:white;
  padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>0</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=297 valign=top style='width:222.75pt;border:none;border-bottom:
  solid windowtext 1.0pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span style='color:black'>          Not evaluable</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>2.6</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>0</span></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border:none;border-bottom:solid windowtext 1.0pt;
  background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>2.7</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=618 colspan=5 valign=top style='width:463.7pt;border:none;
  background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal style='margin-left:10.9pt;text-indent:-10.9pt;line-height:
  normal;page-break-after:avoid'><sup><span style='color:black'>1</span></sup><span
  style='color:black'>   according to independent central radiology review</span></p>
  <p class=MsoNormal style='margin-left:10.9pt;text-indent:-10.9pt;line-height:
  normal;page-break-after:avoid'><sup><span style='color:black'>2</span></sup><span
  style='color:black'>   SEGA responses were confirmed with a repeat scan.
  Response was defined as: &#8805;50% reduction in the sum of SEGA volume
  relative to baseline, plus no unequivocal worsening of non&#8209;target SEGA
  lesions, plus absence of new SEGA &#8805;1&nbsp;cm in longest diameter, plus
  no new or worsening hydrocephalus</span></p>
  <p class=MsoNormal style='margin-left:10.9pt;text-indent:-10.9pt;line-height:
  normal;page-break-after:avoid'><sup><span style='color:black'>3</span></sup><span
  style='color:black'>   Primary analysis for double blind period</span></p>
  <p class=MsoNormal style='margin-left:10.9pt;text-indent:-10.9pt;line-height:
  normal;page-break-after:avoid'><sup><span style='color:black'>4</span></sup><span
  style='color:black'>   Final analysis includes patients who crossed over from
  the placebo group; median duration of exposure to everolimus of
  204.9&nbsp;weeks</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>Consistent treatment effects were
observed across all subgroups evaluated (i.e. <span lang=EN-GB>enzyme&#8209;inducing
antiepileptic</span> use versus <span lang=EN-GB>enzyme&#8209;inducing
antiepileptic</span> non&#8209;use, sex and age) at the primary analysis.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>During the double-blind period,
reduction of SEGA volume was evident within the initial 12&nbsp;weeks of
Votubia treatment: 29.7% (22/74) of patients had &#8805;50% reductions in
volume and 73.0% (54/74) had &#8805;30% reductions in volume. Sustained
reductions were evident at week&nbsp;24, 41.9% (31/74) of patients had
&#8805;50% reductions and 78.4% (58/74) of patients had &#8805;30% reductions
in SEGA volume.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>In the everolimus treated
population (N=111) of the study, including patients who crossed over from the
placebo group, tumour response, starting as early as after 12&nbsp;weeks on
everolimus, was sustained at later time points. The proportion of patients
achieving at least 50% reductions in SEGA volume was 45.9% (45/98) and 62.1%
(41/66) at weeks&nbsp;96 and 192 after start of everolimus treatment.
Similarly, the proportion of patients achieving at least 30% reductions in SEGA
volume was 71.4% (70/98) and 77.3% (51/66) at weeks&nbsp;96 and 192 after start
of everolimus treatment.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>Analysis of the first key
secondary endpoint, change in seizure frequency, was inconclusive; thus,
despite the fact that positive results were observed for the two subsequent
secondary endpoints (time to SEGA progression and skin lesion response rate),
they could not be declared formally statistically significant.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>Median time to SEGA progression
based on central radiology review was not reached in either treatment arm.
Progressions were only observed in the placebo arm (15.4%; p=0.0002). Estimated
progression&#8209;free rates at 6&nbsp;months were 100% for the Votubia arm and
85.7% for the placebo arm. The long-term follow-up of patients randomised to
everolimus and patients randomised to placebo who thereafter crossed over to
everolimus demonstrated durable responses.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>At the time of the primary
analysis, Votubia demonstrated clinically meaningful improvements in skin
lesion response (p=0.0004), with response rates of 41.7% (95% CI: 30.2, 53.9)
for the Votubia arm and 10.5% (95% CI: 2.9, 24.8) for the placebo arm. At the
final analysis, the skin lesion response rate increased to 58.1% (95% CI: 48.1,
67.7).</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Phase II study in patients with SEGA</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A prospective,
open&#8209;label, single&#8209;arm phase II study (Study CRAD001C2485) was
conducted to evaluate the safety and efficacy of Votubia in patients with SEGA.
Radiological evidence of serial SEGA growth was required for entry.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Change in SEGA
volume during the core 6&#8209;month treatment phase, as assessed via an
independent central radiology review, was the primary efficacy endpoint. After
the core treatment phase, patients could be enrolled into an extension phase
where SEGA volume was assessed every 6&nbsp;months.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In total,
28&nbsp;patients received treatment with Votubia; median age was 11&nbsp;years
(range 3 to 34), 61% male, 86% Caucasian. Thirteen patients (46%) had a
secondary smaller SEGA, including 12 in the contralateral ventricle.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Primary SEGA
volume was reduced at month&nbsp;6 compared to baseline (p&lt;0.001 [see Table&nbsp;7]).
No patient developed new lesions, worsening hydrocephalus or increased
intracranial pressure, and none required surgical resection or other therapy
for SEGA.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Table&nbsp;7       Change in primary SEGA volume over time</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=612
 style='border-collapse:collapse;border:none'>
 <tr style='height:10.4pt'>
  <td width=83 valign=top style='width:62.1pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:10.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>SEGA
  volume (cm<sup>3</sup>)</b></p>
  </td>
  <td width=529 colspan=7 valign=top style='width:396.85pt;border:none;
  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>Independent
  central review</b></p>
  </td>
 </tr>
 <thead>
  <tr style='height:23.6pt'>
   <td width=83 valign=top style='width:62.1pt;border:none;border-bottom:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:23.6pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>&nbsp;</b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:23.6pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b>Baseline</b></p>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b>n=28</b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:23.6pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b>Month&nbsp;6</b></p>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b>n=27</b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:23.6pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b>Month&nbsp;12</b></p>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b>n=26</b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:23.6pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b>Month&nbsp;24</b></p>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b>n=24</b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:23.6pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b>Month&nbsp;36</b></p>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b>n=23</b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:23.6pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b>Month&nbsp;48</b></p>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b>n=24</b></p>
   </td>
   <td width=76 valign=top style='width:56.65pt;border:none;border-bottom:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:23.6pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b>Month&nbsp;60</b></p>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b>n=23</b></p>
   </td>
  </tr>
 </thead>
 <tr style='height:11.15pt'>
  <td width=612 colspan=8 valign=top style='width:458.95pt;border:none;
  padding:0in 5.4pt 0in 5.4pt;height:11.15pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>Primary
  tumour volume</b></p>
  </td>
 </tr>
 <tr style='height:15.2pt'>
  <td width=83 valign=top style='width:62.1pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>Mean
  (standard deviation)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>2.45 (2.813)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1.33 (1.497)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1.26 (1.526)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1.19 (1.042)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1.26 (1.298)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1.16 (0.961)</p>
  </td>
  <td width=76 valign=top style='width:56.65pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1.24 (0.959)</p>
  </td>
 </tr>
 <tr style='height:15.2pt'>
  <td width=83 valign=top style='width:62.1pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>Median</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1.74</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.93</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.84</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.94</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1.12</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1.02</p>
  </td>
  <td width=76 valign=top style='width:56.65pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1.17</p>
  </td>
 </tr>
 <tr style='height:15.2pt'>
  <td width=83 valign=top style='width:62.1pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>     Range</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.49 - 14.23</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.31 - 7.98</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.29 - 8.18</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.20 - 4.63</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.22 - 6.52</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.18 - 4.19</p>
  </td>
  <td width=76 valign=top style='width:56.65pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.21 - 4.39</p>
  </td>
 </tr>
 <tr style='height:15.2pt'>
  <td width=612 colspan=8 valign=top style='width:458.95pt;border:none;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>Reduction
  from baseline</b></p>
  </td>
 </tr>
 <tr style='height:15.2pt'>
  <td width=83 valign=top style='width:62.1pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>Mean
  (standard deviation)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1.19 (1.433)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1.07 (1.276)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1.25 (1.994)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1.41 (1.814)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1.43 (2.267)</p>
  </td>
  <td width=76 valign=top style='width:56.65pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1.44 (2.230)</p>
  </td>
 </tr>
 <tr style='height:15.2pt'>
  <td width=83 valign=top style='width:62.1pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>Median</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.83</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.85</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.71</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.71</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.83</p>
  </td>
  <td width=76 valign=top style='width:56.65pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.50</p>
  </td>
 </tr>
 <tr style='height:15.2pt'>
  <td width=83 valign=top style='width:62.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>     Range</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.06 - 6.25</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.02 - 6.05</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>-0.55 - 9.60</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.15 - 7.71</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.00 - 10.96</p>
  </td>
  <td width=76 valign=top style='width:56.65pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>-0.74 - 9.84</p>
  </td>
 </tr>
 <tr style='height:15.2pt'>
  <td width=612 colspan=8 valign=top style='width:458.95pt;border:none;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>Percentage
  reduction from baseline, n (%)</b></p>
  </td>
 </tr>
 <tr style='height:15.2pt'>
  <td width=83 valign=top style='width:62.1pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>     &#8805;50%</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>9 (33.3)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>9 (34.6)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>12 (50.0)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>10 (43.5)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>14 (58.3)</p>
  </td>
  <td width=76 valign=top style='width:56.65pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>12 (52.2)</p>
  </td>
 </tr>
 <tr style='height:15.2pt'>
  <td width=83 valign=top style='width:62.1pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>     &#8805;30%</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>21 (77.8)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>20 (76.9)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>19 (79.2)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>18 (78.3)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>19 (79.2)</p>
  </td>
  <td width=76 valign=top style='width:56.65pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>14 (60.9)</p>
  </td>
 </tr>
 <tr style='height:15.2pt'>
  <td width=83 valign=top style='width:62.1pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>     &gt;0%</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>27</p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>(100.0)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>26</p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>(100.0)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>23</p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>(95.8)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>23</p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>(100.0)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>23</p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>(95.8)</p>
  </td>
  <td width=76 valign=top style='width:56.65pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>21</p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>(91.3)</p>
  </td>
 </tr>
 <tr style='height:15.2pt'>
  <td width=83 valign=top style='width:62.1pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;line-height:
  normal;page-break-after:avoid'>     No change</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1 (4.2)</p>
  </td>
  <td width=76 valign=top style='width:56.65pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0</p>
  </td>
 </tr>
 <tr style='height:15.2pt'>
  <td width=83 valign=top style='width:62.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>     Increase</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1 (4.2)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0</p>
  </td>
  <td width=76 valign=top style='width:56.65pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>2 (8.7)</p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The robustness and consistency of the primary analysis were
supported by the:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>change in primary SEGA volume as per local
investigator assessment (p&lt;0.001), with 75.0% and 39.3% of patients
experiencing reductions of &#8805;30% and &#8805;50%, respectively</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>change in total SEGA volume as per independent
central review (p&lt;0.001) or local investigator assessment (p&lt;0.001).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>One patient met
the pre&#8209;specified criteria for treatment success (&gt;75% reduction in
SEGA volume) and was temporarily taken off trial therapy; however, SEGA re&#8209;growth
was evident at the next assessment at 4.5&nbsp;months and treatment was
restarted.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Long&#8209;term
follow&#8209;up to a median duration of 67.8&nbsp;months (range: 4.7 to 83.2)
demonstrated sustained efficacy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Other studies</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Stomatitis is
the most commonly reported adverse reaction in patients treated with Votubia
(see sections&nbsp;4.4 and 4.8). </span><span lang=EN-GB>In a post-marketing
single-arm study in postmenopausal women with advanced </span><span lang=EN-GB
style='font-size:11.5pt'>breast cancer (N=92), topical treatment with
dexamethasone 0.5&nbsp;mg/5&nbsp;ml alcohol-free oral solution was administered
as a mouthwash </span><span lang=EN-GB>(4&nbsp;times daily for the initial
8&nbsp;weeks of treatment)</span><span lang=EN-GB style='font-size:11.5pt'> to
patients at the time of initiating treatment with Afinitor (everolimus,
10&nbsp;mg/day) plus exemestane (25&nbsp;mg/day) to reduce the incidence and
severity of stomatitis. The incidence of Grade&nbsp;&#8805;2 stomatitis at
8&nbsp;weeks was 2.4% (n=2/85&nbsp;evaluable patients) which was lower than
historically reported. The incidence of Grade&nbsp;1 stomatitis was 18.8%
(n=16/85) and no cases of Grade&nbsp;3 or 4 stomatitis were reported. The
overall safety profile in this study was consistent with that established for
everolimus in the oncology and TSC settings, with the exception of a slightly
increased frequency of oral candidiasis which was reported in 2.2% (n=2/92) of
patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The European
Medicines Agency has</span><span lang=EN-GB> waived the obligation to submit
the results of studies with Votubia in all subsets of the paediatric population
in angiomyolipoma (see section&nbsp;4.2 for information on paediatric use).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The European
Medicines Agency has deferred the obligation to submit the results of studies
with Votubia in one or more subsets of the paediatric population in refractory
epilepsy associated with tuberous sclerosis complex (see section&nbsp;4.2 for
information on paediatric use).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>5.2     Pharmacokinetic properties</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Absorption</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In patients with
advanced solid tumours, peak everolimus concentrations (C<sub>max</sub>) are
reached at a median time of 1&nbsp;hour after daily administration of 5 and
10&nbsp;mg everolimus under fasting conditions or with a light fat&#8209;free
snack. C<sub>max</sub> is dose&#8209;proportional between 5 and 10&nbsp;mg.
Everolimus is a substrate and moderate inhibitor of PgP.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Food effect</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In healthy
subjects, high fat meals reduced systemic exposure to Votubia 10&nbsp;mg
tablets (as measured by AUC) by 22% and the peak blood concentration C<sub>max</sub>
by 54%. Light fat meals reduced AUC by 32% and C<sub>max </sub>by 42%.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In healthy
subjects taking a single 9&nbsp;mg dose (3 x 3&nbsp;mg) of Votubia dispersible
tablets in suspension, high fat meals reduced AUC by 11.7% and the peak blood
concentration C<sub>max</sub> by 59.8%. Light fat meals reduced AUC by 29.5%
and C<sub>max</sub> by 50.2%.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Food, however,
had no apparent effect on the post absorption phase concentration&#8209;time
profile 24&nbsp;hours post-dose of either dosage form.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Relative bioavailability/bioequivalence</span></u></i></p>

<p class=MsoNormal style='line-height:normal'>In a relative bioavailability
study,<span style='color:#4F81BD'> </span>AUC<sub>0&#8209;inf</sub> of 5 x
1&nbsp;mg everolimus tablets when administered as suspension in water was
equivalent to 5 x 1&nbsp;mg everolimus tablets administered as intact tablets,
and C<sub>max</sub> of 5 x 1&nbsp;mg everolimus tablets in suspension was 72%
of 5 x 1&nbsp;mg intact everolimus tablets.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>In a bioequivalence study,<span
style='color:#4F81BD'> </span>AUC<sub>0&#8209;inf</sub> of the 5&nbsp;mg
dispersible tablet when administered as suspension in water was equivalent to 5
x 1&nbsp;mg intact everolimus tablets, and C<sub>max</sub> of the 5&nbsp;mg
dispersible tablet in suspension was 64% of 5 x 1&nbsp;mg intact everolimus
tablets.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Distribution</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The blood&#8209;to&#8209;plasma
ratio of everolimus, which is concentration&#8209;dependent over the range of 5
to 5,000&nbsp;ng/ml, is 17% to 73%. </span><span lang=EN-GB>Approximately 20%
of the everolimus concentration in whole blood is confined to plasma of cancer
patients given Votubia 10&nbsp;mg/day. </span><span lang=EN-GB>Plasma protein
binding is approximately 74% both in healthy subjects and in patients with
moderate hepatic impairment. In patients with advanced solid tumours, V<sub>d</sub>
was 191&nbsp;l for the apparent central compartment and 517&nbsp;l for the
apparent peripheral compartment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Nonclinical studies in rats indicate:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>A rapid uptake of everolimus in the brain followed by a slow
efflux.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>The radioactive metabolites of [3H]everolimus do not
significantly cross the blood&#8209;brain barrier.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>A dose&#8209;dependent brain penetration of everolimus, which is
consistent with the hypothesis of saturation of an efflux pump present in the
brain capillary endothelial cells.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>The co&#8209;administration of the PgP inhibitor, cyclosporine,
enhances the exposure of everolimus in the brain cortex, which is consistent
with the inhibition of PgP at the blood&#8209;brain barrier.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span style='color:black'>There
are no clinical data on the distribution of everolimus in the human brain. </span><span
lang=EN-GB>Non&#8209;clinical studies in rats demonstrated distribution into
the brain following administration by both the intravenous and oral routes.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Biotransformation</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Everolimus is a
substrate of CYP3A4 and PgP. Following oral administration, everolimus is the
main circulating component in human blood. Six main metabolites of everolimus
have been detected in human blood, including three monohydroxylated
metabolites, two hydrolytic ring&#8209;opened products, and a
phosphatidylcholine conjugate of everolimus. These metabolites were also
identified in animal species used in toxicity studies, and showed approximately
100&nbsp;times less activity than everolimus itself. Hence, everolimus is
considered to contribute the majority of the overall pharmacological activity.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Elimination</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Mean CL/F of
everolimus after 10&nbsp;mg daily dose in patients with advanced solid tumours
was 24.5&nbsp;l/h. The mean elimination half&#8209;life of everolimus is approximately
30&nbsp;hours.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No specific
excretion studies have been undertaken in cancer patients; however, data are
available from the studies in transplant patients. Following the administration
of a single dose of radiolabelled everolimus in conjunction with ciclosporin,
80% of the radioactivity was recovered from the faeces, while 5% was excreted
in the urine. The parent substance was not detected in urine or faeces.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Steady&#8209;state pharmacokinetics</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After
administration of everolimus in patients with advanced solid tumours, steady&#8209;state
AUC<sub>0&#8209;&#964;</sub> was dose&#8209;proportional over the range of 5 to
10&nbsp;mg daily dose. Steady&#8209;state was achieved within 2&nbsp;weeks. C<sub>max</sub>
is dose&#8209;proportional between 5 and 10&nbsp;mg. t<sub>max</sub> occurs at
1 to 2&nbsp;hours post&#8209;dose. There was a significant correlation between
AUC<sub>0&#8209;&#964;</sub> and pre&#8209;dose trough concentration at steady&#8209;state.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Special populations</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Hepatic impairment</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The safety,
tolerability and pharmacokinetics of Votubia were evaluated in two single oral
dose studies of Votubia tablets in 8 and 34&nbsp;adult subjects with impaired
hepatic function relative to subjects with normal hepatic function.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the first
study, the average AUC of everolimus in 8&nbsp;subjects with moderate hepatic
impairment (Child-Pugh B) was twice that found in 8&nbsp;subjects with normal
hepatic function.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the second
study of 34&nbsp;subjects with different impaired hepatic function compared to
normal subjects, there was a 1.6&#8209;fold, 3.3&#8209;fold and 3.6&#8209;fold
increase in exposure (i.e. AUC<sub>0&#8209;inf</sub>) for subjects with mild
(Child&#8209;Pugh A), moderate (Child&#8209;Pugh B) and severe (Child&#8209;Pugh
C) hepatic impairment, respectively.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Simulations of
multiple dose pharmacokinetics support the dosing recommendations in subjects
with hepatic impairment based on their Child&#8209;Pugh status.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Based on the
results of the two studies, dose adjustment is recommended for patients with
hepatic impairment (see sections&nbsp;4.2 and 4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Renal impairment</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In a population
pharmacokinetic analysis of 170&nbsp;patients with advanced solid tumours, no
significant influence of creatinine clearance (25&#8209;178&nbsp;ml/min) was
detected on CL/F of everolimus. Post&#8209;transplant renal impairment (creatinine
clearance range 11&#8209;107&nbsp;ml/min) did not affect the pharmacokinetics
of everolimus in transplant patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Paediatric population</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In patients with
SEGA, everolimus C<sub>min</sub> was approximately dose&#8209;proportional
within the dose range from 1.35&nbsp;mg/m<sup>2</sup> to 14.4&nbsp;mg/m<sup>2</sup>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In patients with
SEGA, the geometric mean C<sub>min</sub> values normalised to mg/m<sup>2</sup>
dose in patients aged &lt;10&nbsp;years and 10&#8209;18&nbsp;years were lower by
54% and 40%, respectively, than those observed in adults (&gt;18&nbsp;years of
age), suggesting that everolimus clearance was higher in younger patients.
Limited data in patients &lt;3&nbsp;years of age (n=13) indicate that BSA&#8209;normalised
clearance is about two&#8209;fold higher in patients with low BSA (BSA of 0.556&nbsp;m<sup>2</sup>)
than in adults. Therefore it is assumed that steady&#8209;state could be
reached earlier in patients &lt;3&nbsp;years of age (see section&nbsp;4.2 for
dosing recommendations).</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>The pharmacokinetics of
everolimus have not been studied in patients younger than 1&nbsp;year of age.
It is reported, however, that CYP3A4 activity is reduced at birth and increases
during the first year of life, which could affect the clearance in this patient
population.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>A population pharmacokinetic
analysis including 111&nbsp;patients with SEGA who ranged from 1.0 to
27.4&nbsp;years (including 18&nbsp;patients 1 to less than 3&nbsp;years of age with
BSA 0.42&nbsp;m<sup>2</sup> to 0.74&nbsp;m<sup>2</sup>) showed that
BSA-normalised clearance is in general higher in younger patients. Population
pharmacokinetic model simulations showed that a starting dose of 7&nbsp;mg/m<sup>2</sup>
would be necessary to attain C<sub>min</sub> within the 5 to 15&nbsp;ng/ml
range in patients younger than 3&nbsp;years of age. A higher starting dose of
7&nbsp;mg/m<sup>2</sup> is therefore recommended for patients 1 to less than 3&nbsp;years
of age with SEGA (see section&nbsp;4.2).</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Elderly</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In a population
pharmacokinetic evaluation in cancer patients, no significant influence of age
(27&#8209;85&nbsp;years) on oral clearance of everolimus was detected.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Ethnicity</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral clearance
(CL/F) is similar in Japanese and Caucasian cancer patients with similar liver
functions. Based on analysis of population pharmacokinetics, oral clearance
(CL/F) is on average 20% higher in black transplant patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>5.3     Preclinical safety data</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The non&#8209;clinical
safety profile of everolimus was assessed in mice, rats, minipigs, monkeys and
rabbits. The major target organs were male and female reproductive systems
(testicular tubular degeneration, reduced sperm content in epididymides and
uterine atrophy) in several species; lungs (increased alveolar macrophages) in rats
and mice; </span><span lang=EN-GB>pancreas (degranulation and vacuolation of
exocrine cells in monkeys and minipigs, respectively, and degeneration of islet
cells in monkeys), </span><span lang=EN-GB>and eyes (lenticular anterior suture
line opacities) in rats only. Minor kidney changes were seen in the rat
(exacerbation of age&#8209;related lipofuscin in tubular epithelium, increases
in hydronephrosis) and mouse (exacerbation of background lesions). There was no
indication of kidney toxicity in monkeys or minipigs.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Everolimus
appeared to spontaneously exacerbate background diseases (chronic myocarditis
in rats, coxsackie virus infection of plasma and heart in monkeys, coccidian
infestation of the gastrointestinal tract in minipigs, skin lesions in mice and
monkeys). These findings were generally observed at systemic exposure levels
within the range of therapeutic exposure or above, with the exception of the
findings in rats, which occurred below therapeutic exposure due to a high
tissue distribution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In a male fertility
study in rats, testicular morphology was affected at 0.5&nbsp;mg/kg and above,
and sperm motility, sperm head count, and plasma testosterone levels were
diminished at 5&nbsp;mg/kg, which is within the range of therapeutic exposure
and which caused a reduction in male fertility. There was evidence of
reversibility.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In animal
reproductive studies female fertility was not affected. However, oral doses of
everolimus in female rats at &#8805; 0.1&nbsp;mg/kg (approximately 4% of the
AUC<sub>0-24h</sub> in patients receiving the 10&nbsp;mg daily dose) resulted
in increases in pre-implantation loss.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Everolimus
crossed the placenta and was toxic to the foetus. In rats, everolimus caused
embryo/foetotoxicity at systemic exposure below the therapeutic level. This was
manifested as mortality and reduced foetal weight. The incidence of skeletal
variations and malformations (e.g. sternal cleft) was increased at 0.3 and
0.9&nbsp;mg/kg. In rabbits, embryotoxicity was evident in an increase in late
resorptions.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In juvenile rat
toxicity studies, systemic toxicity included decreased body weight gain, food
consumption, and delayed attainment of some developmental landmarks, with full
or partial recovery after cessation of dosing. With the possible exception of
the rat&#8209;specific lens finding (where young animals appeared to be more
susceptible), it appears that there is no significant difference in the
sensitivity of juvenile animals to the adverse reactions of everolimus as
compared to adult animals. Toxicity study with juvenile monkeys did not show
any relevant toxicity.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Genotoxicity
studies covering relevant genotoxicity endpoints showed no evidence of
clastogenic or mutagenic activity. Administration of everolimus for up to
2&nbsp;years did not indicate any oncogenic potential in mice and rats up to
the highest doses, corresponding respectively to 4.3 and 0.2&nbsp;times the
estimated clinical exposure.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.       PHARMACEUTICAL PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.1     List of excipients</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Butylated hydroxytoluene (E321)</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Magnesium stearate</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Lactose monohydrate</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Hypromellose</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Crospovidone type A</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lactose
anhydrous</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.2     Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not applicable.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.3     Shelf life</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>3&nbsp;years.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.4     Special precautions for storage</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not store
above 25°C. Store in the original package in order to protect from light and
moisture.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.5     Nature and contents of container</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aluminium/polyamide/aluminium/PVC
perforated unit-dose blister containing 10&nbsp;x&nbsp;1&nbsp;tablets.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Votubia 2.5&nbsp;mg tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Packs containing
10&nbsp;x&nbsp;1, 30&nbsp;x&nbsp;1 or 100&nbsp;x&nbsp;1&nbsp;tablets.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Votubia 5&nbsp;mg tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Packs containing
30&nbsp;x&nbsp;1 or 100&nbsp;x&nbsp;1&nbsp;tablets.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Votubia 10&nbsp;mg tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Packs containing
10&nbsp;x&nbsp;1, 30&nbsp;x&nbsp;1 or 100&nbsp;x&nbsp;1&nbsp;tablets.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not all pack
sizes may be marketed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.6     Special precautions for disposal and other handling</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The extent of
absorption of everolimus through topical exposure is not known. Therefore
caregivers are advised to avoid contact with the suspension. Hands should be washed
thoroughly before and after preparation of the suspension.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Any unused medicinal
product or waste material should be disposed of in accordance with local
requirements.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>7.       MARKETING AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ireland</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>8.       MARKETING AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=FR-CH>Votubia 2.5&nbsp;mg tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>EU/1/11/710/001&#8209;003</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=FR-CH>Votubia 5&nbsp;mg tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>EU/1/11/710/004&#8209;005</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=FR-CH>Votubia 10&nbsp;mg tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>EU/1/11/710/006&#8209;008</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Date of first authorisation: </span><span lang=EN-GB>02 September
2011</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of latest renewal:</span><span
lang=EN-GB> 28 July 2015</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>10.     DATE OF REVISION OF
THE TEXT</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Detailed information on this medicinal product </span><span
lang=EN-GB style='color:black'>is available on the website of the European
Medicines Agency </span><span lang=EN-GB><a href="http://www.ema.europa.eu">http://www.ema.europa.eu</a></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia
1&nbsp;mg dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>Votubia
2&nbsp;mg dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>Votubia
3&nbsp;mg dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>Votubia
5&nbsp;mg dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=FR-CH>2.       QUALITATIVE AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=FR-CH>Votubia 1&nbsp;mg dispersible tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>Each dispersible
tablet contains 1&nbsp;mg everolimus.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=FR-CH>Excipient with known effect</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>Each dispersible
tablet contains 0.98&nbsp;mg lactose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=FR-CH>Votubia 2&nbsp;mg dispersible tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>Each dispersible
tablet contains 2&nbsp;mg everolimus.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=FR-CH>Excipient with known effect</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>Each dispersible
tablet contains 1.96&nbsp;mg lactose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=FR-CH>Votubia 3&nbsp;mg dispersible tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>Each dispersible
tablet contains 3&nbsp;mg everolimus.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=FR-CH>Excipient with known effect</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>Each dispersible
tablet contains 2.94&nbsp;mg lactose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=FR-CH>Votubia 5&nbsp;mg dispersible tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>Each dispersible
tablet contains 5&nbsp;mg everolimus.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=FR-CH>Excipient with known effect</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>Each dispersible
tablet contains 4.90&nbsp;mg lactose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the full
list of excipients, see section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>3.       PHARMACEUTICAL FORM</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Dispersible
tablet.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Votubia 1&nbsp;mg dispersible tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>White to
slightly yellowish, round, flat tablets of approximately 7.1&nbsp;mm in
diameter, with a bevelled edge and no score, engraved with D1 on one side and
NVR on the other.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Votubia 2&nbsp;mg dispersible tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>White to
slightly yellowish, round, flat tablets of approximately 9.1&nbsp;mm in
diameter, with a bevelled edge and no score, engraved with D2 on one side and
NVR on the other.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Votubia 3&nbsp;mg dispersible tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>White to
slightly yellowish, round, flat tablets of approximately 10.1&nbsp;mm in
diameter, with a bevelled edge and no score, engraved with D3 on one side and
NVR on the other.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Votubia 5&nbsp;mg dispersible tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>White to
slightly yellowish, round, flat tablets of approximately 12.1&nbsp;mm in
diameter, with a bevelled edge and no score, engraved with D5 on one side and
NVR on the other.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB style='text-transform:uppercase'>4.       Clinical particulars</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.1     Therapeutic indications</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Refractory seizures associated with tuberous sclerosis complex (TSC)</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia is
indicated as adjunctive treatment of patients aged 2&nbsp;years and older whose
refractory partial onset seizures, with or without secondary generalisation,
are associated with tuberous sclerosis complex (TSC).</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Subependymal giant cell astrocytoma (SEGA) associated with tuberous
sclerosis complex (TSC)</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia is
indicated for the </span><span lang=EN-GB>treatment of adult and paediatric patients
with subependymal giant cell astrocytoma (SEGA) associated with tuberous
sclerosis complex (TSC) who require therapeutic intervention but are not
amenable to surgery.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The evidence is
based on analysis of change in SEGA volume. Further clinical benefit, such as
improvement in disease&#8209;related symptoms, has not been demonstrated.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.2     Posology and method
of administration</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment with
Votubia should be initiated by a physician experienced in the treatment of patients
with TSC and therapeutic drug monitoring.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Careful
titration may be required to obtain the optimal therapeutic effect. Doses that
will be tolerated and effective vary between patients. Concomitant
antiepileptic therapy may affect the metabolism of everolimus and may
contribute to this variance (see section&nbsp;4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Dosing is
individualised based on Body Surface Area (BSA) using the Dubois formula, where
weight (W) is in kilograms and height (H) is in centimetres:</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>BSA = (W<sup>0.425</sup> x H<sup>0.725</sup>) x 0.007184</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Starting dose and target trough concentrations in SEGA associated
with TSC</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The recommended
starting dose for Votubia for the treatment of patients with SEGA is
4.5&nbsp;mg/m<sup>2</sup>. A higher starting dose of 7&nbsp;mg/m<sup>2</sup> is
recommended for patients 1 to less than 3&nbsp;years of age based on
pharmacokinetic simulations (see section&nbsp;5.2). Different strengths of
Votubia dispersible tablets can be combined to attain the desired dose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Dosing
recommendations for paediatric patients with SEGA are consistent with those for
the adult SEGA population, except for patients in the range from 1&nbsp;year to
less than 3&nbsp;years of age, and those with hepatic impairment (see section&nbsp;Hepatic
impairment below and section&nbsp;5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Starting dose and target trough concentrations in TSC with refractory
seizures</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The recommended
starting dose for Votubia for the treatment of patients with seizures is shown
in Table&nbsp;1. </span><span lang=EN-GB>Different strengths of Votubia
dispersible tablets can be combined to attain the desired dose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>Table&nbsp;1       Votubia
starting dose for patients with TSC and refractory seizures</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=628
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=191 valign=top style='width:143.55pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Age</span></b></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Starting dose
  without co&#8209;administration of CYP3A4/PgP inducer</span></b></p>
  </td>
  <td width=220 valign=top style='width:164.7pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Starting dose
  with co&#8209;administration of CYP3A4/PgP inducer</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=191 valign=top style='width:143.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&lt;6&nbsp;years</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>6&nbsp;mg/m<sup>2</sup></span></p>
  </td>
  <td width=220 valign=top style='width:164.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>9&nbsp;mg/m<sup>2</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=191 valign=top style='width:143.55pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&#8805;6&nbsp;years</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>5&nbsp;mg/m<sup>2</sup></span></p>
  </td>
  <td width=220 valign=top style='width:164.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>8&nbsp;mg/m<sup>2</sup></span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Dosing
recommendations for paediatric patients with seizures are consistent with those
for the adult population, except for patients in the range from 2&nbsp;years to
less than 6&nbsp;years of age (see Table&nbsp;1 above), and those with hepatic
impairment (see section&nbsp;Hepatic impairment below and section&nbsp;5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Dose monitoring</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Everolimus whole
blood trough concentrations should be assessed at least 1&nbsp;week after
commencing treatment. Dosing should be titrated to attain trough concentrations
of 5 to 15&nbsp;ng/ml. </span>The dose may be increased to attain a higher
trough concentration within the target range to obtain optimal efficacy,
subject to tolerability.</p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Titration</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Individualised
dosing should be titrated by increasing the dose by increments of 1 to
4&nbsp;mg to attain the target trough concentration for optimal clinical
response. Efficacy, safety, concomitant therapy, and the current trough
concentration should be considered when planning for dose titration.
Individualised dose titration can be based on simple proportion:</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>New everolimus dose = current dose x (target concentration / current
concentration)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For example, a
patients current dose based on BSA is 4&nbsp;mg with a steady-state
concentration of 4&nbsp;ng/ml. In order to achieve a target concentration above
the lower C<sub>min</sub> limit of 5&nbsp;ng/ml, e.g. 8&nbsp;ng/ml, the new
everolimus dose would be 8&nbsp;mg (an increase of 4&nbsp;mg from the current
daily dose).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Long-term monitoring</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For patients
with TSC who have SEGA, SEGA volume should be evaluated approximately
3&nbsp;months after commencing Votubia therapy, with subsequent dose
adjustments taking changes in SEGA volume, corresponding trough concentration,
and tolerability into consideration.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For patients
with TSC who have SEGA and patients with TSC and refractory seizures, once a
stable dose is attained, trough concentrations should be monitored every 3 to
6&nbsp;months in patients with changing body surface area, or every 6 to
12&nbsp;months in patients with stable body surface area, for the duration of
treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment should
continue as long as clinical benefit is observed or until unacceptable toxicity
occurs.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If a dose is
missed, the patient should not take an additional dose, but take the usual
prescribed next dose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Dose adjustments due to adverse reactions</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Management of severe and/or intolerable suspected adverse reactions
may require dose reduction and/or temporary interruption of Votubia therapy. <span
style='color:black'>For adverse reactions of Grade&nbsp;1, dose adjustment is
usually not required.</span> If dose reduction is required, the recommended
dose is </span><span lang=EN-GB>approximately 50% lower than the daily dose
previously administered</span><span lang=EN-GB>. For dose reductions below the
lowest available strength, alternate day dosing should be considered.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
style='color:black'>Table&nbsp;2 summarises dose adjustment recommendations for
specific adverse reactions (see also section&nbsp;4.4).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><b><span lang=EN-GB>Table&nbsp;2       </span></b><b>Votubia
dose adjustment recommendations</b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>&nbsp;</p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=639
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Adverse </span></b><b><span
  lang=DE-CH style='font-size:11.0pt;font-family:"Times New Roman",serif'>r</span></b><b><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>eaction</span></b></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Severity<sup>1</sup></span></b></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Votubia </span></b><b><span
  lang=DE-CH style='font-size:11.0pt;font-family:"Times New Roman",serif'>d</span></b><b><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>ose </span></b><b><span
  lang=DE-CH style='font-size:11.0pt;font-family:"Times New Roman",serif'>a</span></b><b><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>djustment</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Non&#8209;infectious
  pneumonitis</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;2</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Consider
  interruption of therapy until symptoms improve to Grade&nbsp;</span><span
  style='font-size:11.0pt;font-family:Symbol'>£</span><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>1.</span></p>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Re&#8209;initiate
  Votubia at approximately 50% lower than the daily dose previously
  administered.</span></p>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Discontinue
  treatment if failure to recover within </span><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>4</span><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;weeks.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;3</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Interrupt
  Votubia until symptoms resolve to Grade&nbsp;</span><span style='font-size:
  11.0pt;font-family:Symbol'>£</span><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>1.</span></p>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Consider re&#8209;initiating
  Votubia at approximately 50% lower than the daily dose previously
  administered. If toxicity recurs at Grade&nbsp;3, consider discontinuation.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;4</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.35pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Discontinue Votubia.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Stomatitis</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;2</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Temporary dose
  interruption until recovery to Grade&nbsp;</span><span style='font-size:11.0pt;
  font-family:Symbol'>£</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>1.</span></p>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Re&#8209;initiate
  Votubia at same dose.</span></p>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>If stomatitis
  recurs at Grade&nbsp;2, interrupt dose until recovery to Grade&nbsp;</span><span
  style='font-size:11.0pt;font-family:Symbol'>£</span><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>1. Re&#8209;initiate Votubia at
  approximately 50% lower than the daily dose previously administered.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;3</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Temporary dose
  interruption until recovery to Grade&nbsp;</span><span style='font-size:11.0pt;
  font-family:Symbol'>£</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>1.</span></p>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Re&#8209;initiate
  Votubia </span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>at
  </span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>approximately
  50% lower than the daily dose previously administered.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;4</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.35pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Discontinue Votubia.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Other non&#8209;haematological toxicities</span></p>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>(excluding metabolic events)</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;2</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>If toxicity is tolerable, no dose adjustment
  required.</span></p>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>If toxicity becomes intolerable, temporary dose
  interruption until recovery to Grade&nbsp;</span><span style='font-size:11.0pt;
  font-family:Symbol'>£</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>1.
  Re&#8209;initiate Votubia at same dose.</span></p>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>If toxicity recurs at Grade&nbsp;2, interrupt
  Votubia until recovery to Grade&nbsp;</span><span style='font-size:11.0pt;
  font-family:Symbol'>£</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>1.
  Re&#8209;initiate Votubia at approximately 50% lower than the daily dose
  previously administered.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;3</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Temporary dose interruption until recovery to
  Grade&nbsp;</span><span style='font-size:11.0pt;font-family:Symbol'>£</span><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>1.</span></p>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Consider re&#8209;initiating Votubia at
  approximately 50% lower than the daily dose previously administered. If
  toxicity recurs at Grade&nbsp;3, consider discontinuation.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;4</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.35pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Discontinue Votubia.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Metabolic events</span></p>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>(e.g. hyperglycaemia,
  dyslipidaemia)</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;2</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>No dose
  adjustment required.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=139 colspan=3 valign=top style='width:104.5pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;3</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.7pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Temporary dose
  interruption.</span></p>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Re&#8209;initiate
  Votubia at approximately 50% lower than the daily dose previously
  administered.</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=7><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;4</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.35pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Discontinue Votubia.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Thrombocytopenia</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;2</span></p>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>(&lt;75,
  &#8805;50x10<sup>9</sup>/l)</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Temporary dose interruption until recovery to
  Grade&nbsp;</span><span style='font-size:11.0pt;font-family:Symbol'>£</span><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>1 (&#8805;75x10<sup>9</sup>/l).
  Re&#8209;initiate Votubia at same</span><span lang=EN-GB style='font-size:
  11.0pt;font-family:"Times New Roman",serif'> dose.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;3
  &amp; 4</span></p>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>(&lt;50x10<sup>9</sup>/l)</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.35pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Temporary dose interruption until recovery to
  Grade&nbsp;</span><span style='font-size:11.0pt;font-family:Symbol'>£</span><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>1 (&#8805;75x10<sup>9</sup>/l).
  Re&#8209;initiate Votubia at approximately 50% lower than the daily dose
  previously administered.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Neutropenia</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;2</span></p>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>(&#8805;1x10<sup>9</sup>/l)</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>No dose adjustment required</span><span lang=DE-CH
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;3</span></p>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>(&lt;1,
  &#8805;0.5x10<sup>9</sup>/l)</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Temporary dose interruption until recovery to
  Grade&nbsp;</span><span style='font-size:11.0pt;font-family:Symbol'>£</span><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>2 (&#8805;1x10<sup>9</sup>/l).
  Re&#8209;initiate Votubia at same dose.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;border-bottom:solid windowtext 1.0pt' width=9
  colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;4</span></p>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>(&lt;0.5x10<sup>9</sup>/l)</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.35pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Temporary dose interruption until recovery to
  Grade&nbsp;</span><span style='font-size:11.0pt;font-family:Symbol'>£</span><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>2 (&#8805;1x10<sup>9</sup>/l).
  Re&#8209;initiate Votubia at approximately 50% lower than the daily dose
  previously administered.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Febrile neutropenia</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>Grade&nbsp;3</p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.4pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Temporary dose
  interruption until recovery to Grade&nbsp;</span><span style='font-size:11.0pt;
  font-family:Symbol'>£</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>2
  (&#8805;1.25x10<sup>9</sup>/l) and no fever.</span></p>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Re&#8209;initiate
  Votubia at approximately 50% lower than the daily dose previously
  administered.</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=140 colspan=3 valign=top style='width:104.65pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=117 colspan=3 valign=top style='width:87.5pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Grade&nbsp;4</span></p>
  </td>
  <td width=374 colspan=3 valign=top style='width:280.4pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=DE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Discontinue </span><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Votubia</span><span
  lang=DE style='font-size:11.0pt;font-family:"Times New Roman",serif'>.</span></p>
  </td>
  <td style='border:none;border-bottom:solid windowtext 1.0pt' width=9
  colspan=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=9 colspan=2><p class='MsoNormal'>&nbsp;</td>
  <td width=630 colspan=9 valign=top style='width:472.5pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin-left:28.1pt;text-indent:-28.1pt'><sup><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>1</span></sup><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>        Grading
  based on National Cancer Institute (NCI) Common Terminology Criteria for
  Adverse Events (CTCAE) v3.0</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=2 style='border:none'></td>
  <td width=8 style='border:none'></td>
  <td width=130 style='border:none'></td>
  <td width=1 style='border:none'></td>
  <td width=8 style='border:none'></td>
  <td width=107 style='border:none'></td>
  <td width=1 style='border:none'></td>
  <td width=8 style='border:none'></td>
  <td width=365 style='border:none'></td>
  <td width=2 style='border:none'></td>
  <td width=7 style='border:none'></td>
 </tr>
</table>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=X-NONE>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Therapeutic drug monitoring</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Therapeutic drug
monitoring of everolimus blood concentrations, using a validated assay, is <b>required</b>.
Trough concentrations should be assessed at least 1&nbsp;week after the initial
dose, after any change in dose or pharmaceutical form, after initiation of or change
in co&#8209;administration of CYP3A4 inhibitors (see sections&nbsp;4.4 and 4.5)
or after any change in hepatic status (Child&#8209;Pugh) (see Hepatic
impairment below and section&nbsp;5.2). Trough concentrations should be
assessed 2 to 4&nbsp;weeks after initiation of or change in co-administration
of CYP3A4 inducers (see sections&nbsp;4.4 and 4.5) since the natural
degradation time of the induced enzymes has to be taken into account. When
possible, the same assay and laboratory for therapeutic drug monitoring should
be used throughout the treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Switching pharmaceutical forms</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia is
available in two pharmaceutical forms: tablets and dispersible tablets. Votubia
tablets and Votubia dispersible tablets are <b>not</b> to be used
interchangeably. The two pharmaceutical forms must not be combined to achieve
the desired dose. The same pharmaceutical form must be used consistently, as
appropriate for the indication being treated.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>When switching
pharmaceutical forms, the dose should be adjusted to the closest milligram
strength of the new pharmaceutical form and the everolimus trough concentration
should be assessed at least 1&nbsp;week later (see section&nbsp;Therapeutic
drug monitoring above).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Special populations</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Elderly</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No dose
adjustment is required (see section&nbsp;5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Renal impairment</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No dose
adjustment is required (see section&nbsp;5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Hepatic impairment</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Patients &lt;18&nbsp;years of age:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia is not
recommended for patients &lt;18&nbsp;years of age with SEGA or refractory
seizures and hepatic impairment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Patients &#8805;18&nbsp;years of age:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Mild hepatic impairment (Child&#8209;Pugh A):
75% of the recommended starting dose calculated based on BSA (rounded to the
nearest strength)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Moderate hepatic impairment (Child&#8209;Pugh
B): 50% of the recommended starting dose calculated based on BSA (rounded to
the nearest strength)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Severe hepatic impairment (Child&#8209;Pugh C): </span><span
lang=EN-GB>Votubia is only recommended if the desired benefit outweighs the
risk. In this case,</span><span lang=EN-GB> 25% of the dose calculated based on
BSA (rounded to the nearest strength) must not be exceeded.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Everolimus whole
blood trough concentrations should be assessed at least 1&nbsp;week after any
change in hepatic status (Child&#8209;Pugh).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Paediatric population</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The safety,
efficacy and pharmacokinetic profile of Votubia in children below the age of
1&nbsp;year with TSC who have SEGA have not been established. No data are
available (see sections&nbsp;5.1 and 5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>The safety, efficacy and pharmacokinetic profile of
Votubia has not been established in children below the age of 2&nbsp;years with
TSC and refractory seizures. Currently available data are described in section
5.2, but no recommendation on a posology can be made.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Clinical study
results did not show an impact of Votubia on growth and pubertal development.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Method of administration</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia must be
administered orally once daily at the same time every day, consistently either
with or without food (see section&nbsp;5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia
dispersible tablets are to be taken as a suspension only and must not be
swallowed whole, chewed, or crushed. The suspension can be prepared either in
an oral syringe or in a small glass. Care should be taken to ensure the entire
dose is ingested.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The suspension
must be administered immediately after preparation. If not administered within
30&nbsp;minutes of preparation when using an oral syringe or 60&nbsp;minutes
when using a small glass, the suspension must be discarded and a new suspension
must be prepared (see section&nbsp;6.3). Only water should be used as the
vehicle.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For further
details on handling, see section&nbsp;6.6.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.3     Contraindications</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypersensitivity
to the active substance, to other rapamycin derivatives or to any of the
excipients listed in section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.4     Special warnings and precautions for use</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Non&#8209;infectious pneumonitis</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Non&#8209;infectious
pneumonitis is a class effect of rapamycin derivatives, including everolimus.
Non&#8209;infectious pneumonitis (including interstitial lung disease) was
described very commonly in patients taking everolimus in the advanced renal
cell carcinoma (RCC) setting (see section&nbsp;4.8). Some cases were severe and
on rare occasions, a fatal outcome was observed. A diagnosis of non&#8209;infectious
pneumonitis should be considered in patients presenting with non&#8209;specific
respiratory signs and symptoms such as hypoxia, pleural effusion, cough or
dyspnoea, and in whom infectious, neoplastic and other non&#8209;medicinal
causes have been excluded by means of appropriate investigations. </span>Opportunistic
infections such as pneumocystis jirovecii (carinii) pneumonia (PJP, PCP) should
be ruled out in the differential diagnosis of non-infectious pneumonitis (see <span
lang=EN-GB>section&nbsp;</span>Infections below). <span lang=EN-GB>Patients
should be advised to report promptly any new or worsening respiratory symptoms.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients who
develop radiological changes suggestive of non&#8209;infectious pneumonitis and
have few or no symptoms may continue Votubia therapy without dose adjustments.
If symptoms are moderate, consideration should be given to interruption of
therapy until symptoms improve. The use of corticosteroids may be indicated. </span><span
lang=EN-GB>Votubia may be reinitiated at a daily dose approximately 50% lower
than the dose previously administered.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For cases where
symptoms of non&#8209;infectious pneumonitis are severe, Votubia therapy should
be discontinued and the use of corticosteroids may be indicated until clinical
symptoms resolve. </span><span lang=EN-GB>Votubia may be reinitiated at a daily
dose approximately 50% lower than the dose previously administered depending on
the individual clinical circumstances.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>For patients who require use of
corticosteroids for treatment of non-infectious pneumonitis, prophylaxis for
pneumocystis jirovecii (carinii) pneumonia (PJP, PCP) may be considered.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Infections</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Everolimus has
immunosuppressive properties and may predispose patients to </span><span
lang=EN-GB>bacterial, fungal, viral or protozoal</span><span lang=EN-GB>
infections, including infections with opportunistic pathogens (see
section&nbsp;4.8). Localised and systemic infections, including pneumonia,
other bacterial infections, invasive fungal infections such as aspergillosis,
candidiasis </span><span lang=EN-GB>or pneumocystis jirovecii (carinii)
pneumonia (PJP, PCP) and viral infections including reactivation of
hepatitis&nbsp;B virus</span><span lang=EN-GB>, have been described in patients
taking everolimus. Some of these infections have been severe (e.g. leading to
sepsis [including septic shock], respiratory or hepatic failure) and
occasionally fatal in adult and paediatric patients (see section&nbsp;4.8).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Physicians and
patients should be aware of the increased risk of infection with Votubia. Pre&#8209;existing
infections should be treated appropriately and should have resolved fully
before starting treatment with Votubia. While taking Votubia, be vigilant for
symptoms and signs of infection; </span><span lang=EN-GB style='color:black'>if
a diagnosis of infection is made,</span><span lang=EN-GB> institute appropriate
treatment promptly </span><span lang=EN-GB>and consider interruption or
discontinuation of Votubia</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span class=TextChar><span
lang=EN-GB style='font-family:"Times New Roman",serif'>If a diagnosis of
invasive systemic fungal infection is made, Votubia treatment should be
promptly and permanently discontinued and the patient treated with appropriate
antifungal therapy.</span></span></p>

<p class=MsoNormal style='line-height:normal'><span class=TextChar><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></span></p>

<p class=MsoNormal style='line-height:normal'>Cases of pneumocystis jirovecii (carinii)
pneumonia (PJP, PCP), some with fatal outcome, have been reported in patients
who received everolimus. PJP/PCP may be associated with concomitant use of
corticosteroids or other immunosuppressive agents. Prophylaxis for PJP/PCP
should be considered when concomitant use of corticosteroids or other immunosuppressive
agents are required.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Hypersensitivity reactions</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypersensitivity
reactions manifested by symptoms including, but not limited to, anaphylaxis,
dyspnoea, flushing, chest pain or angioedema (e.g. swelling of the airways or
tongue, with or without respiratory impairment) have been observed with
everolimus (see section&nbsp;4.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u>Concomitant
use of angiotensin-converting enzyme (ACE) inhibitors</u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>Patients taking concomitant ACE
inhibitor (e.g. ramipril) therapy may be at increased risk for angioedema (e.g.
swelling of the airways or tongue, with or without respiratory impairment) (see
section&nbsp;4.5).</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Stomatitis</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Stomatitis,
including mouth ulcerations and oral mucositis, is the most commonly reported
adverse reaction in patients treated with Votubia (see section&nbsp;4.8).
Stomatitis mostly occurs within the first 8&nbsp;weeks of treatment. A
single-arm study in postmenopausal breast cancer patients treated with Afinitor
(everolimus) plus exemestane suggested that an alcohol-free corticosteroid oral
solution, administered as a mouthwash during the initial 8&nbsp;weeks of
treatment, may decrease the incidence and severity of stomatitis (see
section&nbsp;5.1). Management of stomatitis may therefore include prophylactic
(in adults) and/or therapeutic use of topical treatments, such as an
alcohol-free corticosteroid oral solution as a mouthwash. However products
containing alcohol, hydrogen peroxide, iodine and thyme derivatives should be
avoided as they may exacerbate the condition. Monitoring for and treatment of
fungal infection is recommended, especially in patients being treated with
steroid-based medicinal products. Antifungal agents should not be used unless
fungal infection has been diagnosed (see section&nbsp;4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Haemorrhage</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p style='margin:0in'><span style='font-size:11.0pt'>Serious cases of
haemorrhage, some with a fatal outcome, have been reported in patients treated
with everolimus</span><span lang=EN-GB style='font-size:11.0pt'> in the
oncology setting. No serious cases of renal haemorrhage were reported in the
TSC setting.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Caution is
advised in patients taking Votubia, particularly during concomitant use with active
substances known to affect platelet function or that can increase the risk of
haemorrhage as well as in patients with a history of bleeding disorders.
Healthcare professionals and patients should be vigilant for signs and symptoms
of bleeding throughout the treatment period, especially if risk factors for
haemorrhage are combined.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Renal failure events</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cases of renal
failure (including acute renal failure), some with a fatal outcome, have been
observed in patients treated with Votubia (see section&nbsp;4.8). Renal
function of patients should be monitored particularly where patients have
additional risk factors that may further impair renal function.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Laboratory tests and monitoring</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Renal function</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Elevations of
serum creatinine, usually mild, and proteinuria have been reported in patients
treated with Votubia (see section&nbsp;4.8). Monitoring of renal function,
including measurement of blood urea nitrogen (BUN), urinary protein or serum
creatinine, is recommended prior to the start of Votubia therapy and periodically
thereafter.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Blood glucose</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hyperglycaemia
has been reported in patients taking Votubia (see section&nbsp;4.8). Monitoring
of fasting serum glucose is recommended prior to the start of Votubia therapy
and periodically thereafter. More frequent monitoring is recommended when
Votubia is co-administered with other medicinal products that may induce
hyperglycaemia. When possible optimal glycaemic control should be achieved
before starting a patient on Votubia.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Blood lipids</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Dyslipidaemia
(including hypercholesterolaemia and hypertriglyceridaemia) has been reported
in patients taking Votubia. Monitoring of blood cholesterol and triglycerides
prior to the start of Votubia therapy and periodically thereafter, as well as
management with appropriate medical therapy, is also recommended.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Haematological parameters</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Decreased
haemoglobin, lymphocytes, neutrophils and platelets have been reported in
patients treated with Votubia (see section&nbsp;4.8). Monitoring of complete
blood count is recommended prior to the start of Votubia therapy and
periodically thereafter.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Interactions</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Co&#8209;administration
with inhibitors and inducers of CYP3A4 and/or the multidrug efflux pump P&#8209;glycoprotein
(PgP) should be avoided. If </span><span lang=EN-GB>co&#8209;administration of
a <b><i>moderate</i></b> CYP3A4 and/or PgP inhibitor or inducer cannot be
avoided, dose adjustments of Votubia may be required (see section&nbsp;4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant
treatment with <b><i>potent</i></b> CYP3A4 inhibitors result in dramatically
increased blood concentrations of everolimus (see section&nbsp;4.5). There are
currently not sufficient data to allow dosing recommendations in this
situation. Hence, concomitant treatment of Votubia and <b><i>potent</i></b>
inhibitors is not recommended.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>Caution should be exercised when
Votubia is taken in combination with orally administered CYP3A4 substrates with
a narrow therapeutic index due to the potential for drug interactions. If
Votubia is taken with orally administered CYP3A4 substrates with a narrow
therapeutic index (e.g. pimozide, terfenadine, astemizole, cisapride,
quinidine, ergot alkaloid derivatives or carbamazepine), the patient should be
monitored for undesirable effects described in the product information of the
orally administered CYP3A4 substrate (see section&nbsp;4.5).</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Hepatic
impairment</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Votubia is
not recommended for use in patients:</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&#8805;</span></b><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>18&nbsp;years of age
with SEGA or refractory seizures</span></b><span lang=EN-GB style='font-family:
"Times New Roman",serif'> and concomitant severe hepatic impairment (Child&#8209;Pugh
C) unless the potential benefit outweighs the risk (see sections&nbsp;4.2 and
5.2).</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&lt;18&nbsp;years
of age with SEGA or refractory seizures</span></b><span lang=EN-GB
style='font-family:"Times New Roman",serif'> and concomitant hepatic impairment
(Child&#8209;Pugh A, B and C) (see sections&nbsp;4.2 and 5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Vaccinations</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>The use of live vaccines should be avoided during
treatment with Votubia (see section&nbsp;4.5). For paediatric patients who do
not require immediate treatment, completion of the recommended childhood series
of live virus vaccinations is advised prior to the start of therapy according
to local treatment guidelines.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Wound healing complications</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Impaired wound
healing is a class effect of rapamycin derivatives, including Votubia. Caution
should therefore be exercised with the use of Votubia in the peri&#8209;surgical
period.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Lactose</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients with
rare hereditary problems of galactose intolerance, total lactase deficiency or
glucose&#8209;galactose malabsorption should not take this medicinal product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.5     Interaction with other medicinal products and other forms of
interaction</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Everolimus is a
substrate of CYP3A4, and also a substrate and moderate inhibitor of PgP.
Therefore, absorption and subsequent elimination of everolimus may be
influenced by products that affect CYP3A4 and/or PgP. <i>In vitro</i>,
everolimus is a competitive inhibitor of CYP3A4 and a mixed inhibitor of
CYP2D6.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Known and
theoretical interactions with selected inhibitors and inducers of CYP3A4 and
PgP are listed in Table&nbsp;3 below.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>CYP3A4 and PgP inhibitors increasing everolimus concentrations</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Substances that
are inhibitors of CYP3A4 or PgP may increase everolimus blood concentrations by
decreasing metabolism or the efflux of everolimus from intestinal cells.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>CYP3A4 and PgP inducers decreasing everolimus concentrations</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Substances that
are inducers of CYP3A4 or PgP may decrease everolimus blood concentrations by
increasing metabolism or the efflux of everolimus from intestinal cells.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Table&nbsp;3       Effects of other active substances on everolimus</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="101%"
 style='width:101.9%;border-collapse:collapse;border:none'>
 <tr>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Active substance by interaction</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width="34%" colspan=2 valign=top style='width:34.24%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Interaction  Change in Everolimus AUC/C<sub>max</sub></span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Geometric mean ratio (observed range)</span></b></p>
  </td>
  <td width="38%" valign=top style='width:38.0%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Recommendations concerning co&#8209;administration</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=4 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><i><span
  lang=EN-GB>Potent</span></i></b><b><span lang=EN-GB> CYP3A4/PgP inhibitors</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Ketoconazole</span></b></p>
  </td>
  <td width="34%" colspan=2 valign=top style='width:34.24%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>AUC
  &#8593;15.3&#8209;fold</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(range 11.2&#8209;22.5)</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>C<sub>max</sub>
  &#8593;4.1&#8209;fold</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(range 2.6&#8209;7.0)</span></p>
  </td>
  <td width="38%" rowspan=5 valign=top style='width:38.0%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant
  treatment of Votubia and potent inhibitors is not recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Itraconazole,
  posaconazole, voriconazole</span></b></p>
  </td>
  <td width="34%" colspan=2 rowspan=4 valign=top style='width:34.24%;
  border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not studied.
  Large increase in everolimus concentration is expected.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Telithromycin,
  clarithromycin</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Nefazodone</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR-CH>Ritonavir, atazanavir,
  saquinavir, darunavir, indinavir, nelfinavir</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=4 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><i><span
  lang=EN-GB>Moderate</span></i></b><b><span lang=EN-GB> CYP3A4/PgP inhibitors</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Erythromycin</span></b></p>
  </td>
  <td width="34%" colspan=2 valign=top style='width:34.24%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>AUC &#8593;4.4&#8209;fold</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(range 2.0&#8209;12.6)</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>C<sub>max</sub>
  &#8593;2.0&#8209;fold</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(range 0.9&#8209;3.5)</span></p>
  </td>
  <td width="38%" rowspan=8 valign=top style='width:38.0%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use caution
  when co&#8209;administration of moderate CYP3A4 inhibitors or PgP inhibitors
  cannot be avoided.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If patients
  require co&#8209;administration of a moderate CYP3A4 or PgP inhibitor, reduce
  the daily dose by approximately 50%. Further dose reduction may be required
  to manage adverse reactions (see sections&nbsp;4.2 and 4.4). Everolimus
  trough concentrations should be assessed at least 1&nbsp;week after the
  addition of a moderate CYP3A4 or PgP inhibitor. If the moderate inhibitor is
  discontinued, consider a washout period of at least 2 to 3&nbsp;days (average
  elimination time for most commonly used moderate inhibitors) before the
  Votubia dose is returned to the dose used prior to initiation of the
  co-administration. The everolimus trough concentration should be assessed at
  least 1&nbsp;week later (see sections&nbsp;4.2 and 4.4).</span></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Imatinib</span></b></p>
  </td>
  <td width="34%" colspan=2 valign=top style='width:34.24%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>AUC </span><span
  lang=EN-GB style='font-family:"Arial",sans-serif;color:black'>&#8593; </span><span
  lang=EN-GB style='color:black'>3.7&#8209;fold</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>C<sub>max</sub> </span><span lang=EN-GB style='font-family:
  "Arial",sans-serif;color:black'>&#8593; </span><span lang=EN-GB
  style='color:black'>2.2&#8209;fold</span></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Verapamil</span></b></p>
  </td>
  <td width="34%" colspan=2 valign=top style='width:34.24%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>AUC &#8593;3.5&#8209;fold</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(range 2.2&#8209;6.3)</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>C<sub>max</sub>
  &#8593;2.3&#8209;fold</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(range1.3&#8209;3.8)</span></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Ciclosporin
  oral</span></b></p>
  </td>
  <td width="34%" colspan=2 valign=top style='width:34.24%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>AUC &#8593;2.7&#8209;fold</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(range 1.5&#8209;4.7)</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>C<sub>max</sub>
  &#8593;1.8&#8209;fold</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(range 1.3&#8209;2.6)</span></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Fluconazole</span></b></p>
  </td>
  <td width="34%" colspan=2 rowspan=2 valign=top style='width:34.24%;
  border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Not studied. Increased exposure expected.</span></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Diltiazem</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Dronedarone</span></b></p>
  </td>
  <td width="34%" colspan=2 valign=top style='width:34.24%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not studied.
  Increased exposure expected.</span></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Amprenavir,
  fosamprenavir</span></b></p>
  </td>
  <td width="34%" colspan=2 valign=top style='width:34.24%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not studied.
  Increased exposure expected.</span></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Grapefruit
  juice or other food affecting CYP3A4/PgP</span></b></p>
  </td>
  <td width="34%" colspan=2 valign=top style='width:34.24%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not studied.
  Increased exposure expected (the effect varies widely).</span></p>
  </td>
  <td width="38%" valign=top style='width:38.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Combination
  should be avoided.</span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=4 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><i><span
  lang=EN-GB>Potent</span></i></b><b><span lang=EN-GB> <i>and moderate</i>
  CYP3A4 inducers</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="29%" colspan=2 valign=top style='width:29.62%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Rifampicin</span></b></p>
  </td>
  <td width="32%" valign=top style='width:32.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>AUC &#8595;63%</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(range 0&#8209;80%)</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>C<sub>max</sub>
  &#8595;58%</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(range 10&#8209;70%)</span></p>
  </td>
  <td width="38%" rowspan=4 valign=top style='width:38.0%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Avoid the use
  of concomitant potent CYP3A4 inducers.</span></p>
  <p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>SEGA patients
  receiving concomitant potent CYP3A4 inducers may require an increased Votubia
  dose to achieve the same exposure as patients not taking potent inducers.
  Dosing should be titrated to attain trough concentrations of 5 to
  15&nbsp;ng/ml as described below.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients with
  seizures receiving concomitant strong CYP3A4 inducers (e.g., enzyme inducing
  antiepileptics carbamazepine, phenobarbital, and phenytoin) at the start of
  treatment with everolimus require an increased starting dose to attain trough
  concentrations of 5 to 15&nbsp;ng/ml (see Table&nbsp;1).</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'>For patients not receiving
  concomitant strong inducers at the start of everolimus treatment, the co&#8209;administration
  may require an increased Votubia dose. <span lang=EN-GB>If concentrations are
  below 5&nbsp;ng/ml, the daily dose may be increased by increments of 1 to
  4&nbsp;mg, checking the trough level and assessing tolerability before
  increasing the dose.</span></p>
  <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
  <p class=MsoNormal style='line-height:normal'>The addition of another
  concomitant strong CYP3A4 inducer may not require additional dose adjustment.
  Assess the everolimus trough level 2&nbsp;weeks after initiating the
  additional inducer. Adjust the dose by increments of 1 to 4&nbsp;mg as
  necessary to maintain the target trough concentration.</p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Discontinuation
  of one of multiple strong CYP3A4 inducers may not require additional dose
  adjustment. Assess the everolimus trough level 2&nbsp;weeks after
  discontinuation of one of multiple strong CYP3A4 inducers. If all potent
  inducers are discontinued, consider a washout period of at least 3 to
  5&nbsp;days (reasonable time for significant enzyme de-induction) before the
  Votubia dose is returned to the dose used prior to initiation of the co&#8209;administration.
  The everolimus trough concentrations should be assessed 2&nbsp;to 4 weeks
  later since the natural degradation time of the induced enzymes has to be
  taken into account (see sections&nbsp;4.2 and 4.4).</span></p>
  </td>
 </tr>
 <tr>
  <td width="29%" colspan=2 valign=top style='width:29.62%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b>Dexamethasone</b></p>
  </td>
  <td width="32%" valign=top style='width:32.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not studied.
  Decreased exposure expected.</span></p>
  </td>
 </tr>
 <tr>
  <td width="29%" colspan=2 valign=top style='width:29.62%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Antiepileptics
  (e.g. carbamazepine, phenobarbital, phenytoin)</span></b></p>
  </td>
  <td width="32%" valign=top style='width:32.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not studied.
  Decreased exposure expected.</span></p>
  </td>
 </tr>
 <tr>
  <td width="29%" colspan=2 valign=top style='width:29.62%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Efavirenz,
  nevirapine</span></b></p>
  </td>
  <td width="32%" valign=top style='width:32.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not studied.
  Decreased exposure expected.</span></p>
  </td>
 </tr>
 <tr>
  <td width="29%" colspan=2 valign=top style='width:29.62%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>St Johns
  Wort (<i>Hypericum perforatum</i>)</span></b></p>
  </td>
  <td width="32%" valign=top style='width:32.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not studied.
  Large decrease in exposure expected.</span></p>
  </td>
  <td width="38%" valign=top style='width:38.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Preparations
  containing St Johns Wort should not be used during treatment with everolimus</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=200 style='border:none'></td>
  <td width=13 style='border:none'></td>
  <td width=233 style='border:none'></td>
  <td width=274 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Agents whose plasma concentration may be altered by everolimus</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Based on <i>in
vitro</i> results, the systemic concentrations obtained after oral daily doses
of 10&nbsp;mg make inhibition of PgP, CYP3A4 and CYP2D6 unlikely. However,
inhibition of CYP3A4 and PgP in the gut cannot be excluded. </span>An
interaction study in healthy subjects demonstrated that co&#8209;administration
of an oral dose of midazolam, a sensitive CYP3A substrate probe, with
everolimus resulted in a 25% increase in midazolam C<sub>max</sub> and a 30%
increase in midazolam AUC<sub>(0-inf)</sub>. The effect is likely to be due to
inhibition of intestinal CYP3A4 by everolimus.<span lang=EN-GB> Hence
everolimus may affect the bioavailability of orally co&#8209;administered
CYP3A4 substrates. However, a clinically relevant effect on the exposure of
systemically administered CYP3A4 substrates is not expected (see
section&nbsp;4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In EXIST-3
(Study CRAD001M2304), everolimus increased pre&#8209;dose concentrations of the
antiepileptics carbamazepine, clobazam, and the clobazam metabolite N&#8209;desmethylclobazam
by about 10%. The increase in the pre&#8209;dose concentrations of these
antiepileptics may not be clinically significant but dose adjustments for
antiepileptics with a narrow therapeutic index, e.g carbamazepine, may be
considered</span><span lang=EN-GB>. Everolimus had no impact on pre&#8209;dose
concentrations of </span><span lang=EN-GB>antiepileptics</span><span
lang=EN-GB> that are substrates of CYP3A4 (clonazepam, diazepam, felbamate and
zonisamide).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u>Concomitant
use of angiotensin-converting enzyme (ACE) inhibitors</u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>Patients taking concomitant ACE
inhibitor (e.g. ramipril) therapy may be at increased risk for angioedema (see
section&nbsp;4.4).</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u>Concomitant
ketogenic diet</u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>The effect of a ketogenic diet
may be mediated through mTOR inhibition. In the absence of clinical data, the
possibility of an additive effect on adverse events cannot be excluded when
everolimus is given in conjunction with a ketogenic diet.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Vaccinations</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The immune
response to vaccination may be affected and, therefore, vaccination may be less
effective during treatment with Votubia. The use of live vaccines should be
avoided during treatment with Votubia. Examples of live vaccines are:
intranasal influenza, measles, mumps, rubella, oral polio, BCG (Bacillus
Calmette&#8209;Guérin), yellow fever, varicella, and TY21a typhoid vaccines.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.6     Fertility, pregnancy and lactation</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Women of childbearing potential/Contraception in males and females</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Women of
childbearing potential must use a highly effective method of contraception
(e.g. oral, injected, or implanted non&#8209;oestrogen&#8209;containing
hormonal method of birth control, progesterone&#8209;based contraceptives,
hysterectomy, tubal ligation, complete abstinence, barrier methods,
intrauterine device [IUD], and/or female/male sterilisation) while receiving
everolimus, and for up to 8&nbsp;weeks after ending treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Male patients
should not be prohibited from attempting to father children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There are no
adequate data from the use of everolimus in pregnant women. Studies in animals
have shown reproductive toxicity effects including embryotoxicity and
foetotoxicity (see section&nbsp;5.3). The potential risk for humans is unknown.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Everolimus is
not recommended during pregnancy and in women of childbearing potential not
using contraception.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Breast&#8209;feeding</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is not known
whether everolimus is excreted in human breast milk. However, in rats,
everolimus and/or its metabolites readily pass into the milk (see
section&nbsp;5.3). Therefore, women taking everolimus should not breast&#8209;feed
during treatment and for 2&nbsp;weeks after the last dose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The potential
for everolimus to cause infertility in male and female patients is unknown,
however secondary amenorrhoea and associated luteinising hormone (LH)/follicle
stimulating hormone (FSH) imbalance has been observed in female patients (see
also section&nbsp;5.3 for preclinical observations on the male and female
reproductive systems).</span><span lang=EN-GB style='color:red'> </span><span
lang=EN-GB>Based on non&#8209;clinical findings, male and female fertility may
be compromised by treatment with everolimus (see section&nbsp;5.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.7     Effects on ability to drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia may have
a minor or moderate influence on the ability to drive and use machines.
Patients should be advised to be cautious when driving or using machines if
they experience fatigue during treatment with Votubia.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.8     Undesirable effects</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Summary of the safety profile</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Three randomised, double&#8209;blind, placebo&#8209;controlled
pivotal phase III studies, including double-blind and open label treatment
periods, and a non-randomised, open-label, single-arm phase II study contribute
to the safety profile of Votubia (n=612, including 409&nbsp;patients
&lt;18&nbsp;years of age; median duration of exposure 36.8&nbsp;months [range
0.5 to 83.2]).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>EXIST-3 (CRAD001M2304): This
was a randomised, double-blind, controlled, phase III trial comparing
adjunctive treatment of low and high everolimus exposure (low trough [LT] range
of 3&#8209;7&nbsp;ng/ml [n=117] and high trough [HT] range of 9&#8209;15&nbsp;ng/ml
[n=130]) versus placebo (n=119), in patients with TSC and refractory
partial-onset seizures receiving 1 to 3&nbsp;antiepileptics. The median
duration of the double-blind period was 18&nbsp;weeks. The cumulative median
duration exposure to Votubia (361&nbsp;patients who took at least one dose of
everolimus) was 30.4&nbsp;months (range 0.5 to 48.8).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>EXIST&#8209;2 (CRAD001M2302): This was a </span><span
lang=EN-GB>randomised, double&#8209;blind, controlled, phase III trial of
everolimus (n=79) versus placebo (n=39) in patients with either TSC plus renal
angiomyolipoma (n=113) or sporadic lymphangioleiomyomatosis (LAM) plus renal
angiomyolipoma (n=5)</span><span lang=EN-GB>. </span><span lang=EN-GB>The
median duration of blinded study treatment was 48.1&nbsp;weeks (range 2 to 115)
for patients receiving Votubia and 45.0&nbsp;weeks (range 9 to 115) for those
receiving <span style='color:black'>placebo. The cumulative median duration of
exposure to Votubia (112&nbsp;patients who took at least one dose of everolimus)
was 46.9&nbsp;months (range 0.5 to 63.9).</span></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>EXIST&#8209;1
(CRAD001M2301): This was a </span><span lang=EN-GB style='color:black'>randomised,
double&#8209;blind, controlled, phase III trial of everolimus (n=78) versus
placebo (n=39) in patients with TSC who have SEGA, irrespective of age. The
median duration of blinded study treatment was 52.2&nbsp;weeks (range 24 to 89)
for patients receiving Votubia and 46.6&nbsp;weeks (range 14 to 88) for those
receiving placebo. The cumulative median duration of exposure to Votubia
(111&nbsp;patients who took at least one dose of everolimus) was
47.1&nbsp;months (range 1.9 to 58.3).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>CRAD001C2485: This was a
prospective, open&#8209;label, single&#8209;arm phase II study of everolimus in
patients with SEGA (n=28). The median duration of exposure was 67.8&nbsp;months
(range 4.7 to 83.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>The adverse events considered to be associated with the use
of Votubia (adverse reactions), based upon the review and medical assessment of
all adverse events reported in the above studies, are described below.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>The most frequent adverse reactions (incidence &#8805;1/10)
from the pooled safety data are (in decreasing order): stomatitis, pyrexia, nasopharyngitis,
diarrhoea, upper respiratory tract infection, vomiting, cough, rash, headache,
amenorrhoea, acne, pneumonia, urinary tract infection, sinusitis, menstruation
irregular, pharyngitis, decreased appetite, fatigue, hypercholesterolaemia, and
hypertension.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>The most frequent grade&nbsp;3&#8209;4 adverse reactions
(incidence &#8805;1%) were pneumonia, stomatitis, amenorrhoea, neutropenia,
pyrexia, menstruation irregular, hypophosphataemia, diarrhoea, and cellulitis.
The grades follow CTCAE Version 3.0 and 4.03.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB style='color:black'>Tabulated list of adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Table&nbsp;4 shows the incidence of adverse reactions based
on pooled data of patients receiving everolimus in the three TSC studies
(including both the double&#8209;blind and open&#8209;label extension phase,
where applicable). Adverse reactions are listed according to MedDRA system
organ class. Frequency categories are defined using the following convention:
very common (&#8805;1/10); common (&#8805;1/100 to &lt;1/10); uncommon
(&#8805;1/1,000 to &lt;1/100); rare (&#8805;1/10,000 to &lt;1/1,000); very rare
(&lt;1/10,000); not known (cannot be estimated from the available data).</span><span
lang=EN-GB style='color:black'> </span><span lang=EN-GB style='color:black'>Within
each frequency grouping, adverse reactions are presented in order of decreasing
seriousness.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB style='color:black'>Table&nbsp;4       Adverse
reactions reported in TSC studies</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=612
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=612 colspan=3 valign=top style='width:459.0pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Infections and infestations</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Very common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Nasopharyngitis, upper respiratory tract infection</span><span
  lang=EN-GB style='color:black'>, pneumonia</span><sup><span lang=EN-GB>&nbsp;</span></sup><sup><span
  lang=EN-GB style='color:black'>a</span></sup><span lang=EN-GB
  style='color:black'>, urinary tract infection, sinusitis, pharyngitis</span></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Otitis media, cellulitis, pharyngitis streptococcal,
  gastroenteritis viral, gingivitis</span></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Uncommon</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Herpes zoster,
  sepsis, bronchitis viral</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=3 valign=top style='width:459.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Blood and lymphatic system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Common</span></p>
  </td>
  <td width=510 colspan=2 valign=top style='width:382.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=IT style='color:black'>Anaemia, neutropenia,
  leucopenia, thrombocytopenia, lymphopenia</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=3 valign=top style='width:459.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Immune system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Common</span></p>
  </td>
  <td width=510 colspan=2 valign=top style='width:382.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Hypersensitivity</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=3 valign=top style='width:459.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Metabolism and nutrition disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Very common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Decreased appetite, hypercholesterolaemia</span></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Hypertriglyceridaemia,
  hyperlipidaemia, hypophosphataemia, hyperglycaemia</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=3 valign=top style='width:459.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Psychiatric disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Insomnia, aggression,
  irritability</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=3 valign=top style='width:459.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Nervous system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Very common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Headache</span></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Uncommon</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Dysgeusia</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=3 valign=top style='width:459.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Vascular disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Very common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Hypertension</span></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Lymphoedema</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=3 valign=top style='width:459.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Respiratory, thoracic and mediastinal disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Very common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Cough</span></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Epistaxis,
  pneumonitis</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=3 valign=top style='width:459.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Gastrointestinal disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Very common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Stomatitis</span><sup><span lang=EN-GB>&nbsp;<span
  style='color:black'>b</span></span></sup><span lang=EN-GB style='color:black'>,
  diarrhoea, vomiting</span></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Constipation, nausea,
  abdominal pain, flatulence, oral pain, gastritis</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=3 valign=top style='width:459.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Skin and subcutaneous tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Very common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Rash</span><sup><span lang=EN-GB>&nbsp;<span
  style='color:black'>c</span></span></sup><span lang=EN-GB style='color:black'>,
  acne</span></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Dry skin, acneiform dermatitis, pruritus, alopecia</span></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Uncommon</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Angioedema</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=3 valign=top style='width:459.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Musculoskeletal and connective tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Uncommon</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Rhabdomyolysis</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=3 valign=top style='width:459.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Renal and urinary disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Proteinuria</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=3 valign=top style='width:459.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB style='color:black'>Reproductive system and breast disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Very common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=ES style='color:
  black'>Amenorrhoea</span><sup><span lang=ES>&nbsp;<span style='color:black'>d</span></span></sup><span
  lang=ES style='color:black'>, menstruation irregular</span><sup><span
  lang=ES>&nbsp;<span style='color:black'>d</span></span></sup></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Menorrhagia, ovarian cyst, vaginal haemorrhage</span></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Uncommon</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Menstruation delayed</span><sup><span lang=EN-GB>&nbsp;</span><span
  lang=EN-GB style='color:black'>d</span></sup></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=3 valign=top style='width:459.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>General disorders and administration site conditions</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Very common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Pyrexia, fatigue</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=3 valign=top style='width:459.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Investigations</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Common</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Blood lactate
  dehydrogenase increased, blood luteinising hormone increased, weight
  decreased</span></p>
  </td>
 </tr>
 <tr>
  <td width=103 colspan=2 valign=top style='width:77.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Uncommon</span></p>
  </td>
  <td width=509 valign=top style='width:381.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Blood follicle
  stimulating hormone increased</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=3 valign=top style='width:459.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><sup><span lang=EN-GB>a                 </span></sup><span
  lang=EN-GB>Includes </span>pneumocystis jirovecii (carinii) pneumonia (PJP,
  PCP)</p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><sup><span lang=EN-GB
  style='color:black'>b</span></sup><span lang=EN-GB style='color:black'>        Includes
  (very common) stomatitis, mouth ulceration, aphthous ulcer; (common) tongue
  ulceration, lip ulceration and (uncommon) gingival pain, glossitis</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><sup><span lang=EN-GB style='color:black'>c</span></sup><span
  lang=EN-GB style='color:black'>         Includes (very common) rash; (common)
  rash erythematous, erythema, and (uncommon) rash generalised, rash maculo&#8209;papular,
  rash macular</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><sup><span lang=EN-GB style='color:black'>d                 </span></sup><span
  lang=EN-GB style='color:black'>F</span><span style='color:black'>requenc</span><span
  style='color:black'>y based upon number of women from 10 to 55&nbsp;years of
  age while on treatment in the pooled data</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=102 style='border:none'></td>
  <td width=2 style='border:none'></td>
  <td width=509 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB style='color:black'>Description of selected adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>In clinical studies, everolimus has been associated with
serious cases of hepatitis&nbsp;B reactivation, including fatal outcome. Reactivation
of infection is an expected reaction during periods of immunosuppression.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>In clinical studies and
post&#8209;marketing spontaneous reports, everolimus has been associated with
renal failure events (including fatal outcome), proteinuria and increased serum
creatinine. Monitoring of renal function is recommended (see section&nbsp;4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>In clinical studies,
everolimus has been associated with haemorrhage events. On rare occasions,
fatal outcomes were observed in the oncology setting (see section&nbsp;4.4). No
serious cases of renal haemorrhage were reported in the TSC setting.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>In clinical studies and post&#8209;marketing spontaneous
reports, everolimus has been associated with cases of pneumocystis jirovecii
(carinii) pneumonia (PJP, PCP), some with fatal outcome (see section&nbsp;4.4).</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Additional adverse reactions of relevance observed in
oncology clinical studies and post&#8209;marketing spontaneous reports, were
cardiac failure, pulmonary embolism, deep vein thrombosis, impaired wound
healing and hyperglycaemia.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>In clinical trials and post-marketing spontaneous reports,
angioedema has been reported with and without concomitant use of ACE inhibitors
(see section&nbsp;</span><span lang=EN-GB style='color:black'>4.4</span><span
lang=EN-GB style='color:black'>).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='color:black'>Paediatric population</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>In the pivotal phase II
study, 22 of the 28 SEGA patients studied were below the age of 18&nbsp;years
and in the pivotal phase III study, 101 of the 117 SEGA patients studied were
below the age of 18&nbsp;years. In the pivotal phase III study in patients with
TSC and refractory seizures, 299 of the 366&nbsp;patients studied were below
the age of 18&nbsp;years. The overall type, frequency and severity of adverse
reactions observed in children and adolescents have been generally consistent
with those observed in adults, with the exception of infections which were
reported at a higher frequency and severity in children below the age of
6&nbsp;years. A total of 49 out of 137&nbsp;patients (36%) aged
&lt;6&nbsp;years had Grade&nbsp;3/4 infections, compared to 53 out of
272&nbsp;patients (19%) aged 6 to &lt;18&nbsp;years and 27 out of
203&nbsp;patients (13%) aged &#8805;18&nbsp;years. Two fatal cases due to
infection were reported in 409&nbsp;patients aged &lt;18&nbsp;years receiving
everolimus.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='color:black'>Elderly</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>In the oncology safety
pooling, 37% of the patients treated with everolimus were &#8805;65&nbsp;years
of age. The number of oncology patients with an adverse reaction leading to
discontinuation of everolimus was higher in patients &#8805;65&nbsp;years of
age (20% versus 13%). The most common adverse reactions leading to
discontinuation were pneumonitis (including interstitial lung disease),
fatigue, dyspnoea, and stomatitis.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB style='color:black'>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Reporting suspected
adverse reactions after authorisation of the medicinal product is important. It
allows continued monitoring of the benefit/risk balance of the medicinal
product. Healthcare professionals are asked to report any suspected adverse
reactions via <span style='background:#D9D9D9'>the national reporting system
listed in </span></span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:black;background:#D9D9D9'>Appendix V</span></a></span><span
lang=EN-GB style='color:black'>.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.9     Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Reported
experience with overdose in humans is very limited. Single doses of up to
70&nbsp;mg have been given with acceptable acute tolerability in the adult
population.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is essential
to assess everolimus blood levels in cases of suspected overdose. General
supportive measures should be initiated in all cases of overdose. Everolimus is
not considered dialysable to any relevant degree (less than 10% was removed
within 6&nbsp;hours of haemodialysis).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A limited number
of paediatric patients have been exposed to doses higher than 10&nbsp;mg/m<sup>2</sup>/day.
No signs of acute toxicity have been reported in these cases.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>5.       PHARMACOLOGICAL PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>5.1     Pharmacodynamic properties</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>Pharmacotherapeutic group: Antin<span style='color:black'>eoplastic
agents, other antineoplastic agents, protein </span>kinase inhibitors, ATC
code: <span style='color:black'>L01XE10</span></span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Mechanism of action</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Everolimus is a
selective mTOR (mammalian target of rapamycin) inhibitor. mTOR is a key serine&#8209;threonine
kinase, the activity of which is known to be upregulated in a number of human
cancers. Everolimus binds to the intracellular protein FKBP&#8209;12, forming a
complex that inhibits mTOR complex&#8209;1 (mTORC1) activity.</span><b><i><span
lang=EN-GB> </span></i></b><span lang=EN-GB>Inhibition of the mTORC1 signalling
pathway interferes with the translation and synthesis of proteins by reducing
the activity of S6 ribosomal protein kinase (S6K1) and eukaryotic elongation
factor 4E&#8209;binding protein (4EBP&#8209;1) that regulate proteins involved
in the cell cycle, angiogenesis and glycolysis. Everolimus can reduce levels of
vascular endothelial growth factor (VEGF). In patients with TSC, treatment with
everolimus increases VEGF&#8209;A and decreases VEGF&#8209;D levels. Everolimus
is a potent inhibitor of the growth and proliferation of tumour cells,
endothelial cells, fibroblasts and blood&#8209;vessel&#8209;associated smooth
muscle cells and has been shown to reduce glycolysis in solid tumours <i>in
vitro</i> and <i>in vivo</i>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Two primary
regulators of mTORC1 signalling are the oncogene suppressors tuberin&#8209;sclerosis
complexes&nbsp;1 &amp; 2 (TSC1, TSC2). Loss of either TSC1 or TSC2 leads to
elevated rheb&#8209;GTP levels, a ras family GTPase, which interacts with the
mTORC1 complex to cause its activation. mTORC1 activation leads to a downstream
kinase signalling cascade, including activation of the S6 kinases. In tuberous
sclerosis complex syndrome, inactivating mutations in the TSC1 or the TSC2 gene
lead to hamartoma formation throughout the body. Besides pathological changes
in brain tissue (such as cortical tubers) which may cause seizures, </span><span
lang=EN-GB>the mTOR pathway is also implicated in the pathogenesis of epilepsy
in TSC. The mTOR regulates protein synthesis and multiple downstream cellular
functions that may influence neuronal excitability and epileptogenesis.
Overactivation of mTOR results in neuronal dysplasia, aberrant axonogenesis and
dendrite formation, increased excitatory synaptic currents, reduced
myelination, and disruption of the cortical laminar structure causing
abnormalities in neuronal development and function. Preclinical studies in
models of mTOR dysregulation in the brain demonstrated that treatment with an
mTOR inhibitor such as everolimus could prolong survival, suppress seizures,
prevent the development of new-onset seizures and prevent premature death. </span><span
lang=EN-GB>In summary, everolimus is highly active in this neuronal model of
TSC, with benefit apparently attributable to effects on mTORC1 inhibition.
However, the exact mechanism of action in the reduction of seizures associated
with TSC is not fully elucidated.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Clinical efficacy and safety</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Phase III study in patients with TSC and refractory seizures</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXIST-3 (Study
CRAD001M2304), a randomised, double-blind, multicentre, three-arm, parallel&#8209;group
phase III study of Votubia versus placebo as adjunctive therapy was conducted
in TSC patients with refractory partial-onset seizures. In the study,
partial-onset seizures were defined as all electroencephalogram (EEG)-confirmed
sensory seizures or motor seizures in which a generalised onset had not been
demonstrated on a past EEG. Patients were treated with concomitant and stable
dose of 1 to 3&nbsp;antiepileptics prior to study entry. </span><span
lang=EN-GB>The study consisted of three phases: an 8-week baseline observation
phase; an 18-week double-blind, placebo-controlled core treatment phase
(composed of titration and maintenance periods), an extension phase of
&#8805;48&nbsp;weeks in which all patients received Votubia and a
post-extension phase of &#8804;48&nbsp;weeks in which all patients received
Votubia.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The study
independently tested two different primary endpoints: 1) response rate defined
as at least a 50% reduction from baseline in frequency of partial-onset
seizures during the maintenance period of the core phase; and 2) percentage
reduction from baseline in frequency of partial-onset seizures during the
maintenance period of the core phase.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Secondary endpoints
included seizure freedom, proportion of patients with <u>&gt;</u>25% seizure
frequency reduction from baseline, distribution of reduction from baseline in
seizure frequency (&#8804;&#8209;25%, &gt;&#8209;25% to &lt;25%; &#8805;25% to
&lt;50%; &#8805;50% to &lt;75%; &#8805;75% to &lt;100%; 100%), long-term evaluation
of seizure frequency and overall quality of life.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A total of
366&nbsp;patients were randomised in a 1:1.09:1 ratio to Votubia (n=117) low
trough (LT) range (3 to 7&nbsp;ng/ml), Votubia (n=130) high trough (HT) range
(9 to 15&nbsp;ng/ml) or placebo (n=119). The median age for the total
population was 10.1&nbsp;years (range: 2.2&#8209;56.3; 28.4% &lt;6&nbsp;years,
30.9% 6 to &lt;12&nbsp;years, 22.4% 12 to &lt;18&nbsp;years and 18.3%
&gt;18&nbsp;years). Median duration of treatment was 18&nbsp;weeks for all
three arms in the core phase and 90&nbsp;weeks (21&nbsp;months) when considering
both the core and extension phases.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>At baseline,
19.4% of patients had focal seizures with retained awareness (sensory
previously confirmed on EEG or motor), 45.1% had focal seizures with impaired
awareness (predominantly non-motor), 69.1% had focal motor seizures (i.e. focal
motor seizures with impaired awareness and/or secondary generalised seizures),
and 1.6% had generalised onset seizures (previously confirmed by EEG). The
median baseline seizure frequency across the treatment arms was 35, 38, and
42&nbsp;seizures per 28&nbsp;days for the Votubia LT, Votubia HT, and placebo
groups, respectively. The majority of patients (67%) failed 5 or more
antiepileptics prior to the study and 41.0% and 47.8% of patients were taking 2
and &#8805;3&nbsp;antiepileptics during the study. The baseline data indicated
mild to moderate mental retardation in patients 6&#8209;18&nbsp;years of age
(scores of 60&#8209;70 on the Adaptive Behavior Composite and Communication,
Daily Living Skills, and Socialization Domain Scores).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>The efficacy results for the primary endpoint are
summarised in Table&nbsp;5.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Table&nbsp;5       EXIST&#8209;3  Seizure frequency response rate
(primary endpoint)</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:3.0pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=294 valign=bottom style='width:220.5pt;border:none;border-top:solid black 1.0pt;
  background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal style='margin-bottom:1.0pt;page-break-after:avoid'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=208 colspan=2 valign=bottom style='width:156.0pt;border:none;
  border-top:solid black 1.0pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='margin-bottom:1.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='color:black'>Votubia</span></b></p>
  </td>
  <td width=104 valign=bottom style='width:78.0pt;border:none;border-top:solid black 1.0pt;
  background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='margin-bottom:1.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='color:black'>Placebo</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=294 valign=bottom style='width:220.5pt;background:white;padding:
  0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal style='margin-bottom:1.0pt;page-break-after:avoid'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=104 valign=bottom style='width:78.0pt;background:white;padding:
  0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='margin-bottom:1.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='color:black'>LT target of
  3&#8209;7&nbsp;ng/ml</span></b></p>
  </td>
  <td width=104 valign=bottom style='width:78.0pt;background:white;padding:
  0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='margin-bottom:1.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='color:black'>HT target of
  9&#8209;15&nbsp;ng/ml</span></b></p>
  </td>
  <td width=104 valign=bottom style='width:78.0pt;background:white;padding:
  0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='margin-bottom:1.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=294 valign=bottom style='width:220.5pt;border:none;border-bottom:
  solid black 1.0pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal style='margin-bottom:1.0pt;page-break-after:avoid'><b><span
  lang=EN-GB style='color:black'>Statistic</span></b></p>
  </td>
  <td width=104 valign=bottom style='width:78.0pt;border:none;border-bottom:
  solid black 1.0pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='margin-bottom:1.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='color:black'>N=117</span></b></p>
  </td>
  <td width=104 valign=bottom style='width:78.0pt;border:none;border-bottom:
  solid black 1.0pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='margin-bottom:1.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='color:black'>N=130</span></b></p>
  </td>
  <td width=104 valign=bottom style='width:78.0pt;border:none;border-bottom:
  solid black 1.0pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='margin-bottom:1.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='color:black'>N=119</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=294 valign=top style='width:220.5pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal style='margin-bottom:1.0pt;page-break-after:avoid'><b><span
  lang=EN-GB style='color:black'>Responders  n (%)</span></b></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='margin-bottom:1.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='color:black'>33  (28.2)</span></b></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='margin-bottom:1.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='color:black'>52  (40.0)</span></b></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='margin-bottom:1.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='color:black'>18  (15.1)</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=294 valign=top style='width:220.5pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal style='margin-bottom:1.0pt;page-break-after:avoid'><span
  lang=EN-GB style='color:black'>     Response rate 95% CI<sup>&nbsp;a</sup></span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='margin-bottom:1.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='color:black'>20.3, 37.3</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='margin-bottom:1.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='color:black'>31.5, 49.0</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='margin-bottom:1.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='color:black'>9.2, 22.8</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=294 valign=top style='width:220.5pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal style='margin-bottom:1.0pt;page-break-after:avoid'><b><span
  lang=EN-GB style='color:black'>Odds ratio (versus placebo)<sup>&nbsp;b</sup></span></b></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='margin-bottom:1.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='color:black'>2.21</span></b></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='margin-bottom:1.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='color:black'>3.93</span></b></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='margin-bottom:1.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=294 valign=top style='width:220.5pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal style='margin-bottom:1.0pt;page-break-after:avoid'><span
  lang=EN-GB style='color:black'>     95% CI</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='margin-bottom:1.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='color:black'>1.16, 4.20</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='margin-bottom:1.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='color:black'>2.10, 7.32</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='margin-bottom:1.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=294 valign=top style='width:220.5pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal style='margin-bottom:1.0pt;page-break-after:avoid'><span
  lang=EN-GB style='color:black'>     p-value (versus placebo)<sup>&nbsp;c</sup></span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='margin-bottom:1.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='color:black'>0.008</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='margin-bottom:1.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='color:black'>&lt;0.001</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='margin-bottom:1.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=294 valign=top style='width:220.5pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:1.0pt;
  margin-left:15.0pt;text-indent:-15.0pt;page-break-after:avoid'><span
  lang=EN-GB style='color:black'>     Statistically significant per
  Bonferroni-Holm procedure<sup>&nbsp;d</sup></span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='margin-bottom:1.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='color:black'>Yes</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='margin-bottom:1.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='color:black'>Yes</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='margin-bottom:1.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=294 valign=top style='width:220.5pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal style='margin-bottom:1.0pt;page-break-after:avoid'><span
  lang=EN-GB style='color:black'>Non-responders  n (%)</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='margin-bottom:1.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='color:black'>84  (71.8)</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='margin-bottom:1.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='color:black'>78  (60.0)</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='margin-bottom:1.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='color:black'>101  (84.9)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=606 colspan=4 valign=top style='width:454.5pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal style='margin-bottom:1.0pt;page-break-after:avoid'><sup><span
  lang=EN-GB style='color:black'>a</span></sup><span lang=EN-GB
  style='color:black'> Exact 95% CI obtained using Clopper-Pearson method</span></p>
  <p class=MsoNormal style='margin-bottom:1.0pt;page-break-after:avoid'><sup><span
  lang=EN-GB style='color:black'>b</span></sup><span lang=EN-GB
  style='color:black'> Odds ratio and its 95% CI obtained using logistic
  regression stratified by age subgroup. Odds ratio &gt;1 favours everolimus
  arm.</span></p>
  <p class=MsoNormal style='margin-bottom:1.0pt;page-break-after:avoid'><sup><span
  lang=EN-GB style='color:black'>c</span></sup><span lang=EN-GB
  style='color:black'> p-values computed from the Cochran-Mantel-Haenszel test
  stratified by age subgroup</span></p>
  <p class=MsoNormal style='margin-bottom:1.0pt;page-break-after:avoid'><sup><span
  lang=EN-GB style='color:black'>d</span></sup><span lang=EN-GB
  style='color:black'> Family-wise error rate of 2.5% one-sided</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>Consistent results were found for
the supportive analysis of the median percentage reduction from baseline in
seizure frequency (other primary endpoint): 29.3% (95% CI: 18.8, 41.9) in the
Votubia LT arm, 39.6% (95% CI: 35.0, 48.7) in the Votubia HT arm and 14.9% (95%
CI: 0.1, 21.7) in the placebo arm. The p-values for superiority versus placebo
were 0.003 (LT) and &lt;0.001 (HT).</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The seizure-free
rate (the proportion of patients who became seizure-free during the maintenance
period of the core phase) was 5.1% (95% CI: 1.9, 10.8) and 3.8% (95% CI: 1.3,
8.7) in the Votubia LT and HT arms, respectively, versus 0.8% (95% CI: 0.0,
4.6) of patients in the placebo arm.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>Higher proportions of responders were evident for all response
categories in the Votubia LT and HT arms relative to placebo (Figure&nbsp;1).
Furthermore, almost twice as many patients in the placebo arm experienced
seizure exacerbation relative to the Votubia LT and HT arms.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Figure&nbsp;1      EXIST&#8209;3  Distribution of reduction from
baseline in seizure frequency</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span style='position:relative;z-index:251684864'><span
style='left:0px;position:absolute;left:-23px;top:-8514px;width:697px;
height:1px'><img width=697 height=1
src="Votubia-II-61%20EN%20PI%20clean_files/image001.png"
alt="0,10,20,30,40,50,Exacerbation&#13;&#10;&#8804;-25&#13;&#10;,No change&#13;&#10;&gt;-25 to &lt;25&#13;&#10;,25% resp.&#13;&#10;25 to &lt;50&#13;&#10;,50% resp.&#13;&#10;50 to &lt;75&#13;&#10;,75% resp.&#13;&#10;75 to &lt;100&#13;&#10;,Seizure-free&#13;&#10;100&#13;&#10;,Missing,Reduction from baseline in seizure frequency (%),Proportion of patients (%),Wide upward diagonal,Votubia 3-7 ng/ml,Votubia 9-15 ng/ml,Placebo,12.8,11.5,20.2,35.0,18.5,41.2,23.9,30.0,22.7,17.1,20.8,9.2,6.0,15.4,5.0,5.1,3.8,0.8,0.8"></span></span><span
style='position:relative;z-index:-1895800832'><span style='left:0px;position:
absolute;left:136px;top:-8129px;width:572px;height:1px'><img width=572
height=1 src="Votubia-II-61%20EN%20PI%20clean_files/image002.png"></span></span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<br clear=ALL>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>A homogeneous and consistent everolimus effect was
observed across all subgroups evaluated for the primary efficacy endpoints by:
age categories (Table&nbsp;6), gender, race and ethnicity, seizure types,
seizure frequency at baseline, number and name of concomitant </span>antiepileptics<span
style='font-size:11.0pt'>, and TSC features (angiomyolipoma, SEGA, cortical
tuber status). The effect of everolimus on infantile/epileptic spasms or on
seizures associated with Lennox-Gastaut syndrome has not been studied and is
not established for generalised-onset seizures and subjects without cortical
tubers.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>Table&nbsp;6       EXIST-3 
Seizure frequency response rate by age</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=620
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width=247 valign=top style='width:185.4pt;border:none;border-top:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=Table style='margin:0in;page-break-after:avoid'><b><span
   style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
   </td>
   <td width=248 colspan=2 valign=top style='width:186.35pt;border:none;
   border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Table align=center style='margin:0in;text-align:center'><b><span
   style='font-size:11.0pt;font-family:"Times New Roman",serif'>Votubia</span></b></p>
   </td>
   <td width=124 valign=top style='width:93.2pt;border:none;border-top:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=Table align=center style='margin:0in;text-align:center'><b><span
   style='font-size:11.0pt;font-family:"Times New Roman",serif'>Placebo</span></b></p>
   </td>
  </tr>
  <tr>
   <td width=247 valign=top style='width:185.4pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Table style='margin:0in;page-break-after:avoid'><b><span
   style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
   </td>
   <td width=124 valign=top style='width:93.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Table align=center style='margin:0in;text-align:center'><b><span
   style='font-size:11.0pt;font-family:"Times New Roman",serif'>LT target of 3&#8209;7&nbsp;ng/ml</span></b></p>
   </td>
   <td width=124 valign=top style='width:93.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Table align=center style='margin:0in;text-align:center'><b><span
   style='font-size:11.0pt;font-family:"Times New Roman",serif'>HT target of 9&#8209;15&nbsp;ng/ml</span></b></p>
   </td>
   <td width=124 valign=top style='width:93.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Table align=center style='margin:0in;text-align:center'><b><span
   style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
   </td>
  </tr>
  <tr>
   <td width=247 valign=top style='width:185.4pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Table style='margin:0in;page-break-after:avoid'><b><span
   style='font-size:11.0pt;font-family:"Times New Roman",serif'>Age category</span></b></p>
   </td>
   <td width=124 valign=top style='width:93.15pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Table align=center style='margin:0in;text-align:center'><b><span
   style='font-size:11.0pt;font-family:"Times New Roman",serif'>N=117</span></b></p>
   </td>
   <td width=124 valign=top style='width:93.2pt;border:none;border-bottom:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=Table align=center style='margin:0in;text-align:center'><b><span
   style='font-size:11.0pt;font-family:"Times New Roman",serif'>N=130</span></b></p>
   </td>
   <td width=124 valign=top style='width:93.2pt;border:none;border-bottom:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=Table align=center style='margin:0in;text-align:center'><b><span
   style='font-size:11.0pt;font-family:"Times New Roman",serif'>N=119</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width=247 valign=top style='width:185.4pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&lt;6&nbsp;years</span></b></p>
  </td>
  <td width=124 valign=top style='width:93.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><b><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>n=33</span></b></p>
  </td>
  <td width=124 valign=top style='width:93.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><b><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>n=37</span></b></p>
  </td>
  <td width=124 valign=top style='width:93.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><b><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>n=34</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=247 valign=top style='width:185.4pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>     Response rate (95% CI)<sup>&nbsp;a</sup></span></p>
  </td>
  <td width=124 valign=top style='width:93.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>30.3 (15.6,
  48.7)</span></p>
  </td>
  <td width=124 valign=top style='width:93.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>59.5 (42.1,
  75.2)</span></p>
  </td>
  <td width=124 valign=top style='width:93.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>17.6 (6.8, 34.5)</span></p>
  </td>
 </tr>
 <tr>
  <td width=247 valign=top style='width:185.4pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>6 to
  &lt;12&nbsp;years</span></b></p>
  </td>
  <td width=124 valign=top style='width:93.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><b><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>n=37</span></b></p>
  </td>
  <td width=124 valign=top style='width:93.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><b><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>n=39</span></b></p>
  </td>
  <td width=124 valign=top style='width:93.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><b><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>n=37</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=247 valign=top style='width:185.4pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>     Response rate (95% CI)<sup>&nbsp;a</sup></span></p>
  </td>
  <td width=124 valign=top style='width:93.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>29.7 (15.9,
  47.0)</span></p>
  </td>
  <td width=124 valign=top style='width:93.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>28.2 (15.0,
  44.9)</span></p>
  </td>
  <td width=124 valign=top style='width:93.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>10.8 (3.0, 25.4)</span></p>
  </td>
 </tr>
 <tr>
  <td width=247 valign=top style='width:185.4pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>12 to
  &lt;18&nbsp;years</span></b></p>
  </td>
  <td width=124 valign=top style='width:93.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><b><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>n=26</span></b></p>
  </td>
  <td width=124 valign=top style='width:93.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><b><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>n=31</span></b></p>
  </td>
  <td width=124 valign=top style='width:93.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><b><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>n=25</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=247 valign=top style='width:185.4pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>     Response rate (95% CI)<sup>&nbsp;a</sup></span></p>
  </td>
  <td width=124 valign=top style='width:93.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>23.1 (9.0, 43.6)</span></p>
  </td>
  <td width=124 valign=top style='width:93.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>32.3 (16.7,
  51.4)</span></p>
  </td>
  <td width=124 valign=top style='width:93.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>16.0 (4.5, 36.1)</span></p>
  </td>
 </tr>
 <tr>
  <td width=247 valign=top style='width:185.4pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&#8805;18&nbsp;years<sup>
  b</sup></span></b></p>
  </td>
  <td width=124 valign=top style='width:93.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><b><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>n=21</span></b></p>
  </td>
  <td width=124 valign=top style='width:93.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><b><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>n=23</span></b></p>
  </td>
  <td width=124 valign=top style='width:93.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><b><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>n=23</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=247 valign=top style='width:185.4pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>     Response rate (95% CI)<sup>&nbsp;a</sup></span></p>
  </td>
  <td width=124 valign=top style='width:93.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>28.6 (11.3,
  52.2)</span></p>
  </td>
  <td width=124 valign=top style='width:93.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>39.1 (19.7,
  61.5)</span></p>
  </td>
  <td width=124 valign=top style='width:93.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>17.4 (5.0, 38.8)</span></p>
  </td>
 </tr>
 <tr>
  <td width=620 colspan=4 valign=top style='width:464.95pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><sup><span style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>a</span></sup><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'> Exact 95% CI obtained using
  Clopper-Pearson method</span></p>
  <p class=Table style='margin:0in'><sup><span style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>b </span></sup><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>No efficacy data available in
  elderly patients</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>At the end of
the core phase, overall quality of life in patients aged 2 to &lt;11&nbsp;years
(as measured by the mean change from baseline in overall Quality Of Life score
[total score] in the Childhood Epilepsy Questionnaire [QOLCE]) was maintained
in each Votubia treatment arm as well as in the placebo arm.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>Reduction in seizure frequency was sustained over an
evaluation period of approximately 2&nbsp;years. Based on a sensitivity
analysis considering patients who prematurely discontinued everolimus as
non-responders, response rates of 38.4% (95% CI: 33.4, 43.7) and 44.4% (95% CI:
38.2, 50.7) were observed after 1 and 2&nbsp;years of exposure to everolimus,
respectively.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Phase III study in SEGA patients </span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXIST&#8209;1
(Study CRAD001M2301), a randomised, double&#8209;blind, multicentre phase III
study of Votubia versus placebo, was conducted in patients with SEGA,
irrespective of age. Patients were randomised in a 2:1&nbsp;ratio to receive
either Votubia or matching placebo. Presence of at least one SEGA lesion &#8805;1.0&nbsp;cm
in longest diameter using MRI (based on local radiology assessment) was
required for entry. In addition, serial radiological evidence of SEGA growth,
presence of a new SEGA lesion &#8805;1&nbsp;cm in longest diameter, or new or
worsening hydrocephalus was required for entry.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The primary
efficacy endpoint was SEGA response rate based on independent central radiology
review. The analysis was stratified by use of enzyme&#8209;inducing
antiepileptics at randomisation (yes/no).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Key secondary
endpoints in hierarchal order of testing included the absolute change in
frequency of total seizure events per 24&#8209;hour EEG from baseline to
week&nbsp;24, time to SEGA progression, and skin lesion response rate.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A total of
117&nbsp;patients were randomised, 78 to Votubia and 39 to placebo. The two
treatment arms were generally well balanced with respect to demographic and
baseline disease characteristics and history of prior anti&#8209;SEGA
therapies. In the total population, 57.3% of patients were male and 93.2% were
Caucasian. The median age for the total population was 9.5&nbsp;years (age
range for the Votubia arm: 1.0 to 23.9; age range for the placebo arm: 0.8 to
26.6), 69.2% of the patients were aged 3 to &lt;18&nbsp;years and 17.1% were
&lt;3&nbsp;years at enrolment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Of the enrolled
patients, 79.5% had bilateral SEGAs, 42.7% had &#8805;2&nbsp;target SEGA
lesions, 25.6% had inferior growth, 9.4% had evidence of deep parenchymal
invasion, 6.8% had radiographic evidence of hydrocephalus, and 6.8% had
undergone prior SEGA&#8209;related surgery. 94.0% had skin lesions at baseline
and 37.6% had target renal angiomyolipoma lesions (at least one angiomyolipoma
&#8805;1&nbsp;cm in longest diameter).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The median
duration of blinded study treatment was 9.6&nbsp;months (range: 5.5 to 18.1)
for patients receiving Votubia and 8.3&nbsp;months (range: 3.2 to 18.3) for
those receiving placebo.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Results showed
that Votubia was superior to placebo for the primary endpoint of best overall
SEGA response (p&lt;0.0001). Response rates were 34.6% (95% CI: 24.2, 46.2) for
the Votubia arm compared with 0% (95% CI: 0.0, 9.0) for the placebo arm
(Table&nbsp;7). In addition, all 8&nbsp;patients on the Votubia arm who had
radiographic evidence of hydrocephalus at baseline had a decrease in
ventricular volume.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients
initially treated with placebo were allowed to cross over to everolimus at the
time of SEGA progression and upon recognition that treatment with everolimus
was superior to treatment with placebo. All patients receiving at least one
dose of everolimus were followed until drug discontinuation or study
completion. At the time of the final analysis, the median duration of exposure
among all such patients was 204.9&nbsp;weeks (range: 8.1 to 253.7). The best
overall SEGA response rate had increased to 57.7% (95% CI: 47.9, 67.0) at the
final analysis.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No patient
required surgical intervention for SEGA during the entire course of the study.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Table&nbsp;7       EXIST&#8209;1  SEGA response</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=618
 style='border-collapse:collapse'>
 <thead>
  <tr style='page-break-inside:avoid;height:11.5pt'>
   <td width=297 valign=top style='width:222.75pt;border:none;border-top:solid black 1.0pt;
   background:white;padding:0in 3.0pt 0in 3.0pt;height:11.5pt'>
   <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
   avoid'><b>&nbsp;</b></p>
   </td>
   <td width=151 colspan=2 valign=top style='width:113.4pt;border:none;
   border-top:solid black 1.0pt;background:white;padding:0in 3.0pt 0in 3.0pt;
   height:11.5pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span style='color:black'>Primary analysis<sup>3</sup></span></b></p>
   </td>
   <td width=66 valign=top style='width:49.6pt;border-top:solid black 1.0pt;
   border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 3.0pt 0in 3.0pt;height:11.5pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b>&nbsp;</b></p>
   </td>
   <td width=104 valign=top style='width:77.95pt;border:none;border-top:solid black 1.0pt;
   background:white;padding:0in 3.0pt 0in 3.0pt;height:11.5pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span style='color:black'>Final analysis<sup>4</sup></span></b></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid;height:11.5pt'>
   <td width=297 valign=top style='width:222.75pt;border:none;border-top:solid black 1.0pt;
   background:white;padding:0in 3.0pt 0in 3.0pt;height:11.5pt'>
   <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
   avoid'><b>&nbsp;</b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border:none;border-top:solid black 1.0pt;
   background:white;padding:0in 3.0pt 0in 3.0pt;height:11.5pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span style='color:black'>Votubia</span></b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border:none;border-top:solid black 1.0pt;
   background:white;padding:0in 3.0pt 0in 3.0pt;height:11.5pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span style='color:black'>Placebo</span></b></p>
   </td>
   <td width=66 valign=top style='width:49.6pt;border-top:solid black 1.0pt;
   border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 3.0pt 0in 3.0pt;height:11.5pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span style='color:black'>p&#8209;value</span></b></p>
   </td>
   <td width=104 valign=top style='width:77.95pt;border:none;border-top:solid black 1.0pt;
   background:white;padding:0in 3.0pt 0in 3.0pt;height:11.5pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span style='color:black'>Votubia</span></b></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=297 valign=bottom style='width:222.75pt;background:white;
   padding:0in 3.0pt 0in 3.0pt'>
   <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
   avoid'><b>&nbsp;</b></p>
   </td>
   <td width=76 valign=bottom style='width:56.7pt;background:white;padding:
   0in 3.0pt 0in 3.0pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span style='color:black'>N=78</span></b></p>
   </td>
   <td width=76 valign=bottom style='width:56.7pt;background:white;padding:
   0in 3.0pt 0in 3.0pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span style='color:black'>N=39</span></b></p>
   </td>
   <td width=66 valign=bottom style='width:49.6pt;border:none;border-right:
   solid windowtext 1.0pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b>&nbsp;</b></p>
   </td>
   <td width=104 valign=top style='width:77.95pt;border:none;background:white;
   padding:0in 3.0pt 0in 3.0pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span style='color:black'>N=111</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width=297 valign=top style='width:222.75pt;border:none;border-top:solid windowtext 1.0pt;
  background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span style='color:black'>          SEGA response rate<sup>1,2</sup> -
  (%)</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-top:solid windowtext 1.0pt;
  background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>34.6</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-top:solid windowtext 1.0pt;
  background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>0</span></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>&lt;0.0001</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border:none;border-top:solid windowtext 1.0pt;
  background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>57.7</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=297 valign=top style='width:222.75pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span style='color:black'>          95% CI</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>24.2, 46.2</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>0.0, 9.0</span></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border:none;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border:none;background:white;
  padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>47.9, 67.0</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=297 valign=top style='width:222.75pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><b><span style='color:black'>Best overall SEGA response - (%)</span></b></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b>&nbsp;</b></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b>&nbsp;</b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border:none;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b>&nbsp;</b></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border:none;background:white;
  padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b>&nbsp;</b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=297 valign=top style='width:222.75pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span style='color:black'>          Response</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>34.6</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>0</span></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border:none;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border:none;background:white;
  padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>57.7</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=297 valign=top style='width:222.75pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span style='color:black'>          Stable disease</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>62.8</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>92.3</span></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border:none;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border:none;background:white;
  padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>39.6</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=297 valign=top style='width:222.75pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span style='color:black'>          Progression</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>0</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>7.7</span></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border:none;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border:none;background:white;
  padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>0</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=297 valign=top style='width:222.75pt;border:none;border-bottom:
  solid windowtext 1.0pt;background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal style='text-align:justify;line-height:normal;page-break-after:
  avoid'><span style='color:black'>          Not evaluable</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>2.6</span></p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>0</span></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border:none;border-bottom:solid windowtext 1.0pt;
  background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='color:black'>2.7</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=618 colspan=5 valign=top style='width:463.7pt;border:none;
  background:white;padding:0in 3.0pt 0in 3.0pt'>
  <p class=MsoNormal style='margin-left:10.9pt;text-indent:-10.9pt;line-height:
  normal;page-break-after:avoid'><sup><span style='color:black'>1</span></sup><span
  style='color:black'>   according to independent central radiology review</span></p>
  <p class=MsoNormal style='margin-left:10.9pt;text-indent:-10.9pt;line-height:
  normal;page-break-after:avoid'><sup><span style='color:black'>2</span></sup><span
  style='color:black'>   SEGA responses were confirmed with a repeat scan.
  Response was defined as: &#8805;50% reduction in the sum of SEGA volume
  relative to baseline, plus no unequivocal worsening of non&#8209;target SEGA
  lesions, plus absence of new SEGA &#8805;1&nbsp;cm in longest diameter, plus
  no new or worsening hydrocephalus</span></p>
  <p class=MsoNormal style='margin-left:10.9pt;text-indent:-10.9pt;line-height:
  normal;page-break-after:avoid'><sup><span style='color:black'>3</span></sup><span
  style='color:black'>   Primary analysis for double blind period</span></p>
  <p class=MsoNormal style='margin-left:10.9pt;text-indent:-10.9pt;line-height:
  normal;page-break-after:avoid'><sup><span style='color:black'>4</span></sup><span
  style='color:black'>   Final analysis includes patients who crossed over from
  the placebo group; median duration of exposure to everolimus of
  204.9&nbsp;weeks</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>Consistent treatment effects were
observed across all subgroups evaluated (i.e. <span lang=EN-GB>enzyme&#8209;inducing
antiepileptic</span> use versus <span lang=EN-GB>enzyme&#8209;inducing
antiepileptic</span> non&#8209;use, sex and age) at the primary analysis.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>During the double-blind period,
reduction of SEGA volume was evident within the initial 12&nbsp;weeks of
Votubia treatment: 29.7% (22/74) of patients had &#8805;50% reductions in
volume and 73.0% (54/74) had &#8805;30% reductions in volume. Sustained
reductions were evident at week&nbsp;24, 41.9% (31/74) of patients had
&#8805;50% reductions and 78.4% (58/74) of patients had &#8805;30% reductions
in SEGA volume.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>In the everolimus treated
population (N=111) of the study, including patients who crossed over from the
placebo group, tumour response, starting as early as after 12&nbsp;weeks on
everolimus, was sustained at later time points. The proportion of patients
achieving at least 50% reductions in SEGA volume was 45.9% (45/98) and 62.1%
(41/66) at weeks&nbsp;96 and 192 after start of everolimus treatment.
Similarly, the proportion of patients achieving at least 30% reductions in SEGA
volume was 71.4% (70/98) and 77.3% (51/66) at weeks&nbsp;96 and 192 after start
of everolimus treatment.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>Analysis of the first key
secondary endpoint, change in seizure frequency, was inconclusive; thus,
despite the fact that positive results were observed for the two subsequent
secondary endpoints (time to SEGA progression and skin lesion response rate),
they could not be declared formally statistically significant.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>Median time to SEGA progression
based on central radiology review was not reached in either treatment arm.
Progressions were only observed in the placebo arm (15.4%; p=0.0002). Estimated
progression&#8209;free rates at 6&nbsp;months were 100% for the Votubia arm and
85.7% for the placebo arm. The long-term follow-up of patients randomised to
everolimus and patients randomised to placebo who thereafter crossed over to
everolimus demonstrated durable responses.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>At the time of the primary
analysis, Votubia demonstrated clinically meaningful improvements in skin
lesion response (p=0.0004), with response rates of 41.7% (95% CI: 30.2, 53.9)
for the Votubia arm and 10.5% (95% CI: 2.9, 24.8) for the placebo arm. At the
final analysis, the skin lesion response rate increased to 58.1% (95% CI: 48.1,
67.7).</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Phase II study in patients with SEGA</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A prospective,
open&#8209;label, single&#8209;arm phase II study (Study CRAD001C2485) was
conducted to evaluate the safety and efficacy of Votubia in patients with SEGA.
Radiological evidence of serial SEGA growth was required for entry.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Change in SEGA
volume during the core 6&#8209;month treatment phase, as assessed via an
independent central radiology review, was the primary efficacy endpoint. After
the core treatment phase, patients could be enrolled into an extension phase
where SEGA volume was assessed every 6&nbsp;months.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In total,
28&nbsp;patients received treatment with Votubia; median age was 11&nbsp;years
(range 3 to 34), 61% male, 86% Caucasian. Thirteen patients (46%) had a
secondary smaller SEGA, including 12 in the contralateral ventricle.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Primary SEGA
volume was reduced at month&nbsp;6 compared to baseline (p&lt;0.001 [see
Table&nbsp;8]). No patient developed new lesions, worsening hydrocephalus or
increased intracranial pressure, and none required surgical resection or other
therapy for SEGA.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Table&nbsp;8       Change in primary SEGA volume over time</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=612
 style='border-collapse:collapse;border:none'>
 <tr style='height:10.4pt'>
  <td width=83 valign=top style='width:62.1pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:10.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>SEGA
  volume (cm<sup>3</sup>)</b></p>
  </td>
  <td width=529 colspan=7 valign=top style='width:396.85pt;border:none;
  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>Independent
  central review</b></p>
  </td>
 </tr>
 <thead>
  <tr style='height:23.6pt'>
   <td width=83 valign=top style='width:62.1pt;border:none;border-bottom:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:23.6pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>&nbsp;</b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:23.6pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b>Baseline</b></p>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b>n=28</b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:23.6pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b>Month&nbsp;6</b></p>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b>n=27</b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:23.6pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b>Month&nbsp;12</b></p>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b>n=26</b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:23.6pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b>Month&nbsp;24</b></p>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b>n=24</b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:23.6pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b>Month&nbsp;36</b></p>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b>n=23</b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:23.6pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b>Month&nbsp;48</b></p>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b>n=24</b></p>
   </td>
   <td width=76 valign=top style='width:56.65pt;border:none;border-bottom:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:23.6pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b>Month&nbsp;60</b></p>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b>n=23</b></p>
   </td>
  </tr>
 </thead>
 <tr style='height:11.15pt'>
  <td width=612 colspan=8 valign=top style='width:458.95pt;border:none;
  padding:0in 5.4pt 0in 5.4pt;height:11.15pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>Primary
  tumour volume</b></p>
  </td>
 </tr>
 <tr style='height:15.2pt'>
  <td width=83 valign=top style='width:62.1pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>Mean
  (standard deviation)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>2.45 (2.813)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1.33 (1.497)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1.26 (1.526)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1.19 (1.042)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1.26 (1.298)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1.16 (0.961)</p>
  </td>
  <td width=76 valign=top style='width:56.65pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1.24 (0.959)</p>
  </td>
 </tr>
 <tr style='height:15.2pt'>
  <td width=83 valign=top style='width:62.1pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>Median</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1.74</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.93</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.84</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.94</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1.12</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1.02</p>
  </td>
  <td width=76 valign=top style='width:56.65pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1.17</p>
  </td>
 </tr>
 <tr style='height:15.2pt'>
  <td width=83 valign=top style='width:62.1pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>     Range</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.49 - 14.23</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.31 - 7.98</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.29 - 8.18</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.20 - 4.63</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.22 - 6.52</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.18 - 4.19</p>
  </td>
  <td width=76 valign=top style='width:56.65pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.21 - 4.39</p>
  </td>
 </tr>
 <tr style='height:15.2pt'>
  <td width=612 colspan=8 valign=top style='width:458.95pt;border:none;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>Reduction
  from baseline</b></p>
  </td>
 </tr>
 <tr style='height:15.2pt'>
  <td width=83 valign=top style='width:62.1pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>Mean
  (standard deviation)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1.19 (1.433)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1.07 (1.276)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1.25 (1.994)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1.41 (1.814)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1.43 (2.267)</p>
  </td>
  <td width=76 valign=top style='width:56.65pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1.44 (2.230)</p>
  </td>
 </tr>
 <tr style='height:15.2pt'>
  <td width=83 valign=top style='width:62.1pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>Median</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.83</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.85</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.71</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.71</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.83</p>
  </td>
  <td width=76 valign=top style='width:56.65pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.50</p>
  </td>
 </tr>
 <tr style='height:15.2pt'>
  <td width=83 valign=top style='width:62.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>     Range</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.06 - 6.25</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.02 - 6.05</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>-0.55 - 9.60</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.15 - 7.71</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0.00 - 10.96</p>
  </td>
  <td width=76 valign=top style='width:56.65pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>-0.74 - 9.84</p>
  </td>
 </tr>
 <tr style='height:15.2pt'>
  <td width=612 colspan=8 valign=top style='width:458.95pt;border:none;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>Percentage
  reduction from baseline, n (%)</b></p>
  </td>
 </tr>
 <tr style='height:15.2pt'>
  <td width=83 valign=top style='width:62.1pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>     &#8805;50%</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>9 (33.3)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>9 (34.6)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>12 (50.0)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>10 (43.5)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>14 (58.3)</p>
  </td>
  <td width=76 valign=top style='width:56.65pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>12 (52.2)</p>
  </td>
 </tr>
 <tr style='height:15.2pt'>
  <td width=83 valign=top style='width:62.1pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>     &#8805;30%</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>21 (77.8)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>20 (76.9)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>19 (79.2)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>18 (78.3)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>19 (79.2)</p>
  </td>
  <td width=76 valign=top style='width:56.65pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>14 (60.9)</p>
  </td>
 </tr>
 <tr style='height:15.2pt'>
  <td width=83 valign=top style='width:62.1pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>     &gt;0%</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>27</p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>(100.0)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>26</p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>(100.0)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>23</p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>(95.8)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>23</p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>(100.0)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>23</p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>(95.8)</p>
  </td>
  <td width=76 valign=top style='width:56.65pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>21</p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>(91.3)</p>
  </td>
 </tr>
 <tr style='height:15.2pt'>
  <td width=83 valign=top style='width:62.1pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;line-height:
  normal;page-break-after:avoid'>     No change</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1 (4.2)</p>
  </td>
  <td width=76 valign=top style='width:56.65pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0</p>
  </td>
 </tr>
 <tr style='height:15.2pt'>
  <td width=83 valign=top style='width:62.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>     Increase</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>1 (4.2)</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0</p>
  </td>
  <td width=76 valign=top style='width:56.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>0</p>
  </td>
  <td width=76 valign=top style='width:56.65pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>2 (8.7)</p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The robustness and consistency of the primary analysis were
supported by the:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>change in primary SEGA volume as per local
investigator assessment (p&lt;0.001), with 75.0% and 39.3% of patients
experiencing reductions of &#8805;30% and &#8805;50%, respectively</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>change in total SEGA volume as per independent
central review (p&lt;0.001) or local investigator assessment (p&lt;0.001).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>One patient met
the pre&#8209;specified criteria for treatment success (&gt;75% reduction in
SEGA volume) and was temporarily taken off trial therapy; however, SEGA re&#8209;growth
was evident at the next assessment at 4.5&nbsp;months and treatment was
restarted.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Long&#8209;term
follow&#8209;up to a median duration of 67.8&nbsp;months (range: 4.7 to 83.2)
demonstrated sustained efficacy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Other studies</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Stomatitis is
the most commonly reported adverse reaction in patients treated with Votubia
(see sections&nbsp;4.4 and 4.8). In a post-marketing single-arm study in
postmenopausal women with advanced breast cancer (N=92), topical treatment with
dexamethasone 0.5&nbsp;mg/5&nbsp;ml alcohol-free oral solution was administered
as a mouthwash (4&nbsp;times daily for the initial 8&nbsp;weeks of treatment)
to patients at the time of initiating treatment with Afinitor (everolimus,
10&nbsp;mg/day) plus exemestane (25&nbsp;mg/day) to reduce the incidence and
severity of stomatitis. The incidence of Grade&nbsp;&#8805;2 stomatitis at
8&nbsp;weeks was 2.4% (n=2/85&nbsp;evaluable patients) which was lower than
historically reported. The incidence of Grade&nbsp;1 stomatitis was 18.8%
(n=16/85) and no cases of Grade&nbsp;3 or 4 stomatitis were reported. The
overall safety profile in this study was consistent with that established for
everolimus in the oncology and TSC settings, with the exception of a slightly
increased frequency of oral candidiasis which was reported in 2.2% (n=2/92) of patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The European
Medicines Agency has</span><span lang=EN-GB> waived the obligation to submit
the results of studies with Votubia in all subsets of the paediatric population
in angiomyolipoma (see section&nbsp;4.2 for information on paediatric use).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span style='color:black'>The marketing
authorisation holder has completed the Paediatric Investigation Plans for
Votubia for </span><span lang=EN-GB>refractory seizures associated with </span><span
style='color:black'>TSC. This </span><span lang=EN-GB>summary of product
characteristics</span><span lang=EN-GB style='color:black'> </span><span
style='color:black'>has been updated to include the results of studies with
Votubia in the paediatric population (see section 5.2).</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>5.2     Pharmacokinetic properties</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Absorption</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In patients with
advanced solid tumours, peak everolimus concentrations (C<sub>max</sub>) are
reached at a median time of 1&nbsp;hour after daily administration of 5 and
10&nbsp;mg everolimus under fasting conditions or with a light fat&#8209;free
snack. C<sub>max</sub> is dose&#8209;proportional between 5 and 10&nbsp;mg.
Everolimus is a substrate and moderate inhibitor of PgP.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Food effect</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In healthy
subjects, high fat meals reduced systemic exposure to Votubia 10&nbsp;mg
tablets (as measured by AUC) by 22% and the peak blood concentration C<sub>max</sub>
by 54%. Light fat meals reduced AUC by 32% and C<sub>max </sub>by 42%.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In healthy
subjects taking a single 9&nbsp;mg dose (3 x 3&nbsp;mg) of Votubia dispersible
tablets in suspension, high fat meals reduced AUC by 11.7% and the peak blood
concentration C<sub>max</sub> by 59.8%. Light fat meals reduced AUC by 29.5%
and C<sub>max</sub> by 50.2%.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Food, however,
had no apparent effect on the post absorption phase concentration&#8209;time
profile 24&nbsp;hours post-dose of either dosage form.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Relative bioavailability/bioequivalence</span></u></i></p>

<p class=MsoNormal style='line-height:normal'>In a relative bioavailability
study,<span style='color:#4F81BD'> </span>AUC<sub>0&#8209;inf</sub> of 5 x
1&nbsp;mg everolimus tablets when administered as suspension in water was
equivalent to 5 x 1&nbsp;mg everolimus tablets administered as intact tablets,
and C<sub>max</sub> of 5 x 1&nbsp;mg everolimus tablets in suspension was 72%
of 5 x 1&nbsp;mg intact everolimus tablets.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>In a bioequivalence study,<span
style='color:#4F81BD'> </span>AUC<sub>0&#8209;inf</sub> of the 5&nbsp;mg
dispersible tablet when administered as suspension in water was equivalent to 5
x 1&nbsp;mg intact everolimus tablets, and C<sub>max</sub> of the 5&nbsp;mg
dispersible tablet in suspension was 64% of 5 x 1&nbsp;mg intact everolimus
tablets.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Distribution</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The blood&#8209;to&#8209;plasma
ratio of everolimus, which is concentration&#8209;dependent over the range of 5
to 5,000&nbsp;ng/ml, is 17% to 73%. </span><span lang=EN-GB>Approximately 20%
of the everolimus concentration in whole blood is confined to plasma of cancer
patients given Votubia 10&nbsp;mg/day. </span><span lang=EN-GB>Plasma protein
binding is approximately 74% both in healthy subjects and in patients with
moderate hepatic impairment. In patients with advanced solid tumours, V<sub>d</sub>
was 191&nbsp;l for the apparent central compartment and 517&nbsp;l for the
apparent peripheral compartment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Nonclinical studies in rats indicate:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
-28.35pt;line-height:normal;text-autospace:none'><span style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>A rapid uptake of everolimus in the brain followed by a slow
efflux.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
-28.35pt;line-height:normal;text-autospace:none'><span style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>The radioactive metabolites of [3H]everolimus do not
significantly cross the blood&#8209;brain barrier.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
-28.35pt;line-height:normal;text-autospace:none'><span style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>A dose&#8209;dependent brain penetration of everolimus, which is
consistent with the hypothesis of saturation of an efflux pump present in the
brain capillary endothelial cells.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-indent:
-28.35pt;line-height:normal;text-autospace:none'><span style='font-family:Symbol;
color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>The co&#8209;administration of the PgP inhibitor, cyclosporine,
enhances the exposure of everolimus in the brain cortex, which is consistent
with the inhibition of PgP at the blood&#8209;brain barrier.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='text-autospace:none'><span style='color:black'>There
are no clinical data on the distribution of everolimus in the human brain. </span><span
lang=EN-GB>Non&#8209;clinical studies in rats demonstrated distribution into
the brain following administration by both the intravenous and oral routes.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Biotransformation</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Everolimus is a
substrate of CYP3A4 and PgP. Following oral administration, everolimus is the
main circulating component in human blood. Six main metabolites of everolimus
have been detected in human blood, including three monohydroxylated
metabolites, two hydrolytic ring&#8209;opened products, and a
phosphatidylcholine conjugate of everolimus. These metabolites were also
identified in animal species used in toxicity studies, and showed approximately
100&nbsp;times less activity than everolimus itself. Hence, everolimus is
considered to contribute the majority of the overall pharmacological activity.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Elimination</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Mean CL/F of
everolimus after 10&nbsp;mg daily dose in patients with advanced solid tumours
was 24.5&nbsp;l/h. The mean elimination half&#8209;life of everolimus is
approximately 30&nbsp;hours.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No specific
excretion studies have been undertaken in cancer patients; however, data are
available from the studies in transplant patients. Following the administration
of a single dose of radiolabelled everolimus in conjunction with ciclosporin,
80% of the radioactivity was recovered from the faeces, while 5% was excreted
in the urine. The parent substance was not detected in urine or faeces.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Steady&#8209;state pharmacokinetics</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After
administration of everolimus in patients with advanced solid tumours, steady&#8209;state
AUC<sub>0&#8209;&#964;</sub> was dose&#8209;proportional over the range of 5 to
10&nbsp;mg daily dose. Steady&#8209;state was achieved within 2&nbsp;weeks. C<sub>max</sub>
is dose&#8209;proportional between 5 and 10&nbsp;mg. t<sub>max</sub> occurs at
1 to 2&nbsp;hours post&#8209;dose. There was a significant correlation between
AUC<sub>0&#8209;&#964;</sub> and pre&#8209;dose trough concentration at steady&#8209;state.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Special populations</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Hepatic impairment</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The safety,
tolerability and pharmacokinetics of Votubia were evaluated in two single oral
dose studies of Votubia tablets in 8 and 34&nbsp;adult subjects with impaired
hepatic function relative to subjects with normal hepatic function.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the first
study, the average AUC of everolimus in 8&nbsp;subjects with moderate hepatic
impairment (Child-Pugh B) was twice that found in 8&nbsp;subjects with normal
hepatic function.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the second
study of 34&nbsp;subjects with different impaired hepatic function compared to
normal subjects, there was a 1.6&#8209;fold, 3.3&#8209;fold and 3.6&#8209;fold
increase in exposure (i.e. AUC<sub>0&#8209;inf</sub>) for subjects with mild
(Child&#8209;Pugh A), moderate (Child&#8209;Pugh B) and severe (Child&#8209;Pugh
C) hepatic impairment, respectively.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Simulations of
multiple dose pharmacokinetics support the dosing recommendations in subjects
with hepatic impairment based on their Child&#8209;Pugh status.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Based on the
results of the two studies, dose adjustment is recommended for patients with
hepatic impairment (see sections&nbsp;4.2 and 4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Renal impairment</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In a population
pharmacokinetic analysis of 170&nbsp;patients with advanced solid tumours, no
significant influence of creatinine clearance (25&#8209;178&nbsp;ml/min) was
detected on CL/F of everolimus. Post&#8209;transplant renal impairment
(creatinine clearance range 11&#8209;107&nbsp;ml/min) did not affect the
pharmacokinetics of everolimus in transplant patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Paediatric population</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In patients with
SEGA, everolimus C<sub>min</sub> was approximately dose&#8209;proportional
within the dose range from 1.35&nbsp;mg/m<sup>2</sup> to 14.4&nbsp;mg/m<sup>2</sup>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In patients with
SEGA, the geometric mean C<sub>min</sub> values normalised to mg/m<sup>2</sup>
dose in patients aged &lt;10&nbsp;years and 10&#8209;18&nbsp;years were lower
by 54% and 40%, respectively, than those observed in adults (&gt;18&nbsp;years
of age), suggesting that everolimus clearance was higher in younger patients.
Limited data in patients &lt;3&nbsp;years of age (n=13) indicate that BSA&#8209;normalised
clearance is about two&#8209;fold higher in patients with low BSA (BSA of
0.556&nbsp;m<sup>2</sup>) than in adults. Therefore it is assumed that steady&#8209;state
could be reached earlier in patients &lt;3&nbsp;years of age (see
section&nbsp;4.2 for dosing recommendations).</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>The pharmacokinetics of
everolimus have not been studied in patients younger than 1&nbsp;year of age.
It is reported, however, that CYP3A4 activity is reduced at birth and increases
during the first year of life, which could affect the clearance in this patient
population.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>A population pharmacokinetic
analysis including 111&nbsp;patients with SEGA who ranged from 1.0 to
27.4&nbsp;years (including 18&nbsp;patients 1 to less than 3&nbsp;years of age
with BSA 0.42&nbsp;m<sup>2</sup> to 0.74&nbsp;m<sup>2</sup>) showed that
BSA-normalised clearance is in general higher in younger patients. Population
pharmacokinetic model simulations showed that a starting dose of 7&nbsp;mg/m<sup>2</sup>
would be necessary to attain C<sub>min</sub> within the 5 to 15&nbsp;ng/ml
range in patients younger than 3&nbsp;years of age. A higher starting dose of
7&nbsp;mg/m<sup>2</sup> is therefore recommended for patients 1 to less than
3&nbsp;years of age with SEGA (see section&nbsp;4.2).</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>In patients with TSC and
refractory seizures receiving Votubia dispersible tablets, a trend was observed
toward lower C<sub>min</sub> normalised to dose (as mg/m<sup>2</sup>) in
younger patients. Median C<sub>min</sub> normalised to mg/m<sup>2</sup> dose
was lower for the younger age groups, indicating that everolimus clearance
(normalised to body surface area) was higher in younger patients.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>In patients with TSC and
refractory seizures Votubia concentrations were investigated in n=9 patients in
the age between 1 and&lt;2 years. Doses of 6 mg/m2 (absolute doses range 1-5
mg) were administered and resulted in minimal concentrations between 2 and 10
ng/ml <span lang=EN-GB>(median of 5 ng/mL; total of &gt;50 measurements)</span>.
No data are available in patients with TSC-seizures below the age of 1 year. </p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Elderly</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In a population
pharmacokinetic evaluation in cancer patients, no significant influence of age
(27&#8209;85&nbsp;years) on oral clearance of everolimus was detected.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Ethnicity</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral clearance
(CL/F) is similar in Japanese and Caucasian cancer patients with similar liver
functions. Based on analysis of population pharmacokinetics, oral clearance
(CL/F) is on average 20% higher in black transplant patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Pharmacokinetic/pharmacodynamic relationship(s)</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>In patients with TSC and
refractory seizures, a conditional logistic regression analysis based on the
core phase of Study CRAD001M2304 to estimate the probability of seizure
response versus Time Normalized(TN)-C<sub>min</sub> stratified by age
sub-group, indicated that a 2-fold increase in TN-C<sub>min</sub> was
associated with a 2.172-fold increase (95% CI: 1.339, 3.524) in the odds for a
seizure response <span lang=EN-GB>over the observed TN-C<sub>min</sub> ranges
of 0.97&nbsp;ng/ml to 16.40&nbsp;ng/ml</span>. Baseline seizure frequency was a
significant factor in the seizure response (with an odds ratio of 0.978 [95%
CI: 0.959, 0.998]). This outcome was consistent with the results of a linear
regression model predicting the log of absolute seizure frequency during the
maintenance period of the core phase, which indicated that for a 2-fold
increase in TN-C<sub>min</sub> there was a statistically significant 28%
reduction (95% CI: 12%, 42%) in absolute seizure frequency. Baseline seizure
frequency and TN-C<sub>min</sub> were both significant factors (&#945;=0.05) in
predicting the absolute seizure frequency in the linear regression model.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>5.3     Preclinical safety data</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The non&#8209;clinical
safety profile of everolimus was assessed in mice, rats, minipigs, monkeys and
rabbits. The major target organs were male and female reproductive systems
(testicular tubular degeneration, reduced sperm content in epididymides and
uterine atrophy) in several species; lungs (increased alveolar macrophages) in
rats and mice; </span><span lang=EN-GB>pancreas (degranulation and vacuolation
of exocrine cells in monkeys and minipigs, respectively, and degeneration of
islet cells in monkeys), </span><span lang=EN-GB>and eyes (lenticular anterior
suture line opacities) in rats only. Minor kidney changes were seen in the rat
(exacerbation of age&#8209;related lipofuscin in tubular epithelium, increases
in hydronephrosis) and mouse (exacerbation of background lesions). There was no
indication of kidney toxicity in monkeys or minipigs.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Everolimus
appeared to spontaneously exacerbate background diseases (chronic myocarditis
in rats, coxsackie virus infection of plasma and heart in monkeys, coccidian
infestation of the gastrointestinal tract in minipigs, skin lesions in mice and
monkeys). These findings were generally observed at systemic exposure levels
within the range of therapeutic exposure or above, with the exception of the
findings in rats, which occurred below therapeutic exposure due to a high
tissue distribution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In a male
fertility study in rats, testicular morphology was affected at 0.5&nbsp;mg/kg
and above, and sperm motility, sperm head count, and plasma testosterone levels
were diminished at 5&nbsp;mg/kg, which is within the range of therapeutic
exposure and which caused a reduction in male fertility. There was evidence of
reversibility.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In animal
reproductive studies female fertility was not affected. However, oral doses of
everolimus in female rats at &#8805; 0.1&nbsp;mg/kg (approximately 4% of the
AUC<sub>0-24h</sub> in patients receiving the 10&nbsp;mg daily dose) resulted
in increases in pre-implantation loss.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Everolimus
crossed the placenta and was toxic to the foetus. In rats, everolimus caused
embryo/foetotoxicity at systemic exposure below the therapeutic level. This was
manifested as mortality and reduced foetal weight. The incidence of skeletal
variations and malformations (e.g. sternal cleft) was increased at 0.3 and
0.9&nbsp;mg/kg. In rabbits, embryotoxicity was evident in an increase in late
resorptions.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In juvenile rat
toxicity studies, systemic toxicity included decreased body weight gain, food
consumption, and delayed attainment of some developmental landmarks, with full
or partial recovery after cessation of dosing. With the possible exception of
the rat&#8209;specific lens finding (where young animals appeared to be more
susceptible), it appears that there is no significant difference in the
sensitivity of juvenile animals to the adverse reactions of everolimus as
compared to adult animals. Toxicity study with juvenile monkeys did not show
any relevant toxicity.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Genotoxicity
studies covering relevant genotoxicity endpoints showed no evidence of
clastogenic or mutagenic activity. Administration of everolimus for up to
2&nbsp;years did not indicate any oncogenic potential in mice and rats up to
the highest doses, corresponding respectively to 4.3 and 0.2&nbsp;times the estimated
clinical exposure.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.       PHARMACEUTICAL PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.1     List of excipients</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Butylated hydroxytoluene (E321)</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Magnesium stearate</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Lactose monohydrate</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Hypromellose</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Crospovidone type A</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=IT>Mannitol</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=IT>Cellulose microcrystalline</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=IT>Silica colloidal anhydrous</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=IT>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.2     Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not applicable.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.3     Shelf life</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Votubia 1&nbsp;mg dispersible tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2&nbsp;years.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Votubia 2&nbsp;mg dispersible tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>3&nbsp;years.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Votubia 3&nbsp;mg dispersible tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>3&nbsp;years.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Votubia 5&nbsp;mg dispersible tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>3&nbsp;years.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The stability of
the ready to use suspension has been demonstrated for 30&nbsp;minutes</span><span
lang=EN-GB> when using an oral syringe or 60&nbsp;minutes when using a small
glass</span><span lang=EN-GB>. </span><span lang=EN-GB>The suspension must be
administered immediately after preparation. If not administered within 30&nbsp;minutes
of preparation when using an oral syringe or 60&nbsp;minutes when using a small
glass, the suspension must be discarded and a new suspension must be prepared.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.4     Special precautions for storage</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicinal
product does not require any special temperature storage conditions. Store in
the original package in order to protect from light and moisture.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.5     Nature and contents of container</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aluminium/polyamide/aluminium/PVC
perforated unit-dose blister containing 10&nbsp;x&nbsp;1&nbsp;dispersible
tablets.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Votubia 1&nbsp;mg dispersible tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Packs containing
30&nbsp;x&nbsp;1&nbsp;dispersible tablets.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Votubia 2&nbsp;mg dispersible tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Packs containing
10&nbsp;x&nbsp;1, 30&nbsp;x&nbsp;1 or 100&nbsp;x&nbsp;1&nbsp;dispersible
tablets.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Votubia 3&nbsp;mg dispersible tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Packs containing
30&nbsp;x&nbsp;1 or 100&nbsp;x&nbsp;1&nbsp;dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Votubia 5&nbsp;mg dispersible tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Packs containing
30&nbsp;x&nbsp;1 or 100&nbsp;x&nbsp;1&nbsp;dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not all pack
sizes may be marketed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.6     Special precautions for disposal and other handling</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span style='color:black'>Instructions for use and handling</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><u><span style='color:black'>Using an oral syringe</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
style='color:black'>The prescribed dose of Votubia dispersible tablets should
be placed in a 10&nbsp;ml </span><span lang=EN-GB>oral dosing syringe graduated
in 1&nbsp;ml increments</span><span style='color:black'>. A total of 10&nbsp;mg
of Votubia dispersible tablets per syringe using a maximum of
5&nbsp;dispersible tablets must not be exceeded. If a higher dose or number of
tablets is required, an additional syringe must be prepared. The dispersible
tablets must not be broken or crushed. Approximately 5&nbsp;ml of water and
4&nbsp;ml of air should be drawn into the syringe. The filled syringe should be
placed into a container (with the tip pointing up) for 3&nbsp;minutes, until
the Votubia dispersible tablets are in suspension. The syringe should be gently
inverted 5&nbsp;times immediately prior to administration. After administration
of the prepared suspension, approximately 5&nbsp;ml of water and 4&nbsp;ml of
air should be drawn into the same syringe, and the contents should be swirled
to suspend remaining particles. The entire contents of the syringe should be
administered.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><u><span style='color:black'>Using a </span></u></i><i><u><span
style='color:black'>small</span></u></i><i><u><span style='color:black'> glass</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
style='color:black'>The prescribed dose of Votubia dispersible tablets should
be placed in a small glass (maximum size 100&nbsp;ml) containing approximately
25&nbsp;ml of water. A total of 10&nbsp;mg of Votubia dispersible tablets per
glass using a maximum of 5&nbsp;dispersible tablets must not be exceeded. If a
higher dose or number of tablets is required, an additional glass must be
prepared. The dispersible tablets must not be broken or crushed. Three minutes
must be allowed for suspension to occur. The contents should be gently stirred
with a spoon and then administered immediately. After administration of the
prepared suspension, 25&nbsp;ml of water should be added and be stirred with
the same spoon to re&#8209;suspend any remaining particles. The entire contents
of the glass should be administered.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A complete and
illustrated set of instructions for use is provided at the end of the package
leaflet Instructions for use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Important information for caregivers</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The extent of
absorption of everolimus through topical exposure is not known. Therefore
caregivers are advised to avoid contact with the suspension. Hands should be
washed thoroughly before and after preparation of the suspension.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Disposal</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Any unused
medicinal product or waste material should be disposed of in accordance with
local requirements.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>7.       MARKETING AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ireland</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>8.       MARKETING AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=FR-CH>Votubia 1&nbsp;mg dispersible tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>EU/1/11/710/016</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=FR-CH>Votubia 2&nbsp;mg dispersible tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>EU/1/11/710/009&#8209;011</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=FR-CH>Votubia 3&nbsp;mg dispersible tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>EU/1/11/710/012&#8209;013</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=FR-CH>Votubia 5&nbsp;mg dispersible tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>EU/1/11/710/014&#8209;015</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Date of first authorisation: </span><span lang=EN-GB>02 September
2011</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of latest
renewal:</span><span lang=EN-GB> 28 July 2015</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>10.     DATE OF REVISION OF
THE TEXT</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Detailed information on this medicinal product </span><span
lang=EN-GB style='color:black'>is available on the website of the European
Medicines Agency </span><span lang=EN-GB><a href="http://www.ema.europa.eu">http://www.ema.europa.eu</a></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=No-numheading3Agency align=center style='margin:0in;text-align:center;
page-break-after:auto'><span lang=EN-GB style='font-family:"Times New Roman",serif'>ANNEX
II</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=No-numheading3Agency style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:85.05pt;text-indent:-28.35pt;page-break-after:
auto'><span lang=EN-GB style='font-family:"Times New Roman",serif'>A.      MANUFACTURER
RESPONSIBLE FOR BATCH RELEASE</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=No-numheading3Agency style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:85.05pt;text-indent:-28.35pt;page-break-after:
auto'><span lang=EN-GB style='font-family:"Times New Roman",serif'>B.      CONDITIONS
OR RESTRICTIONS REGARDING SUPPLY AND USE</span></p>

<p class=No-numheading3Agency style='margin:0in;page-break-after:auto'><span
lang=EN-GB style='font-family:"Times New Roman",serif;font-weight:normal'>&nbsp;</span></p>

<p class=No-numheading3Agency style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:85.05pt;text-indent:-28.35pt;page-break-after:
auto'><span lang=EN-GB style='font-family:"Times New Roman",serif'>C.      OTHER
CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-26.55pt;line-height:
normal'><b><span lang=EN-GB>D.     <span style='text-transform:uppercase'>conditions
or restrictions with regard to the safe and effective use of the medicinal
product</span></span></b></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><b><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>A.      MANUFACTURER
RESPONSIBLE FOR BATCH RELEASE</span></b></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Name
and address of the manufacturer responsible for batch release</span></u></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=ES>Novartis Farmacéutica SA</span></p>

<p class=MsoNormal><span lang=ES>Ronda de Santa Maria 158</span></p>

<p class=MsoNormal><span lang=ES>08210 Barberà del Vallès, Barcelona</span></p>

<p class=MsoNormal><span lang=ES>Spain</span></p>

<p class=MsoNormal><span lang=ES>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=ES style='color:black'>Novartis
Pharma GmbH</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB
style='color:black'>Roonstra</span><span lang=EN-GB style='color:black'>sse 25</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB
style='color:black'>D&#8209;90429 Nuremberg</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB
style='color:black'>Germany</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>The printed package leaflet of the medicinal product must
state the name and address of the manufacturer responsible for the release of the
concerned batch.</p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><b><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>B.      CONDITIONS
OR RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Medicinal
product subject to restricted medical prescription (see Annex I: Summary of
Product Characteristics, section&nbsp;4.2).</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;layout-grid-mode:line'>C.      OTHER CONDITIONS AND
REQUIREMENTS OF THE MARKETING AUTHORISATION</span></b></p>

<p class=NormalAgency style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Periodic safety update reports (PSURs)</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>The requirements
for submission of PSURs for this medicinal product are set out in the list of
Union reference dates (EURD list) provided for under Article 107c(7) of
Directive 2001/83/EC and any subsequent updates published on the European
medicines web&#8209;portal.</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.05pt'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>D.      CONDITIONS OR RESTRICTIONS WITH REGARD TO
THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>

<p class=NormalAgency style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:
Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Risk
management plan (RMP)</span></b></p>

<p class=NormalAgency style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>The marketing
authorisation holder (MAH) shall perform the required pharmacovigilance
activities and interventions detailed in the agreed RMP presented in Module
1.8.2 of the marketing authorisation and any agreed subsequent updates of the
RMP.</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>An updated RMP should be submitted:</span></p>

<p class=NormalAgency style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>At
the request of the European Medicines Agency;</span></p>

<p class=NormalAgency style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Whenever
the risk management system is modified, especially as the result of new
information being received that may lead to a significant change to the
benefit/risk profile or as the result of an important (pharmacovigilance or
risk minimisation) milestone being reached.</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:9.0pt;font-family:"Verdana",sans-serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX III</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>LABELLING AND PACKAGE LEAFLET</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>A. LABELLING</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>CARTON</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1.       NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia
2.5&nbsp;mg tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>everolimus</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2.       STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each tablet
contains 2.5&nbsp;mg everolimus.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3.       LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Contains
lactose. See leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Tablet</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>10&nbsp;x&nbsp;1&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>30&nbsp;x&nbsp;1&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>100&nbsp;x&nbsp;1&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5.       METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Read the package leaflet before use</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6.       SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the sight
and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7.       OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8.       EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>Do not store above
25°C. Store in the original package in order to protect from light and
moisture.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>10.     SPECIAL PRECAUTIONS
FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>11.     NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ireland</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>12.     MARKETING AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=621
 style='width:466.1pt;border-collapse:collapse'>
 <tr>
  <td width=168 valign=top style='width:125.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/11/710/001</span></p>
  </td>
  <td width=454 valign=top style='width:340.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;background:#D9D9D9'>10&nbsp;x&nbsp;1&nbsp;tablets</span></p>
  </td>
 </tr>
 <tr>
  <td width=168 valign=top style='width:125.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;background:#D9D9D9'>EU/1/11/710/002</span></p>
  </td>
  <td width=454 valign=top style='width:340.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;background:#D9D9D9'>30&nbsp;x&nbsp;1&nbsp;tablets</span></p>
  </td>
 </tr>
 <tr>
  <td width=168 valign=top style='width:125.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;background:#D9D9D9'>EU/1/11/710/003</span></p>
  </td>
  <td width=454 valign=top style='width:340.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;background:#D9D9D9'>100&nbsp;x&nbsp;1&nbsp;tablets</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>13.     BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia
2.5&nbsp;mg tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17.     UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>2D barcode carrying the unique
identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18.     UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB>NN</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>BLISTER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1.       NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia
2.5&nbsp;mg tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>everolimus</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2.       NAME
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Novartis
Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3.       EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4.       BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5.       OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>CARTON</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1.       NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia
5&nbsp;mg tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>everolimus</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2.       STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each tablet
contains 5&nbsp;mg everolimus.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3.       LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Contains
lactose. See leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Tablet</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>30&nbsp;x&nbsp;1&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>100&nbsp;x&nbsp;1&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5.       METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6.       SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the sight
and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7.       OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8.       EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>Do not store above
25°C. Store in the original package in order to protect from light and
moisture.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>10.     SPECIAL PRECAUTIONS
FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>11.     NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ireland</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>12.     MARKETING AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=621
 style='width:466.1pt;border-collapse:collapse'>
 <tr>
  <td width=168 valign=top style='width:125.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/11/710/004</span></p>
  </td>
  <td width=454 valign=top style='width:340.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;background:#D9D9D9'>30&nbsp;x&nbsp;1&nbsp;tablets</span></p>
  </td>
 </tr>
 <tr>
  <td width=168 valign=top style='width:125.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;background:#D9D9D9'>EU/1/11/710/005</span></p>
  </td>
  <td width=454 valign=top style='width:340.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;background:#D9D9D9'>100&nbsp;x&nbsp;1&nbsp;tablets</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>13.     BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia
5&nbsp;mg tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17.     UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>2D barcode carrying the unique
identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18.     UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB>NN</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>BLISTER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1.       NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia
5&nbsp;mg tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>everolimus</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2.       NAME
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Novartis
Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3.       EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4.       BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5.       OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>CARTON</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1.       NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia
10&nbsp;mg tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>everolimus</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2.       STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each tablet
contains 10&nbsp;mg everolimus.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3.       LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Contains
lactose. See leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Tablet</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>10&nbsp;x&nbsp;1&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>30&nbsp;x&nbsp;1&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>100&nbsp;x&nbsp;1&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5.       METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6.       SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the sight
and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7.       OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8.       EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>Do not store above
25°C. Store in the original package in order to protect from light and
moisture.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>10.     SPECIAL PRECAUTIONS
FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>11.     NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ireland</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>12.     MARKETING AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=621
 style='width:466.1pt;border-collapse:collapse'>
 <tr>
  <td width=168 valign=top style='width:125.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/11/710/006</span></p>
  </td>
  <td width=454 valign=top style='width:340.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;background:#D9D9D9'>30&nbsp;x&nbsp;1&nbsp;tablets</span></p>
  </td>
 </tr>
 <tr>
  <td width=168 valign=top style='width:125.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;background:#D9D9D9'>EU/1/11/710/007</span></p>
  </td>
  <td width=454 valign=top style='width:340.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;background:#D9D9D9'>100&nbsp;x&nbsp;1&nbsp;tablets</span></p>
  </td>
 </tr>
 <tr>
  <td width=168 valign=top style='width:125.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;background:#D9D9D9'>EU/1/11/710/008</span></p>
  </td>
  <td width=454 valign=top style='width:340.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;background:#D9D9D9'>10&nbsp;x&nbsp;1&nbsp;tablets</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>13.     BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia 10&nbsp;mg
tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17.     UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>2D barcode carrying the unique
identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18.     UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB>NN</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>BLISTER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1.       NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia
10&nbsp;mg tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>everolimus</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2.       NAME
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Novartis
Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3.       EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4.       BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5.       OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>CARTON</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1.       NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=SV>Votubia 1&nbsp;mg
dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=SV>everolimus</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=SV>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=SV>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2.       STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each dispersible
tablet contains 1&nbsp;mg everolimus.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3.       LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Contains
lactose. See leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Dispersible tablet</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>30&nbsp;x&nbsp;1&nbsp;dispersible
tablets</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5.       METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The tablets must
be dispersed in water before administration.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6.       SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7.       OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8.       EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt'>Store in the original package
in order to protect from light and moisture.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>10.     SPECIAL PRECAUTIONS
FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>11.     NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ireland</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>12.     MARKETING AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=621
 style='width:466.1pt;border-collapse:collapse'>
 <tr>
  <td width=168 valign=top style='width:125.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/11/710/016</span></p>
  </td>
  <td width=454 valign=top style='width:340.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;background:#D9D9D9'>30&nbsp;x&nbsp;1&nbsp;dispersible
  tablets</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>13.     BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia
1&nbsp;mg dispersible tablets<span style='color:black;background:#D9D9D9'>,
abbreviated form accepted, if required for technical reasons</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17.     UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>2D barcode carrying the unique
identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18.     UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NN</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>BLISTER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1.       NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>Votubia 1&nbsp;mg dispersible
tablets</p>

<p class=MsoNormal style='line-height:normal'>everolimus</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2.       NAME
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Novartis
Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3.       EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4.       BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5.       OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>CARTON</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1.       NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=SV>Votubia 2&nbsp;mg
dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=SV>everolimus</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=SV>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=SV>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2.       STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each dispersible
tablet contains 2&nbsp;mg everolimus.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3.       LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Contains
lactose. See leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Dispersible tablet</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>10&nbsp;x&nbsp;1&nbsp;dispersible
tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR style='color:black;
background:#D9D9D9'>30&nbsp;x&nbsp;1&nbsp;dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span style='color:black;
background:#D9D9D9'>100&nbsp;x&nbsp;1&nbsp;dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5.       METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The tablets must
be dispersed in water before administration.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6.       SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7.       OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8.       EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>Store in the original
package in order to protect from light and moisture.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>10.     SPECIAL PRECAUTIONS
FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>11.     NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ireland</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>12.     MARKETING AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=621
 style='width:466.1pt;border-collapse:collapse'>
 <tr>
  <td width=168 valign=top style='width:125.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/11/710/009</span></p>
  </td>
  <td width=454 valign=top style='width:340.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;background:#D9D9D9'>10&nbsp;x&nbsp;1&nbsp;dispersible tablets</span></p>
  </td>
 </tr>
 <tr>
  <td width=168 valign=top style='width:125.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;background:#D9D9D9'>EU/1/11/710/010</span></p>
  </td>
  <td width=454 valign=top style='width:340.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;background:#D9D9D9'>30&nbsp;x&nbsp;1&nbsp;dispersible tablets</span></p>
  </td>
 </tr>
 <tr>
  <td width=168 valign=top style='width:125.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;background:#D9D9D9'>EU/1/11/710/011</span></p>
  </td>
  <td width=454 valign=top style='width:340.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;background:#D9D9D9'>100&nbsp;x&nbsp;1&nbsp;dispersible tablets</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>13.     BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia
2&nbsp;mg dispersible tablets<span style='color:black;background:#D9D9D9'>,
abbreviated form accepted, if required for technical reasons</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17.     UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>2D barcode carrying the unique
identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18.     UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB>NN</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>BLISTER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1.       NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>Votubia 2&nbsp;mg dispersible
tablets</p>

<p class=MsoNormal style='line-height:normal'>everolimus</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2.       NAME
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Novartis
Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3.       EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4.       BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5.       OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>CARTON</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1.       NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=SV>Votubia 3&nbsp;mg dispersible
tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=SV>everolimus</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=SV>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=SV>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2.       STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each dispersible
tablet contains 3&nbsp;mg everolimus.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3.       LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Contains
lactose. See leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Dispersible tablet</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=SV>30&nbsp;x&nbsp;1&nbsp;dispersible
tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=SV style='color:black;
background:#D9D9D9'>100&nbsp;x&nbsp;1&nbsp;dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5.       METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Read the package leaflet before use</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The tablets must
be dispersed in water before administration.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6.       SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7.       OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8.       EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>Store in the original
package in order to protect from light and moisture.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>10.     SPECIAL PRECAUTIONS
FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>11.     NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ireland</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>12.     MARKETING AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=621
 style='width:466.1pt;border-collapse:collapse'>
 <tr>
  <td width=168 valign=top style='width:125.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/11/710/012</span></p>
  </td>
  <td width=454 valign=top style='width:340.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;background:#D9D9D9'>30&nbsp;x&nbsp;1&nbsp;dispersible
  tablets</span></p>
  </td>
 </tr>
 <tr>
  <td width=168 valign=top style='width:125.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;background:#D9D9D9'>EU/1/11/710/013</span></p>
  </td>
  <td width=454 valign=top style='width:340.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;background:#D9D9D9'>100&nbsp;x&nbsp;1&nbsp;dispersible
  tablets</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>13.     BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia
3&nbsp;mg dispersible tablets<span style='color:black;background:#D9D9D9'>,
abbreviated form accepted, if required for technical reasons</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17.     UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>2D barcode carrying the unique
identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18.     UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB>NN</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>BLISTER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1.       NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>Votubia 3&nbsp;mg dispersible
tablets</p>

<p class=MsoNormal style='line-height:normal'>everolimus</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2.       NAME
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Novartis
Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3.       EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4.       BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5.       OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>CARTON</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1.       NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=SV>Votubia 5&nbsp;mg dispersible
tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=SV>everolimus</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=SV>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=SV>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2.       STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each dispersible
tablet contains 5&nbsp;mg everolimus.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3.       LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Contains
lactose. See leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Dispersible tablet</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=SV>30&nbsp;x&nbsp;1&nbsp;dispersible
tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=SV style='color:black;
background:#D9D9D9'>100&nbsp;x&nbsp;1&nbsp;dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5.       METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The tablets must
be dispersed in water before administration.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6.       SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7.       OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8.       EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>Store in the original
package in order to protect from light and moisture.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>10.     SPECIAL PRECAUTIONS
FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>11.     NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ireland</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>12.     MARKETING AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=621
 style='width:466.1pt;border-collapse:collapse'>
 <tr>
  <td width=168 valign=top style='width:125.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/11/710/014</span></p>
  </td>
  <td width=454 valign=top style='width:340.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;background:#D9D9D9'>30&nbsp;x&nbsp;1&nbsp;dispersible
  tablets</span></p>
  </td>
 </tr>
 <tr>
  <td width=168 valign=top style='width:125.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;background:#D9D9D9'>EU/1/11/710/015</span></p>
  </td>
  <td width=454 valign=top style='width:340.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;background:#D9D9D9'>100&nbsp;x&nbsp;1&nbsp;dispersible
  tablets</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>13.     BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia
5&nbsp;mg dispersible tablets<span style='color:black;background:#D9D9D9'>,
abbreviated form accepted, if required for technical reasons</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17.     UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>2D barcode carrying the unique identifier
included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18.     UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB>NN</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>BLISTER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1.       NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>Votubia 5&nbsp;mg dispersible
tablets</p>

<p class=MsoNormal style='line-height:normal'>everolimus</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2.       NAME
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Novartis
Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3.       EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4.       BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5.       OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>B. PACKAGE LEAFLET</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>P</span><span lang=EN-GB>ackage leaflet: Information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Votubia 2.5&nbsp;mg tablets</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Votubia 5&nbsp;mg tablets</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Votubia 10&nbsp;mg tablets</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>everolimus</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Read all of
this leaflet carefully before you start taking this medicine</span><span
lang=EN-GB> because it contains important information for you</span></b><b><span
lang=EN-GB>.</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their </span><span
lang=EN-GB>signs of illness</span><span lang=EN-GB> are the same as yours.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects</span><span
lang=EN-GB>, talk to your doctor or pharmacist.</span><span lang=EN-GB> </span><span
lang=EN-GB>This includes any possible</span><span lang=EN-GB> side effects not
listed in this leaflet. See section&nbsp;4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What is i</span></b><b><span lang=EN-GB>n this leaflet</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>1.       What Votubia is and what it is used for</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>2.       </span><span lang=EN-GB>What you need to know b</span><span
lang=EN-GB>efore you take Votubia</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>3.       How to take Votubia</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>4.       Possible side effects</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>5.       How to store Votubia</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>6.       </span><span lang=EN-GB>Contents of the pack and other</span><span
lang=EN-GB> information</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>1.       What Votubia is and
what it is used for</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia is an
anti&#8209;tumour medicine which can block certain cells in the body from
growing. It contains an active substance called everolimus which may </span><span
lang=EN-GB>reduce the size of kidney tumours called renal angiomyolipomas and brain
tumours called subependymal giant cell astrocytomas (SEGA). These tumours are
caused by a genetic disorder called tuberous sclerosis complex (TSC).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Votubia tablets are used to treat:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>TSC with angiomyolipoma of the kidney in adults
who do not require immediate surgery.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>SEGA associated with TSC in adults and children for
whom surgery is not appropriate.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>2.       </span><span
lang=EN-GB>What you need to know before you take Votubia</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you are being treated for TSC with angiomyolipoma of the kidney,
Votubia will only be prescribed for you by a doctor with experience in treating
patients with TSC.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you are being treated for </span><span lang=EN-GB>SEGA associated
with TSC, Votubia will only be prescribed by a doctor with experience in
treating patients with SEGA and with access to blood tests which will measure
how much Votubia is in your blood.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Follow all the doctors instructions carefully. They may differ from
the general information contained in this leaflet.</span><span lang=EN-GB> If
you have any questions about Votubia or why it has been prescribed for you, ask
your doctor.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Do not take Votubia</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>if you are allergic</span></b><span
lang=EN-GB> to everolimus, to related substances such as sirolimus or
temsirolimus, or to any of the other ingredients of </span><span lang=EN-GB>this
medicine</span><span lang=EN-GB> (listed in section&nbsp;6).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you had
allergic reactions before, please ask your doctor for advice.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Warnings and precautions</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Talk to</span></b><b><span lang=EN-GB> your doctor before taking Votubia:</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have any problems with your liver or if
you have ever had any disease which may have affected your liver. If this is
the case, your doctor may need to prescribe a different dose of Votubia</span><span
lang=EN-GB> </span><span lang=EN-GB>or stop treatment, either for a short time
or permanently.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have diabetes (high level of sugar in your
blood).</span><span lang=EN-GB> Votubia </span><span lang=EN-GB>may increase
blood sugar levels and worsen diabetes mellitus. This may result in the need
for insulin and/or oral antidiabetic agent therapy. Tell your doctor if you
experience any excessive thirst or increased frequency of urination.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you need to receive a vaccine while taking Votubia</span><span
lang=EN-GB> </span><span lang=EN-GB>as vaccination may be less effective. For children
with SEGA, it is important to have a discussion with the doctor about the childhood
vaccination program before treatment with Votubia.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have high cholesterol. Votubia may
elevate cholesterol and/or other blood fats.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have had recent major surgery, or if you
still have an unhealed wound following surgery. Votubia may increase the risk
of problems with wound healing.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have an infection. It may be necessary to
treat your infection before starting Votubia.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you </span><span lang=EN-GB>have previously
had hepatitis&nbsp;B, because this may occur again during treatment with Votubia
(see section&nbsp;4 Possible side effects).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Votubia may also:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cause mouth sores (oral ulcerations).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>weaken your immune system. </span><span
lang=EN-GB>Therefore</span><span lang=EN-GB>, you may be at risk of getting an
infection while you are taking Votubia. If you have fever or other signs of an
infection, consult with your doctor. Some infections may be severe and may have
fatal consequences in adults and children.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>impact your kidney function. Therefore, your
doctor will monitor your kidney function while you are taking Votubia.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cause shortness of </span><span lang=EN-GB>breath,
cough and fever (see section&nbsp;4 Possible side effects).</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Tell your
doctor immediately</span></b><span lang=EN-GB> if you experience these
symptoms.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>You will have
blood tests before and periodically during treatment. These will check the
amount of blood cells (white blood cells, red blood cells and platelets) in
your body to see if Votubia is having an unwanted effect on these cells. Blood
tests will also be carried out to check your kidney function (levels of
creatinine, </span><span lang=EN-GB>blood urea nitrogen or urinary protein</span><span
lang=EN-GB>), liver function (level of transaminases) and your blood sugar and lipid
levels. This is because these can also be affected by Votubia.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you receive
Votubia for the treatment of </span><span lang=EN-GB>SEGA</span><span
lang=EN-GB> associated with TSC</span><span lang=EN-GB>, regular blood tests
are also necessary to measure how much Votubia is in your blood since this will
help your doctor decide how much Votubia you need to take.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Children </span></b><b><span lang=EN-GB>and</span><span lang=EN-GB>
adolescents</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia can be
used in children and adolescents SEGA associated with TSC.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia is not
to be used in children or adolescents with TSC who have angiomyolipoma of the
kidney in the absence of SEGA, as it has not been studied in such patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Other medicines and Votubia</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Votubia may affect the way some other medicines work. If you are
taking other medicines at the same time as Votubia, your doctor may need to change
the dose of Votubia or the other medicines.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Tell your doctor or pharmacist if you are taking, have recently
taken or might take any other medicines.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The following may increase the risk of side effects with Votubia:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ketoconazole, itraconazole, voriconazole, or
fluconazole and other antifungals used to treat fungal infections.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>clarithromycin, telithromycin or erythromycin,
antibiotics used to treat bacterial infections.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ritonavir, and other medicines used to treat HIV
infection/AIDS.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>verapamil or diltiazem, used to treat heart
conditions or high blood pressure.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dronedarone, a medicine used to help regulate
your heart beat.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ciclosporin, a medicine used to stop the body
from rejecting organ transplants.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>imatinib, used to inhibit the growth of abnormal
cells.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>angiotensin-converting enzyme (ACE) inhibitors
(such as ramipril) used to treat high blood pressure or other cardiovascular
problems.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The following may reduce the effectiveness of Votubia:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>rifampicin, used to treat tuberculosis (TB).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>efavirenz or nevirapine, used to treat HIV
infection/AIDS.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>St. Johns wort (<i>Hypericum perforatum</i>), a
herbal product used to treat depression and other conditions.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>dexamethasone, a
corticosteroid used to treat a wide variety of conditions including
inflammatory or immune problems.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>phenytoin, carbamazepine or phenobarbital and
other anti&#8209;epileptics used to stop seizures or fits.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>All medicines listed above should be avoided during your treatment
with Votubia. If you are taking any of them, your doctor may switch you to a different
medicine, or may change your dose of Votubia.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you are taking an anti&#8209;seizure medicine, a change in the
dose of the anti&#8209;seizure medicine (increase or decrease) may make a
change in the Votubia dose necessary. Your doctor will decide this. If the dose
of your anti&#8209;seizure medicine changes, please inform your doctor.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Votubia with food and drink</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Avoid grapefruit and grapefruit juice </span><span lang=EN-GB>while
you are on Votubia.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Pregnancy, breast&#8209;feeding and fertility</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia could
harm an unborn baby and is not recommended during pregnancy. Tell your doctor if
you are pregnant or think that you may be pregnant.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Women who could
potentially become pregnant must use highly effective contraception during
treatment, and for up to 8&nbsp;weeks after ending treatment. If, despite these
measures, you think you may have become pregnant, ask your doctor for advice <b>before</b>
taking any more Votubia.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Breast-feeding</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia could
harm a breast&#8209;fed baby. You should not breast&#8209;feed during treatment
and for 2&nbsp;weeks after the last dose of Votubia. Tell your doctor if you
are breast&#8209;feeding.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia may
affect male and female fertility. Talk to your doctor if you wish to have
children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Driving and using machines</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you feel
unusually tired (fatigue is a common side effect), take special care when
driving or using machines.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=FR>Votubia contains lactose</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>Votubia contains
lactose (milk sugar). </span><span lang=EN-GB>If you have been told by your
doctor that you have an intolerance to some sugars, contact your doctor before
taking this medicine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>3.       H</span><span
lang=EN-GB>ow to take Votubia</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Always take </span><span lang=EN-GB>this medicine</span><span
lang=EN-GB> exactly as your doctor or pharmacist has told you. Votubia exists
as tablets and dispersible tablets. Consistently take only the tablets or only
the dispersible tablets, and never a combination of both. Check with your
doctor or pharmacist if you are not sure.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>How much Votubia to take</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you receive Votubia for the treatment of TSC with </span><span
lang=EN-GB>angiomyolipoma of the kidney, the usual dose is 10&nbsp;mg, to be
taken once daily.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>A higher or lower dose may be recommended by your doctor based on
your individual treatment needs, for example if you have problems with your
liver or if you are taking certain other medicines in addition to Votubia.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>If you receive Votubia for the treatment of TSC with </span><span
lang=EN-GB>SEGA, your doctor will determine the dose of Votubia you need to
take depending on:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>your age</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>your body size</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>the health of your liver</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>other medicines you are taking.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>You will have blood
tests during treatment with Votubia. This is to measure the amount of Votubia
in your blood and find the best daily dose for you.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you </span><span
lang=EN-GB>experience certain </span><span lang=EN-GB>side effects (see section&nbsp;4)
while you are taking Votubia, your doctor may lower your dose or stop treatment,
either for a short time or permanently.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>How to take this medicine</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Take Votubia tablets once a day.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Take them at the same time every day.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>You can take them either with or without food,
but you need to do this in the same way each day.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Swallow the tablet(s) whole with a glass of water. Do
not chew or crush the tablets. If you are taking Votubia tablets for the
treatment of TSC with SEGA and if you are unable to swallow the tablets, you
can stir them into a glass of water:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Put the required number of tablets into a glass
of water (approximately 30&nbsp;ml).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Gently stir the contents of the glass until the
tablet(s) break apart (approximately 7&nbsp;minutes) and then drink the
contents immediately.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Refill the glass with the same amount of water
(approximately 30&nbsp;ml), gently stir the remaining content and drink the
whole amount to make sure that you get the full dose of Votubia tablets.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If necessary, drink additional water to wash out
any residues in your mouth.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Special information for caregivers</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Caregivers are advised to avoid contact with suspensions of Votubia
tablets. Wash hands thoroughly before and after preparation of the suspension.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>If you take more Votubia than you should</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have taken too much Votubia, or if
someone else accidentally takes your tablets, see a doctor or go to a hospital immediately.
Urgent treatment may be necessary.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Take the carton and this leaflet, so that the
doctor knows what has been taken.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>If you forget to take Votubia</span></b></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>If you miss a dose,
take your next dose as scheduled. Do not take a double dose to make up for the
forgotten tablets.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>If you stop taking Votubia</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not stop taking Votubia tablets unless your doctor tells you to.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you have any further questions on the use of this medicine, ask
your doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.       Possible side effects</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Like all
medicines, this medicine can cause side effects, although not everybody gets
them.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>STOP taking Votubia and seek medical help immediately if you or your
child experiences any of the following signs of an allergic reaction:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>difficulty breathing or swallowing</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling of the face, lips, tongue or throat
(signs of angioedema)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe itching of the skin, with a red rash or
raised bumps</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB style='color:black'>Serious side effects of Votubia include:</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB style='color:black'>Very common side effects</span></b><i><span
lang=EN-GB style='color:black'> (may affect more than 1 in 10&nbsp;people)</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Fever, cough, difficulty
breathing, wheezing (signs of inflammation of the lung due to infection, also
known as pneumonia)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Common side effects</span></b><span lang=EN-GB> <i>(may affect up to
1 in 10&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Swelling, feeling of
heaviness or tightness, pain, limited mobility of body parts (</span><span
lang=EN-GB>this could occur anywhere in the body and is a<span
style='color:black'> potential sign of an abnormal build-up of fluid in soft
tissue due to a blockage in the lymphatic system, </span></span><span lang=EN>also
known as </span><span lang=EN-GB style='color:black'>lymphoedema)</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Rash, itching, hives, difficulty breathing or
swallowing, dizziness (signs of serious allergic reaction, also known as
hypersensitivity)</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Fever, cough, difficulty breathing, wheezing
(signs of inflammation of the lung, also known as pneumonitis)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Uncommon side effects</span></b><span lang=EN-GB> <i>(may affect up
to 1 in 100&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Rash of small fluid-filled blisters, appearing
on reddened skin (signs of viral infection that can be potentially severe, also
known as herpes zoster)</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Fever, chills, rapid breathing and heart rate,
rash, and possibly confusion and disorientation (signs of serious infection,
also known as sepsis)</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>If you experience any of these side
effects, tell your doctor immediately as this might have life-threatening
consequences.</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Other possible side effects of Votubia include:</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB style='color:black'>Very common side effects</span></b><span
lang=EN-GB style='color:black'> <i>(may affect more than 1 in 10&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Upper respiratory tract
infection</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt;
font-family:Symbol;color:black'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;color:black'>Sore throat and runny
nose (nasopharyngitis)</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt;
font-family:Symbol;color:black'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;color:black'>Headache, pressure in
the eyes, nose or cheek area (signs of inflammation of the sinuses and nasal
passages, also known as sinusitis)</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt;
font-family:Symbol;color:black'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;color:black'>Urinary tract
infection</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>High level of lipids (fats)
in the blood (hypercholesterolaemia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Decreased appetite</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Headache</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Cough</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Mouth ulcers</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Diarrhoea</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Being sick (vomiting)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Acne</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Skin rash</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Feeling tired</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Fever</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Menstruation disorders such
as absence of periods (amenorrhoea) or irregular periods</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Sore throat (pharyngitis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Headache, dizziness, signs
of high blood pressure (hypertension)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB style='color:black'>Common side effects</span></b><span lang=EN-GB
style='color:black'> <i>(may affect up to 1 in 10&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Middle ear infection</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Swollen, bleeding gums
(signs of gum inflammation, also known as gingivitis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Skin inflammation
(cellulitis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>High level of lipids (fats)
in the blood (hyperlipidaemia, raised triglycerides)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Low level of phosphate in
the blood (hypophosphataemia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>High level of sugar in the
blood (hyperglycaemia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Tiredness, breathlessness,
dizziness, pale skin (signs of low level of red blood cells, also known as
anaemia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Fever, sore throat or mouth
ulcers due to infections (signs of low level of white blood cells, also known
as leucopenia, lymphopenia, neutropenia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Spontaneous bleeding or
bruising (signs of low level of platelets, also known as thrombocytopenia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Mouth pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Nose bleeds (epistaxis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Stomach upset like feeling
sick (nausea)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Abdominal pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Severe pain in the lower
abdomen and pelvic area that may be sharp, with menstrual irregularities
(ovarian cyst)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Excess amount of gas in the
bowels (flatulence)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Constipation</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Abdominal pain, nausea,
vomiting, diarrhoea, swelling and bloating of the abdomen (signs of
inflammation of the stomach lining, also known as gastritis or gastroenteritis
viral)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Dry skin, itching (pruritus)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>An inflammatory condition of
the skin characterised by redness, itching, and oozing liquid-filled cysts
which become scaly, crusted, or hardened (dermatitis acneiform)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Loss of hair (alopecia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Protein in the urine</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Menstruation disorders such
as heavy periods (menorrhagia) or vaginal bleeding</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Trouble sleeping<span style='color:black'>
(insomnia)</span></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Irritability</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Aggression</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>High level of an enzyme
called blood lactate dehydrogenase that gives information about the health of
certain organs</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>High level of the hormone
that triggers ovulation (blood luteinising hormone increased)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Weight loss</span></p>

<p class=MsoNormal style='line-height:12.0pt'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid'><b><span
lang=EN-GB>Uncommon side effects</span></b><span lang=EN-GB> </span><i><span
lang=EN-GB>(may affect up to 1 in 100&nbsp;people)</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Muscle spasms, fever, red&#8209;brown urine
which may be symptoms of a muscle disorder (rhabdomyolysis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Cough with phlegm, chest pain, fever (signs of
inflammation of airways, also known as bronchitis viral)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Disturbed taste (dysgeusia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Menstruation disorders such as delayed periods</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Higher level of female reproductive hormone
(blood follicle stimulating hormone increased)</span></p>

<p class=MsoNormal style='line-height:12.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>If these side effects get severe please tell your doctor and/or
pharmacist. Most of the side effects are mild to moderate and will generally
disappear if your treatment is interrupted for a few days.</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The following side effects have been reported in patients taking
everolimus for the treatment of conditions other than TSC:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kidney disorders: altered frequency or absence
of urination may be symptoms of kidney failure and have been observed in some
patients receiving everolimus. Other symptoms may include altered kidney
function test (increase in creatinine).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Symptoms of heart failure such as
breathlessness, difficulty breathing when lying down, swelling of the feet or
legs</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Blockage or obstruction of a blood vessel (vein)
in the leg (deep vein thrombosis). Symptoms may include swelling and/or pain in
one of your legs, usually in the calf, redness or warm skin in the affected
area</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Problems with wound healing</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>High levels of sugar in the blood
(hyperglycaemia)</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
lang=EN-GB style='font-size:11.0pt'>Hepatitis&nbsp;B reactivation has been
observed in some patients taking everolimus. Tell your doctor if you experience
symptoms of hepatitis&nbsp;B during treatment with everolimus. The first
symptoms may include fever, skin rash, joint pain and inflammation. Other
symptoms may include fatigue, loss of appetite, nausea, jaundice (yellowing of
the skin), and pain in the upper right abdomen. Pale stools or dark urine may
also be signs of hepatitis.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Reporting of side effects</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you get any side effects, talk to your doctor or pharmacist.<span
style='color:black'> </span>This includes any possible side effects not listed
in this leaflet. You can also report side effects directly via <span
style='color:black;background:#D9D9D9'>the national reporting system listed in </span></span><span
lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:#D9D9D9'>Appendix V</span></a>. By reporting side effects you
can help provide more information on the safety of this medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>5.       How to store Votubia</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep </span><span lang=EN-GB>this medicine </span><span
lang=EN-GB>out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use this medicine after the expiry date
which is stated on the carton and blister foil. The expiry date refers to the
last day of that month.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not store above 25°C.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Store in the original package in order to protect
from light and moisture.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Open the blister just before taking the Votubia
tablets.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use this medicine if the pack is damaged
or shows signs of tampering.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not </span><span lang=EN-GB>throw away any m</span><span
lang=EN-GB>edicines via wastewater or household waste. Ask your pharmacist how
to throw away medicines you no longer use. These measures will help to protect
the environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.       </span><span lang=EN-GB>Contents of the pack and other
information</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What Votubia tablets contain</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substance is everolimus.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><span
lang=EN-GB>Each Votubia 2.5&nbsp;mg tablet contains 2.5&nbsp;mg of everolimus.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><span
lang=EN-GB>Each Votubia 5&nbsp;mg tablet contains 5&nbsp;mg of everolimus.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><span
lang=EN-GB>Each Votubia 10&nbsp;mg tablet contains 10&nbsp;mg of everolimus.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The other ingredients are butylated
hydroxytoluene (E321), magnesium stearate, lactose monohydrate, hypromellose,
crospovidone type A and lactose anhydrous.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What Votubia tablets looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Votubia 2.5&nbsp;mg tablets are white to slightly yellowish,
elongated tablets. They are engraved with LCL on one side and NVR on the
other.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Votubia 5&nbsp;mg tablets are white to slightly yellowish, elongated
tablets. They are engraved with 5 on one side and NVR on the other.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Votubia 10&nbsp;mg tablets are white to slightly yellowish,
elongated tablets. They are engraved with UHE on one side and NVR on the
other.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Votubia 2.5&nbsp;mg tablets are available in packs containing 10&nbsp;x&nbsp;1,
30&nbsp;x&nbsp;1 or 100&nbsp;x&nbsp;1&nbsp;tablets </span><span lang=EN-GB>in perforated
unit-dose blisters of 10&nbsp;x&nbsp;1&nbsp;tablets each</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Votubia 5&nbsp;mg tablets are available in packs containing
30&nbsp;x&nbsp;1 or 100&nbsp;x&nbsp;1&nbsp;tablets </span><span lang=EN-GB
style='color:black'>in perforated unit-dose blisters of 10&nbsp;x&nbsp;1&nbsp;tablets
each</span><span lang=EN-GB style='color:black'>.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
style='color:black'>Votubia 10&nbsp;mg tablets are available in packs
containing </span><span lang=EN-GB>10&nbsp;x&nbsp;1, 30&nbsp;x&nbsp;1 or
100&nbsp;x&nbsp;1&nbsp;</span><span style='color:black'>tablets</span><span
style='color:black'> <span lang=EN-GB>in perforated unit-dose blisters of 10&nbsp;x&nbsp;1&nbsp;tablets
each</span></span><span style='color:black'>.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB style='color:black'>                                             </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB style='color:black'>Not all pack sizes or strengths may be marketed
in your country.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Marketing Authorisation Holder</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR-CH>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>Ireland</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span lang=ES
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=ES>Manufacturer</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=ES>Novartis Farmacéutica SA</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=ES>Ronda de Santa Maria 158</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=ES>08210 Barberà del Vallès, Barcelona</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=FR-CH>Spain</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=FR-CH style='color:black;background:#D9D9D9'>Novartis Pharma
GmbH</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span style='color:black;background:#D9D9D9'>Roonstra</span><span
style='color:black;background:#D9D9D9'>sse 25</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB style='color:black;background:#D9D9D9'>D&#8209;90429
Nuremberg</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB style='color:black;background:#D9D9D9'>Germany</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>For any information about this medicine, please contact
the local representative of the Marketing Authorisation Holder:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR-CH
  style='color:black'>België/Belgique/Belgien</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-CH
  style='color:black'>Novartis Pharma N.V.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Tél/Tel: +32 2 246 16 11</span></p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal'><span
  lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>Lietuva</span></b></p>
  <p class=MsoNormal style='margin-right:-22.45pt;line-height:normal'><span
  lang=LT>SIA Novartis Baltics Lietuvos filialas</span></p>
  <p class=MsoNormal style='margin-right:-22.45pt;line-height:normal'><span
  lang=EN-GB style='color:black'>Tel: +370 5 269 16 50</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Novartis
  Bulgaria EOOD</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>&#1058;&#1077;&#1083;.: +359 2 489 98 28</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-CH
  style='color:black'>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black'>Novartis Pharma N.V.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Tél/Tel: +32 2 246 16 11</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-CH
  style='color:black'>&#268;eská republika</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black'>Novartis s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Tel: +420 225 775 111</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>Magyarország</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Novartis Hungária Kft.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Tel.: +36 1 457 65 00</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>Danmark</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Novartis Healthcare A/S</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Tlf: +45 39 16 84 00</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR-CH
  style='color:black'>Malta</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-CH
  style='color:black'>Novartis Pharma Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Tel: +356 </span><span style='color:black'>2122 2872</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-CH
  style='color:black'>Deutschland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black'>Novartis Pharma GmbH</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black'>Tel: +49 911 273 0</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-CH
  style='color:black'>Nederland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black'>Novartis Pharma B.V.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black'>Tel: +31 26 37 82 111</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>Eesti</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>SIA Novartis
  Baltics Eesti filiaal</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Tel: +372 </span><span lang=EN-GB>66 30 810</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>Norge</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Novartis Norge AS</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Tlf: +47 23 05 20 00</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES style='color:
  black'>Novartis (Hellas) A.E.B.E.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>&#932;&#951;&#955;: +30 210 281 17 12</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-CH
  style='color:black'>Österreich</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black'>Novartis Pharma GmbH</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black'>Tel: +43 1 86 6570</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=ES
  style='color:black'>España</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES style='color:
  black'>Novartis Farmacéutica, S.A.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Tel: +34 93 306 42 00</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeading7 align=left style='text-align:left;line-height:normal;
  page-break-after:auto'><b><span lang=FR-CH style='color:black;font-style:
  normal'>Polska</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-CH
  style='color:black'>Novartis Poland Sp. z o.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Tel.: +48 22 375 4888</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR-CH
  style='color:black'>France</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-CH
  style='color:black'>Novartis Pharma S.A.S.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-CH
  style='color:black'>Tél: +33 1 55 47 66 00</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR-CH
  style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=ES
  style='color:black'>Portugal</span></b></p>
  <p class=Text align=left style='margin-top:0in;text-align:left'><span
  lang=ES style='font-size:11.0pt;color:black'>Novartis Farma &#8209; Produtos
  Farmacêuticos, S.A.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Tel: +351 21 000 8600</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE-CH>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=DE-CH>Novartis Hrvatska d.o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel. +385 1 6274 220</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR-CH
  style='color:black'>România</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-CH
  style='color:black'>Novartis Pharma Services Romania SRL</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Tel: +40 21 31299 01</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>Ireland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Novartis Ireland Limited</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Tel: +353 1 260 12 55</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR-CH
  style='color:black'>Slovenija</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-CH
  style='color:black'>Novartis Pharma Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Tel: +386 1 300 75 50</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>Ísland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Vistor hf.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Sími</span><span lang=EN-GB style='color:black'>: +354
  535 7000</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=IT
  style='color:black'>Slovenská republika</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT style='color:
  black'>Novartis Slovakia s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Tel: +421 2 5542 5439</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>Italia</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Novartis Farma S.p.A.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Tel: +39 02 96 54 1</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-CH
  style='color:black'>Suomi/Finland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black'>Novartis Finland Oy</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black'>Puh/Tel: </span><span lang=DE-CH style='color:black'>+358
  (0)10 6133 200</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-CH
  style='color:black'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-CH
  style='color:black'>Novartis Pharma Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>&#932;&#951;&#955;: +357 22 690 690</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-CH
  style='color:black'>Sverige</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black'>Novartis Sverige AB</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black'>Tel: +46 8 732 32 00</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-CH
  style='color:black'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=IT
  style='color:black'>Latvija</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=LV>SIA Novartis
  Baltics</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT style='color:
  black'>Tel: +371 67 887 070</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT style='color:
  black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>United Kingdom</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Novartis Pharmaceuticals UK Ltd.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Tel: +44 1276 698370</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>This leaflet was last revised in</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=NormalAgency style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Other sources of
information</span></b></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>Detailed information on this medicine is available on
the European Medicines Agency website: </span><span lang=EN-GB><a
href="http://www.ema.europa.eu"><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>http://www.ema.europa.eu</span></a></span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>P</span><span lang=EN-GB>ackage leaflet: Information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=FR-CH>Votubia 1&nbsp;mg dispersible tablets</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=FR-CH>Votubia 2&nbsp;mg dispersible tablets</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=FR-CH>Votubia 3&nbsp;mg dispersible tablets</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=FR-CH>Votubia 5&nbsp;mg dispersible tablets</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>everolimus</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Read all of
this leaflet carefully before you start taking this medicine</span><span
lang=EN-GB> because it contains important information for you</span></b><b><span
lang=EN-GB>.</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their </span><span
lang=EN-GB>signs of illness</span><span lang=EN-GB> are the same as yours.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects</span><span
lang=EN-GB>, talk to your doctor or pharmacist.</span><span lang=EN-GB
style='color:red'> </span><span lang=EN-GB>This includes any possible</span><span
lang=EN-GB> side effects not listed in this leaflet. See section&nbsp;4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What is i</span></b><b><span lang=EN-GB>n this leaflet</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>1.       What Votubia is and what it is used for</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>2.       </span><span lang=EN-GB>What you need to know b</span><span
lang=EN-GB>efore you take Votubia</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>3.       How to take Votubia</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>4.       Possible side effects</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>5.       How to store Votubia</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>6.       </span><span lang=EN-GB>Contents of the pack and other</span><span
lang=EN-GB> information</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>1.       What Votubia is and
what it is used for</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia
dispersible tablets contain an active substance called everolimus. It is </span><span
lang=EN-GB>used to treat children aged 2&nbsp;years and above and adults with partial
seizures with or without secondary generalisation (epilepsy) associated with a
genetic disorder called tuberous sclerosis complex (TSC) and which are not
controlled by other antiepileptic medicines. Partial seizures start by only
affecting one side of the brain but can spread and extend to larger areas on
both sides of the brain (called a secondary generalisation). Votubia
dispersible tablets are given together with other medicines for epilepsy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia is also
an anti&#8209;tumour medicine which can block certain cells in the body from
growing. It may </span><span lang=EN-GB>reduce the size of brain tumours called
subependymal giant cell astrocytomas (SEGA) which are also caused by TSC.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia
dispersible tablets are used to treat SEGA associated with TSC in adults and
children for whom surgery is not appropriate.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>2.       </span><span
lang=EN-GB>What you need to know before you take Votubia</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Votubia will only be prescribed by a doctor with experience in
treating patients with SEGA or seizures and with access to blood tests which
will measure how much Votubia is in your blood.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Follow all the doctors instructions carefully. They may differ from
the general information contained in this leaflet.</span><span lang=EN-GB> If
you have any questions about Votubia or why it has been prescribed for you, ask
your doctor.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Do not take Votubia</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>if you are allergic</span></b><span
lang=EN-GB> to everolimus, to related substances such as sirolimus or
temsirolimus, or to any of the other ingredients of </span><span lang=EN-GB>this
medicine</span><span lang=EN-GB> (listed in section&nbsp;6).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you had
allergic reactions before, please ask your doctor for advice.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Warnings and precautions</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Talk to</span></b><b><span lang=EN-GB> your doctor before taking
Votubia:</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have any problems with your liver or if
you have ever had any disease which may have affected your liver. If this is
the case, your doctor may need to prescribe a different dose of Votubia</span><span
lang=EN-GB> </span><span lang=EN-GB>or stop treatment, either for a short time
or permanently.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have diabetes (high level of sugar in
your blood).</span><span lang=EN-GB> Votubia </span><span lang=EN-GB>may
increase blood sugar levels and worsen diabetes mellitus. This may result in
the need for insulin and/or oral antidiabetic agent therapy. Tell your doctor
if you experience any excessive thirst or increased frequency of urination.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you need to receive a vaccine while taking
Votubia</span><span lang=EN-GB> </span><span lang=EN-GB>as vaccination may be
less effective. For children with SEGA or seizures, it is important to have a
discussion with the doctor about the childhood vaccination program before
treatment with Votubia.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have high cholesterol. Votubia may
elevate cholesterol and/or other blood fats.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have had recent major surgery, or if you
still have an unhealed wound following surgery. Votubia may increase the risk
of problems with wound healing.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have an infection. It may be necessary to
treat your infection before starting Votubia.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you </span><span lang=EN-GB>have previously
had hepatitis&nbsp;B, because this may occur again during treatment with
Votubia (see section&nbsp;4 Possible side effects).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Votubia may also:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cause mouth sores (oral ulcerations).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cause mouth sores (oral ulcerations).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>weaken your immune system. </span><span
lang=EN-GB>Therefore</span><span lang=EN-GB>, you may be at risk of getting an
infection while you are taking Votubia. If you have fever or other signs of an
infection, consult with your doctor. Some infections may be severe and may have
fatal consequences in adults and children.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>impact your kidney function. Therefore, your
doctor will monitor your kidney function while you are taking Votubia.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cause shortness of </span><span lang=EN-GB>breath,
cough and fever (see section&nbsp;4 Possible side effects).</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Tell your
doctor immediately</span></b><span lang=EN-GB> if you experience these
symptoms.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>You will have
blood tests before and periodically during treatment. These will check the amount
of blood cells (white blood cells, red blood cells and platelets) in your body
to see if Votubia is having an unwanted effect on these cells. Blood tests will
also be carried out to check your kidney function (levels of creatinine, </span><span
lang=EN-GB>blood urea nitrogen or urinary protein</span><span lang=EN-GB>),
liver function (level of transaminases) and your blood sugar and lipid levels.
This is because these can also be affected by Votubia.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Regular blood
tests are also necessary to measure how much Votubia is in your blood since
this will help your doctor decide how much Votubia you need to take.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Children and adolescents</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia can be
used in children and adolescents with SEGA associated with TSC.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia is not
to be used in children below the age of 2&nbsp;years&nbsp;with TSC and seizures.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Other medicines and Votubia</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Votubia may affect the way some other medicines work. If you are
taking other medicines at the same time as Votubia, your doctor may need to
change the dose of Votubia or the other medicines.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Tell your doctor or pharmacist</span></b><span lang=EN-GB> if you
are taking, have recently taken or might take any other medicines.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The following may increase the risk of side effects with Votubia:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ketoconazole, itraconazole, voriconazole, or
fluconazole and other antifungals used to treat fungal infections.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>clarithromycin, telithromycin or erythromycin,
antibiotics used to treat bacterial infections.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ritonavir, and other medicines used to treat HIV
infection/AIDS.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>verapamil or diltiazem, used to treat heart
conditions or high blood pressure.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dronedarone, a medicine used to help regulate
your heart beat.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ciclosporin, a medicine used to stop the body
from rejecting organ transplants.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>imatinib, used to inhibit the growth of abnormal
cells.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>angiotensin-converting enzyme (ACE) inhibitors
(such as ramipril) used to treat high blood pressure or other cardiovascular
problems.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The following may reduce the effectiveness of Votubia:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>rifampicin, used to treat tuberculosis (TB).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>efavirenz or nevirapine, used to treat HIV
infection/AIDS.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>St. Johns wort (<i>Hypericum perforatum</i>), a
herbal product used to treat depression and other conditions.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>dexamethasone, a corticosteroid
used to treat a wide variety of conditions including inflammatory or immune
problems.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>phenytoin, carbamazepine or phenobarbital and
other anti&#8209;epileptics used to stop seizures or fits.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>All medicines listed above should be avoided during your treatment
with Votubia. If you are taking any of them, your doctor may switch you to a
different medicine, or may change your dose of Votubia.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you are taking an anti&#8209;seizure medicine, a change in the
dose of the anti&#8209;seizure medicine (increase or decrease) may make a
change in the Votubia dose necessary. Your doctor will decide this. If the dose
of your anti&#8209;seizure medicine changes, please inform your doctor.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you are following a specific diet to reduce the frequency of your
seizures, please inform your doctor before taking Votubia.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Votubia with food and drink</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Avoid grapefruit and grapefruit juice </span><span lang=EN-GB>while
you are on Votubia.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Pregnancy, breast&#8209;feeding and fertility</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia could
harm an unborn baby and is not recommended during pregnancy. Tell your doctor
if you are pregnant or think that you may be pregnant.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Women who could
potentially become pregnant must use highly effective contraception during
treatment, and for up to 8&nbsp;weeks after ending treatment. If, despite these
measures, you think you may have become pregnant, ask your doctor for advice <b>before</b>
taking any more Votubia.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Breast-feeding</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia could
harm a breast&#8209;fed baby. You should not breast&#8209;feed during treatment
and for 2&nbsp;weeks after the last dose of Votubia. Tell your doctor if you
are breast&#8209;feeding.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Votubia may
affect male and female fertility. Talk to your doctor if you wish to have
children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Driving and using machines</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you feel
unusually tired (fatigue is a common side effect), take special care when
driving or using machines.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=FR>Votubia contains lactose</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>Votubia contains
lactose (milk sugar). </span><span lang=EN-GB>If you have been told by your
doctor that you have an intolerance to some sugars, contact your doctor before
taking this medicine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>3.       H</span><span
lang=EN-GB>ow to take Votubia</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Always take </span><span lang=EN-GB>this medicine</span><span
lang=EN-GB> exactly as your doctor or pharmacist has told you. Votubia exists
as tablets and dispersible tablets. Consistently take only the tablets or only the
dispersible tablets, and never a combination of both. Check with your doctor or
pharmacist if you are not sure.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>How much Votubia to take</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Y</span><span lang=EN-GB>our doctor will determine the dose of
Votubia you need to take depending on:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>your age</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>your body size</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>the health of your liver</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>other medicines you are taking.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>You will have
blood tests during treatment with Votubia. This is to measure the amount of
Votubia in your blood and find the best daily dose for you.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you </span><span
lang=EN-GB>experience certain </span><span lang=EN-GB>side effects (see
section&nbsp;4) while you are taking Votubia, your doctor may lower your dose
or stop treatment, either for a short time or permanently.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>How to take this medicine</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Take Votubia dispersible tablets once a day.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Take them at the same time every day.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>You can take them either with or without food,
but you need to do this in the same way each day.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Take Votubia dispersible tablets as an oral suspension only</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not chew or crush the dispersible tablets. Do not swallow them whole.
</span><span lang=EN-GB>You must mix the dispersible tablets with water to
create a cloudy liquid (known as an oral suspension)</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>How to prepare and take the oral suspension</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Prepare the oral suspension by mixing the dispersible tablets with
water either in an oral syringe or in a small glass. You must drink the
suspension immediately after preparing it. If you do not drink it within
30&nbsp;minutes when using an oral syringe or within 60&nbsp;minutes when using
a small glass, throw it away and prepare a new suspension. Please read the
detailed instructions at the end of this leaflet to find out how to do this. Ask
your doctor or pharmacist if you are not sure.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>Special information for caregivers</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Caregivers are advised to avoid contact with suspensions of Votubia
dispersible tablets. Wash hands thoroughly before and after preparation of the
suspension.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>If you take more Votubia than you should</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have taken too much Votubia, or if
someone else accidentally takes your dispersible tablets, see a doctor or go to
a hospital immediately. Urgent treatment may be necessary.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Take the carton and this leaflet, so that the
doctor knows what has been taken.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>If you forget to take Votubia</span></b></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>If you miss a dose,
take your next dose as scheduled. Do not take a double dose to make up for the
forgotten dispersible tablets.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>If you stop taking Votubia</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not stop taking Votubia dispersible tablets unless your doctor
tells you to.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you have any further questions on the use of this medicine, ask
your doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.       Possible side effects</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Like all
medicines, this medicine can cause side effects, although not everybody gets
them.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>STOP taking Votubia and seek medical help immediately if you or your
child experiences any of the following signs of an allergic reaction:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>difficulty breathing or swallowing</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling of the face, lips, tongue or throat
(signs of angioedema)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe itching of the skin, with a red rash or
raised bumps</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB style='color:black'>Serious side effects of Votubia include:</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB style='color:black'>Very common side effects</span></b><i><span
lang=EN-GB style='color:black'> (may affect more than 1 in 10&nbsp;people)</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Fever, cough, difficulty
breathing, wheezing (signs of inflammation of the lung due to infection, also
known as pneumonia)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Common side effects</span></b><span lang=EN-GB> <i>(may affect up to
1 in 10&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Swelling, feeling of
heaviness or tightness, pain, limited mobility of body parts (</span><span
lang=EN-GB>this could occur anywhere in the body and is a <span
style='color:black'>potential sign of an abnormal build-up of fluid in soft
tissue due to a blockage in the lymphatic system, </span></span><span lang=EN>also
known as </span><span lang=EN-GB style='color:black'>lymphoedema)</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Rash, itching, hives, difficulty breathing or
swallowing, dizziness (signs of serious allergic reaction, also known as
hypersensitivity)</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Fever, cough, difficulty breathing, wheezing
(signs of inflammation of the lung, also known as pneumonitis)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Uncommon side effects</span></b><span lang=EN-GB> <i>(may affect up
to 1 in 100&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Rash of small fluid-filled blisters, appearing
on reddened skin (signs of viral infection that can be potentially severe, also
known as herpes zoster)</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Fever, chills, rapid breathing and heart rate,
rash, and possibly confusion and disorientation (signs of serious infection,
also known as sepsis)</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>If you experience any of these side
effects, tell your doctor immediately as this might have life-threatening
consequences.</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Other possible side effects of Votubia include:</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB style='color:black'>Very common side effects</span></b><span
lang=EN-GB style='color:black'> <i>(may affect more than 1 in 10&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Upper respiratory tract
infection</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt;
font-family:Symbol;color:black'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;color:black'>Sore throat and runny
nose (nasopharyngitis)</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt;
font-family:Symbol;color:black'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;color:black'>Headache, pressure in
the eyes, nose or cheek area (signs of inflammation of the sinuses and nasal
passages, also known as sinusitis)</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt;
font-family:Symbol;color:black'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;color:black'>Urinary tract
infection</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>High level of lipids (fats)
in the blood (hypercholesterolaemia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Decreased appetite</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Headache</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Cough</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Mouth ulcers</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Diarrhoea</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Being sick (vomiting)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Acne</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Skin rash</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Feeling tired</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Fever</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Menstruation disorders such
as absence of periods (amenorrhoea) or irregular periods</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Sore throat (pharyngitis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Headache, dizziness, signs
of high blood pressure (hypertension)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB style='color:black'>Common side effects</span></b><span lang=EN-GB
style='color:black'> <i>(may affect up to 1 in 10&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Middle ear infection</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Swollen, bleeding gums
(signs of gum inflammation, also known as gingivitis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Skin inflammation
(cellulitis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>High level of lipids (fats)
in the blood (hyperlipidaemia, raised triglycerides)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Low level of phosphate in
the blood (hypophosphataemia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>High level of sugar in the
blood (hyperglycaemia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Tiredness, breathlessness,
dizziness, pale skin (signs of low level of red blood cells, also known as
anaemia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Fever, sore throat or mouth
ulcers due to infections (signs of low level of white blood cells, also known
as leucopenia, lymphopenia, neutropenia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Spontaneous bleeding or
bruising (signs of low level of platelets, also known as thrombocytopenia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Mouth pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Nose bleeds (epistaxis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Stomach upset like feeling
sick (nausea)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Abdominal pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Severe pain in the lower
abdomen and pelvic area that may be sharp, with menstrual irregularities
(ovarian cyst)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Excess amount of gas in the
bowels (flatulence)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Constipation</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Abdominal pain, nausea,
vomiting, diarrhoea, swelling and bloating of the abdomen (signs of
inflammation of the stomach lining, also known as gastritis or gastroenteritis
viral)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Dry skin, itching (pruritus)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>An inflammatory condition of
the skin characterised by redness, itching, and oozing liquid-filled cysts
which become scaly, crusted, or hardened (dermatitis acneiform)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Loss of hair (alopecia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Protein in the urine</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Menstruation disorders such
as heavy periods (menorrhagia) or vaginal bleeding</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Trouble sleeping<span style='color:black'>
(insomnia)</span></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Irritability</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Aggression</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>High level of an enzyme
called blood lactate dehydrogenase that gives information about the health of
certain organs</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>High level of the hormone
that triggers ovulation (blood luteinising hormone increased)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span lang=EN-GB style='font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Weight loss</span></p>

<p class=MsoNormal style='line-height:12.0pt'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid'><b><span
lang=EN-GB>Uncommon side effects</span></b><span lang=EN-GB> </span><i><span
lang=EN-GB>(may affect up to 1 in 100&nbsp;people)</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Muscle spasms, fever, red&#8209;brown urine
which may be symptoms of a muscle disorder (rhabdomyolysis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Cough with phlegm, chest pain, fever (signs of
inflammation of airways, also known as bronchitis viral)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Disturbed taste (dysgeusia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Menstruation disorders such as delayed periods</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Higher level of female reproductive hormone
(blood follicle stimulating hormone increased)</span></p>

<p class=MsoNormal style='line-height:12.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>If these side effects get severe please tell your doctor and/or
pharmacist. Most of the side effects are mild to moderate and will generally disappear
if your treatment is interrupted for a few days.</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The following side effects have been reported in patients taking
everolimus for the treatment of conditions other than TSC:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kidney disorders: altered frequency or absence
of urination may be symptoms of kidney failure and have been observed in some
patients receiving everolimus. Other symptoms may include altered kidney
function test (increase in creatinine).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Symptoms of heart failure such as
breathlessness, difficulty breathing when lying down, swelling of the feet or
legs</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
12.0pt'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Blockage or obstruction of a blood vessel (vein)
in the leg (deep vein thrombosis). Symptoms may include swelling and/or pain in
one of your legs, usually in the calf, redness or warm skin in the affected
area</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Problems with wound healing</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>High levels of sugar in the blood
(hyperglycaemia)</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
lang=EN-GB style='font-size:11.0pt'>Hepatitis&nbsp;B reactivation has been
observed in some patients taking everolimus. Tell your doctor if you experience
symptoms of hepatitis&nbsp;B during treatment with everolimus. The first
symptoms may include fever, skin rash, joint pain and inflammation. Other
symptoms may include fatigue, loss of appetite, nausea, jaundice (yellowing of
the skin), and pain in the upper right abdomen. Pale stools or dark urine may
also be signs of hepatitis.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Reporting of side effects</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you get any side effects, talk to your doctor or pharmacist.<span
style='color:red'> </span>This includes any possible side effects not listed in
this leaflet. You can also report side effects directly via <span
style='color:black;background:#D9D9D9'>the national reporting system listed in </span></span><span
lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:#D9D9D9'>Appendix V</span></a>. By reporting side effects you
can help provide more information on the safety of this medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>5.       How to store Votubia</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep </span><span lang=EN-GB>this medicine </span><span
lang=EN-GB>out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use this medicine after the expiry date
which is stated on the carton and blister foil. The expiry date refers to the
last day of that month.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine does not require any special
temperature storage conditions.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Store in the original package in order to
protect from light and moisture.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Open the blister just before taking Votubia
dispersible tablets.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The stability of the ready to use suspension has
been demonstrated for 60&nbsp;minutes. After preparation the suspension must be
taken straight away. If you do not use it within 60&nbsp;minutes, throw it away
and prepare a new suspension.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use this medicine if the pack is damaged
or shows signs of tampering.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not </span><span lang=EN-GB>throw away any m</span><span
lang=EN-GB>edicines via wastewater or household waste. Ask your pharmacist how
to throw away medicines you no longer use. These measures will help to protect
the environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.       </span><span lang=EN-GB>Contents of the pack and other
information</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What Votubia dispersible tablets contain</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substance is everolimus.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><span
lang=EN-GB>Each Votubia 1&nbsp;mg dispersible tablet contains 1&nbsp;mg of
everolimus.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><span
lang=EN-GB>Each Votubia 2&nbsp;mg dispersible tablet contains 2&nbsp;mg of
everolimus.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><span
lang=EN-GB>Each Votubia 3&nbsp;mg dispersible tablet contains 3&nbsp;mg of
everolimus.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><span
lang=EN-GB>Each Votubia 5&nbsp;mg dispersible tablet contains 5&nbsp;mg of
everolimus.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The other ingredients are butylated
hydroxytoluene (E321), magnesium stearate, lactose monohydrate, hypromellose,
crospovidone type A, mannitol, cellulose microcrystalline and silica colloidal
anhydrous.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What Votubia dispersible tablets looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Votubia 1&nbsp;mg dispersible tablets are white to slightly
yellowish, round, flat tablets with a bevelled edge and no score. They are
engraved with D1 on one side and NVR on the other.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Votubia 2&nbsp;mg dispersible tablets are white to slightly
yellowish, round, flat tablets with a bevelled edge and no score. They are
engraved with D2 on one side and NVR on the other.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Votubia 3&nbsp;mg dispersible tablets are white to slightly
yellowish, round, flat tablets with a bevelled edge and no score. They are
engraved with D3 on one side and NVR on the other.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Votubia 5&nbsp;mg dispersible tablets are white to slightly
yellowish, round, flat tablets with a bevelled edge and no score. They are
engraved with D5 on one side and NVR on the other.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Votubia 1&nbsp;mg dispersible tablets are available in packs
containing 30&nbsp;dispersible tablets in perforated unit-dose blisters of 10&nbsp;x&nbsp;1&nbsp;tablets
each.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Votubia 2&nbsp;mg dispersible tablets are available in packs
containing 10&nbsp;x&nbsp;1, 30&nbsp;x&nbsp;1 or 100&nbsp;x&nbsp;1&nbsp;dispersible
tablets </span><span lang=EN-GB>in perforated unit-dose blisters of 10&nbsp;x&nbsp;1&nbsp;tablets
each</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Votubia 3&nbsp;mg and Votubia 5&nbsp;mg </span><span lang=EN-GB>dispersible
tablets are available in packs containing 30&nbsp;x&nbsp;1 or 100&nbsp;x1&nbsp;dispersible
tablets </span><span lang=EN-GB>in perforated unit-dose blisters of 10&nbsp;x&nbsp;1&nbsp;tablets
each</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Not all pack sizes or strengths may be marketed in your country.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Marketing Authorisation Holder</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR-CH>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>Ireland</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span lang=ES
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=ES>Manufacturer</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=ES>Novartis Farmacéutica SA</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=ES>Ronda de Santa Maria 158</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=ES>08210 Barberà del Vallès, Barcelona</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=FR-CH>Spain</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=FR-CH style='color:black;background:#D9D9D9'>Novartis Pharma
GmbH</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span style='color:black;background:#D9D9D9'>Roonstra</span><span
style='color:black;background:#D9D9D9'>sse 25</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB style='color:black;background:#D9D9D9'>D&#8209;90429
Nuremberg</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB style='color:black;background:#D9D9D9'>Germany</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>For any information about this medicine, please contact
the local representative of the Marketing Authorisation Holder:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR-CH
  style='color:black'>België/Belgique/Belgien</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-CH
  style='color:black'>Novartis Pharma N.V.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Tél/Tel: +32 2 246 16 11</span></p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal'><span
  lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>Lietuva</span></b></p>
  <p class=MsoNormal style='margin-right:-22.45pt;line-height:normal'><span
  lang=LT>SIA Novartis Baltics Lietuvos filialas</span></p>
  <p class=MsoNormal style='margin-right:-22.45pt;line-height:normal'><span
  lang=EN-GB style='color:black'>Tel: +370 5 269 16 50</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Novartis
  Bulgaria EOOD</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>&#1058;&#1077;&#1083;.: +359 2 489 98 28</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-CH
  style='color:black'>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black'>Novartis Pharma N.V.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Tél/Tel: +32 2 246 16 11</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-CH
  style='color:black'>&#268;eská republika</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black'>Novartis s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Tel: +420 225 775 111</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>Magyarország</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Novartis Hungária Kft.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Tel.: +36 1 457 65 00</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>Danmark</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Novartis Healthcare A/S</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Tlf: +45 39 16 84 00</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR-CH
  style='color:black'>Malta</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-CH
  style='color:black'>Novartis Pharma Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Tel: +356 </span><span style='color:black'>2122 2872</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-CH
  style='color:black'>Deutschland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black'>Novartis Pharma GmbH</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black'>Tel: +49 911 273 0</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-CH
  style='color:black'>Nederland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black'>Novartis Pharma B.V.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black'>Tel: +31 26 37 82 111</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>Eesti</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>SIA Novartis
  Baltics Eesti filiaal</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Tel: +372 </span><span lang=EN-GB>66 30 810</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>Norge</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Novartis Norge AS</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Tlf: +47 23 05 20 00</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES style='color:
  black'>Novartis (Hellas) A.E.B.E.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>&#932;&#951;&#955;: +30 210 281 17 12</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-CH
  style='color:black'>Österreich</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black'>Novartis Pharma GmbH</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black'>Tel: +43 1 86 6570</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=ES
  style='color:black'>España</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES style='color:
  black'>Novartis Farmacéutica, S.A.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Tel: +34 93 306 42 00</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeading7 align=left style='text-align:left;line-height:normal;
  page-break-after:auto'><b><span lang=FR-CH style='color:black;font-style:
  normal'>Polska</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-CH
  style='color:black'>Novartis Poland Sp. z o.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Tel.: +48 22 375 4888</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR-CH
  style='color:black'>France</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-CH
  style='color:black'>Novartis Pharma S.A.S.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-CH
  style='color:black'>Tél: +33 1 55 47 66 00</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR-CH
  style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=ES
  style='color:black'>Portugal</span></b></p>
  <p class=Text align=left style='margin-top:0in;text-align:left'><span
  lang=ES style='font-size:11.0pt;color:black'>Novartis Farma &#8209; Produtos
  Farmacêuticos, S.A.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Tel: +351 21 000 8600</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE-CH>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=DE-CH>Novartis Hrvatska d.o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel. +385 1 6274 220</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR-CH
  style='color:black'>România</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-CH
  style='color:black'>Novartis Pharma Services Romania SRL</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Tel: +40 21 31299 01</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>Ireland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Novartis Ireland Limited</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Tel: +353 1 260 12 55</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR-CH
  style='color:black'>Slovenija</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-CH
  style='color:black'>Novartis Pharma Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Tel: +386 1 300 75 50</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>Ísland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Vistor hf.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Sími</span><span lang=EN-GB style='color:black'>: +354
  535 7000</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=IT
  style='color:black'>Slovenská republika</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT style='color:
  black'>Novartis Slovakia s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Tel: +421 2 5542 5439</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>Italia</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Novartis Farma S.p.A.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Tel: +39 02 96 54 1</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-CH
  style='color:black'>Suomi/Finland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black'>Novartis Finland Oy</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black'>Puh/Tel: </span><span lang=DE-CH style='color:black'>+358
  (0)10 6133 200</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-CH
  style='color:black'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-CH
  style='color:black'>Novartis Pharma Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>&#932;&#951;&#955;: +357 22 690 690</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-CH
  style='color:black'>Sverige</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black'>Novartis Sverige AB</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black'>Tel: +46 8 732 32 00</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-CH
  style='color:black'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=IT
  style='color:black'>Latvija</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=LV>SIA Novartis
  Baltics</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT style='color:
  black'>Tel: +371 67 887 070</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT style='color:
  black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>United Kingdom</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Novartis Pharmaceuticals UK Ltd.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Tel: +44 1276 698370</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>This leaflet was last revised in</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=NormalAgency style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Other sources of
information</span></b></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>Detailed information on this medicine is available on
the European Medicines Agency website: </span><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>http://www.ema.europa.eu</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
line-height:normal'><b><span lang=EN-GB style='color:black'>INSTRUCTIONS FOR
USE</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Read and follow these instructions carefully so that you know how to
correctly prepare the medicine. This will look like a cloudy liquid (known as
an oral suspension).</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Use an oral syringe or a small glass for preparing and taking the
Votubia suspension only  do not use it for anything else.</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Important information:</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Take Votubia dispersible tablets as a suspension only.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>These instructions are for taking a dose between 1&nbsp;mg and 10&nbsp;mg.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The most you can take at one time using the oral
syringe or small glass is 10&nbsp;mg, using a maximum of 5&nbsp;dispersible
tablets.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you need to take a higher dose or need to use
more than 5&nbsp;dispersible tablets, split the dose and repeat the steps using
the same oral syringe or small glass.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Ask your doctor or pharmacist about how to split
the dose if you are not sure.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Caregivers should try to avoid skin contact with the oral suspension.
Keep the medicine out of the reach of children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Only use water (drinkable tap water or non&#8209;sparkling bottled
water) to prepare the oral suspension. Do not use juice or any other liquids.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The patient must drink the suspension immediately after it is
prepared. If the patient does not drink it within 30&nbsp;minutes if an oral
syringe has been used or within 60&nbsp;minutes if a small glass has been used,
throw it away and prepare a new suspension.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><u><span
lang=EN-GB>Instructions for caregivers preparing the suspension using an oral
syringe:</span></u></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>You will need:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The blister with Votubia dispersible tablets</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Scissors to open the blister</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span style='font-size:12.0pt;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>10&nbsp;ml </span><span lang=EN-GB>oral syringe
with 1&nbsp;ml increments</span><span lang=EN-GB> (for single use): see figure below</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>2&nbsp;clean glasses</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Approximately 30&nbsp;ml of water</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
style='position:relative;z-index:251658240'><span style='position:absolute;
left:201px;top:-55474px;width:81px;height:1px'><img width=81 height=1
src="Votubia-II-61%20EN%20PI%20clean_files/image003.png" alt=Plunger></span></span><span
style='position:relative;z-index:251662336'><span style='position:absolute;
left:27px;top:-55474px;width:85px;height:1px'><img width=85 height=1
src="Votubia-II-61%20EN%20PI%20clean_files/image004.png" alt="Volume indicators"></span></span><span
style='position:relative;z-index:251664384'><span style='position:absolute;
left:3px;top:-55474px;width:65px;height:1px'><img width=65 height=1
src="Votubia-II-61%20EN%20PI%20clean_files/image005.png" alt=Tip></span></span><span
style='position:relative;z-index:251660288'><span style='position:absolute;
left:105px;top:-55474px;width:65px;height:1px'><img width=65 height=1
src="Votubia-II-61%20EN%20PI%20clean_files/image005.png" alt=Barrel></span></span><img
border=0 width=343 height=192
src="Votubia-II-61%20EN%20PI%20clean_files/image006.jpg"></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=621
 style='border-collapse:collapse'>
 <thead>
  <tr>
   <td width=414 valign=top style='width:310.2pt;border:none;border-top:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>Getting
   ready</b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>1.       Wash
   and dry your hands.</p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
   </td>
   <td width=208 valign=top style='width:155.9pt;border:none;border-top:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal;page-break-after:avoid'>&nbsp;</p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal;page-break-after:avoid'>&nbsp;</p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal;page-break-after:avoid'>&nbsp;</p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal;page-break-after:avoid'>&nbsp;</p>
   </td>
  </tr>
  <tr>
   <td width=414 valign=top style='width:310.2pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>2.       Take the 10&nbsp;ml oral syringe and pull out
   the plunger, removing it completely from the barrel of the syringe.</p>
   <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
   </td>
   <td width=208 valign=top style='width:155.9pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'><img border=0 width=148 height=95 id="Picture 2"
   src="Votubia-II-61%20EN%20PI%20clean_files/image007.png"></p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>&nbsp;</p>
   </td>
  </tr>
  <tr>
   <td width=414 valign=top style='width:310.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'><b>Adding the dispersible tablets</b></p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>&nbsp;</p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>3.       <span lang=EN-GB>Use scissors to open the
   blister along the dotted line. </span>Remove the dispersible tablets from
   the blister. Place them into the barrel of the oral syringe straight away.</p>
   <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
   </td>
   <td width=208 valign=top style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>&nbsp;</p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>&nbsp;</p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'><img border=0 width=149 height=83 id="Picture 3"
   src="Votubia-II-61%20EN%20PI%20clean_files/image008.png"></p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>&nbsp;</p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>&nbsp;</p>
   </td>
  </tr>
  <tr>
   <td width=414 valign=top style='width:310.2pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>4.       Re&#8209;insert the plunger into the barrel of
   the oral syringe. Push the plunger in until it touches the dispersible
   tablets.</p>
   <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
   </td>
   <td width=208 valign=top style='width:155.9pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'><img border=0 width=148 height=85 id="Picture 4"
   src="Votubia-II-61%20EN%20PI%20clean_files/image009.png"></p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>&nbsp;</p>
   </td>
  </tr>
  <tr style='height:104.85pt'>
   <td width=414 valign=top style='width:310.2pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:104.85pt'>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'><b>Adding water</b></p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>&nbsp;</p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>5.       Fill a small glass with water (drinkable tap
   water or non&#8209;sparkling bottled water). Put the tip of the syringe into
   the water. Draw up about 5&nbsp;ml of water by slowly pulling the plunger
   out until it is at the 5&nbsp;ml mark on the syringe.</p>
   <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
   <p class=MsoNormal style='margin-left:28.35pt;line-height:normal'>Note: The
   amount of water in the oral syringe does not need to be exact but all <span
   lang=EN-GB>the tablets should be covered. If any tablets get stuck in the
   dry upper part of the oral syringe, gently tap the oral syringe until they
   fall down into the water.</span></p>
   <p class=MsoNormal style='margin-left:28.35pt;line-height:normal'>&nbsp;</p>
   </td>
   <td width=208 valign=top style='width:155.9pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:104.85pt'>
   <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
   <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
   <p class=MsoNormal style='line-height:normal'><img border=0 width=148
   height=82 src="Votubia-II-61%20EN%20PI%20clean_files/image010.jpg"></p>
   </td>
  </tr>
  <tr style='height:55.05pt'>
   <td width=414 valign=top style='width:310.2pt;border:none;padding:0in 5.4pt 0in 5.4pt;
   height:55.05pt'>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'><b>Mixing the medicine</b></p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>&nbsp;</p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>6.       Hold the oral syringe with the tip pointing up.
   Pull the plunger slowly down to draw in air until it is at the 9&nbsp;ml
   mark on the syringe.</p>
   <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
   </td>
   <td width=208 valign=top style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt;
   height:55.05pt'>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>&nbsp;</p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'><img border=0 width=147 height=97
   src="Votubia-II-61%20EN%20PI%20clean_files/image011.jpg"></p>
   </td>
  </tr>
  <tr>
   <td width=414 valign=top style='width:310.2pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>&nbsp;</p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>7.       Put the filled <span lang=EN-GB>oral syringe in
   the clean, empty glass with the tip pointing up.</span> Wait for 3&nbsp;minutes<b>
   </b> until the dispersible tablets have completely broken apart.</p>
   <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
   </td>
   <td width=208 valign=top style='width:155.9pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>&nbsp;</p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'><span style='position:relative;z-index:251666432'><span
   style='left:0px;position:absolute;left:73px;top:-56468px;width:66px;
   height:1px'><img width=66 height=1
   src="Votubia-II-61%20EN%20PI%20clean_files/image012.png" alt="3 Min"></span></span><img
   border=0 width=148 height=98
   src="Votubia-II-61%20EN%20PI%20clean_files/image013.jpg"></p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>&nbsp;</p>
   </td>
  </tr>
  <tr>
   <td width=414 valign=top style='width:310.2pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>&nbsp;</p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>8.       Mix the medicine by slowly turning the oral
   syringe upside down and back again five times just before using the dose. Do
   not shake it. Use the oral suspension immediately. <span lang=EN-GB>If you
   do not use it within 30&nbsp;minutes, throw it away and prepare a new suspension.</span></p>
   </td>
   <td width=208 valign=top style='width:155.9pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>&nbsp;</p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'><span style='position:relative;z-index:251680768'><span
   style='left:0px;position:absolute;left:56px;top:-56601px;width:66px;
   height:1px'><img width=66 height=1
   src="Votubia-II-61%20EN%20PI%20clean_files/image012.png" alt="5x&#13;&#10;&#13;&#10;"></span></span><img
   border=0 width=151 height=100
   src="Votubia-II-61%20EN%20PI%20clean_files/image014.jpg"></p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'><span style='position:relative;z-index:251676672'><span
   style='left:0px;position:absolute;left:555px;top:-56701px;width:66px;
   height:1px'><img width=66 height=1
   src="Votubia-II-61%20EN%20PI%20clean_files/image012.png" alt=5x></span></span><span
   style='position:relative;z-index:251678720'><span style='left:0px;
   position:absolute;left:555px;top:-56701px;width:66px;height:1px'><img
   width=66 height=1 src="Votubia-II-61%20EN%20PI%20clean_files/image012.png"
   alt=5x></span></span></p>
   </td>
  </tr>
  <tr>
   <td width=414 valign=top style='width:310.2pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'><b>Removing air</b></p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>&nbsp;</p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>9.       Hold the oral syringe with the tip pointing
   upwards. Push the plunger up slowly to<span lang=EN-GB> remove most of the
   air (it is okay for a small amount of air to remain around the tip).</span></p>
   <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
   </td>
   <td width=208 valign=top style='width:155.9pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>&nbsp;</p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'><img border=0 width=150 height=111
   src="Votubia-II-61%20EN%20PI%20clean_files/image015.jpg"></p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>&nbsp;</p>
   </td>
  </tr>
  <tr>
   <td width=414 valign=top style='width:310.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'><b>Taking the medicine</b></p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>&nbsp;</p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>10.     <span lang=EN-GB>Put the oral syringe into the
   patients mouth. Push the plunger in slowly to release the full contents of
   the oral syringe.</span></p>
   <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
   </td>
   <td width=208 valign=top style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>&nbsp;</p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>&nbsp;</p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'><img border=0 width=151 height=85 id="Picture 10"
   src="Votubia-II-61%20EN%20PI%20clean_files/image016.jpg"></p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>&nbsp;</p>
   </td>
  </tr>
  <tr>
   <td width=414 valign=top style='width:310.2pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:27.65pt;text-indent:-27.65pt;
   line-height:normal'><span lang=EN-GB>11.    Carefully remove the oral
   syringe from the patients mouth.</span></p>
   <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
   </td>
   <td width=208 valign=top style='width:155.9pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:27.65pt;text-indent:-27.65pt;
   line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
   </td>
  </tr>
  <tr>
   <td width=414 valign=top style='width:310.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'><b><span lang=EN-GB>Making sure all of the medicine has
   been taken</span></b></p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'><span lang=EN-GB>12.     Insert the tip of the oral
   syringe into the glass filled with water. </span><span lang=EN-GB>Draw up </span><span
   lang=EN-GB>5&nbsp;ml of water by slowly pulling the plunger up.</span></p>
   <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
   </td>
   <td width=208 valign=top style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>&nbsp;</p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>&nbsp;</p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'><img border=0 width=150 height=95
   src="Votubia-II-61%20EN%20PI%20clean_files/image017.jpg"></p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>&nbsp;</p>
   </td>
  </tr>
  <tr>
   <td width=414 valign=top style='width:310.2pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'><span lang=EN-GB>13.     </span><span lang=EN-GB>Hold
   the oral syringe with the tip pointing up. Pull the plunger slowly down to
   draw in air until it is at the 9&nbsp;ml mark on the syringe</span><span
   lang=EN-GB>.</span></p>
   <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
   </td>
   <td width=208 valign=top style='width:155.9pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>&nbsp;</p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'><img border=0 width=150 height=99
   src="Votubia-II-61%20EN%20PI%20clean_files/image018.jpg"></p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
   </td>
  </tr>
  <tr>
   <td width=414 valign=top style='width:310.2pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'><span lang=EN-GB>14.     </span><span lang=EN-GB>With
   the tip of the oral syringe pointing upwards, </span><span lang=EN-GB>swirl
   the water around </span><span lang=EN-GB>to collect any medicine that is left
   inside</span><span lang=EN-GB>.</span></p>
   <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
   </td>
   <td width=208 valign=top style='width:155.9pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'><img border=0 width=150 height=92 id="Picture 13"
   src="Votubia-II-61%20EN%20PI%20clean_files/image019.png"></p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
   </td>
  </tr>
  <tr>
   <td width=414 valign=top style='width:310.2pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>&nbsp;</p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>15.     <span lang=EN-GB>Hold the oral syringe with the
   tip pointing upward. Push the plunger up slowly to remove most of the air.</span></p>
   <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
   </td>
   <td width=208 valign=top style='width:155.9pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'><img border=0 width=148 height=111
   src="Votubia-II-61%20EN%20PI%20clean_files/image020.jpg"></p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
   </td>
  </tr>
  <tr>
   <td width=414 valign=top style='width:310.2pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>16.     Put<span lang=EN-GB> the oral syringe into the
   patients mouth. Push the plunger in slowly to release the full contents of
   the oral syringe.</span></p>
   <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
   </td>
   <td width=208 valign=top style='width:155.9pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal'><img border=0 width=148
   height=81 id="Picture 15"
   src="Votubia-II-61%20EN%20PI%20clean_files/image021.png"></p>
   <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
   </td>
  </tr>
  <tr>
   <td width=414 valign=top style='width:310.2pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>17.     Carefully remove the oral syringe from the
   patients mouth.</p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>&nbsp;</p>
   <p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><b>If the
   total prescribed dose is more than 10&nbsp;mg or has to be prepared using more
   than 5&nbsp;dispersible tablets, repeat steps 2 to 17 to finish giving the
   dose.</b></p>
   <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
   </td>
   <td width=208 valign=top style='width:155.9pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'><b>&nbsp;</b></p>
   </td>
  </tr>
  <tr>
   <td width=414 valign=top style='width:310.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal'><b>Cleaning up</b></p>
   <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
   <p class=MsoNormal style='line-height:normal'>18.     Ask your pharmacist
   how to throw away the oral syringe.</p>
   <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
   </td>
   <td width=208 valign=top style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>&nbsp;</p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>&nbsp;</p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>&nbsp;</p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>&nbsp;</p>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'>&nbsp;</p>
   </td>
  </tr>
  <tr>
   <td width=414 valign=top style='width:310.2pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal'>19.     Wash and dry your
   hands.</p>
   <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
   </td>
   <td width=208 valign=top style='width:155.9pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
   line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
   </td>
  </tr>
 </thead>
</table>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency style='page-break-after:avoid'><b><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Instructions for
patients or caregivers preparing the suspension using a small glass:</span></u></b></p>

<p class=NormalAgency style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>You will need:</span></p>

<p class=NormalAgency style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Blister
with Votubia dispersible tablets</span></p>

<p class=NormalAgency style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Scissors
to open the blister</span></p>

<p class=NormalAgency style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>1&nbsp;small
glass (maximum size 100&nbsp;ml)</span></p>

<p class=NormalAgency style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>30&nbsp;ml
dose cup for measuring water</span></p>

<p class=NormalAgency style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Approximately
50&nbsp;ml of water to prepare the suspension</span></p>

<p class=NormalAgency style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Spoon
for stirring</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=621
 style='border-collapse:collapse'>
 <thead>
  <tr style='height:.1in'>
   <td width=414 valign=top style='width:310.2pt;border-top:solid windowtext 1.0pt;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
   padding:0in 5.4pt 0in 5.4pt;height:.1in'>
   <p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:28.35pt;text-indent:-28.35pt'><b><span style='font-size:
   11.0pt'>Getting ready</span></b></p>
   <p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt'>&nbsp;</span></p>
   <p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt'>1.       Wash
   and dry your hands.</span></p>
   <p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:28.35pt;text-indent:-28.35pt'>&nbsp;</p>
   </td>
   <td width=208 valign=top style='width:155.9pt;border-top:solid windowtext 1.0pt;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
   padding:0in 5.4pt 0in 5.4pt;height:.1in'>
   <p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:21.25pt'>&nbsp;</p>
   <p class=Listlevel1 style='margin:0in;text-indent:0in'>&nbsp;</p>
   </td>
  </tr>
  <tr>
   <td width=414 valign=top style='width:310.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:
   -28.35pt'><b><span style='font-size:11.0pt'>Adding water</span></b></p>
   <p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:
   -28.35pt'><span style='font-size:11.0pt'>&nbsp;</span></p>
   <p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:
   -28.35pt'><span style='font-size:11.0pt'>2.       Add about 25&nbsp;ml of
   water to the 30&nbsp;ml dose cup. The amount of water added does not need to
   be exact.</span></p>
   </td>
   <td width=208 valign=top style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:21.25pt'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
   <p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:21.25pt'><span style='position:relative;z-index:251670528'><span
   style='left:0px;position:absolute;left:76px;top:-58179px;width:76px;
   height:1px'><img width=76 height=1
   src="Votubia-II-61%20EN%20PI%20clean_files/image022.png"
   alt="25 ml&#13;&#10;of water&#13;&#10;"></span></span><span
   style='position:relative;z-index:251672576'><span style='left:0px;
   position:absolute;left:47px;top:-58179px;width:47px;height:1px'><img
   width=47 height=1 src="Votubia-II-61%20EN%20PI%20clean_files/image023.png"></span></span><span
   style='position:relative;z-index:251674624'><span style='left:0px;
   position:absolute;left:46px;top:-58179px;width:5px;height:1px'><img width=5
   height=1 src="Votubia-II-61%20EN%20PI%20clean_files/image024.png"></span></span><img
   border=0 width=149 height=83
   src="Votubia-II-61%20EN%20PI%20clean_files/image025.jpg"></p>
   <p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:21.25pt'>&nbsp;</p>
   </td>
  </tr>
  <tr>
   <td width=414 valign=top style='width:310.2pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt'>3.       Pour
   the water from the dose cup into the small glass.</span></p>
   </td>
   <td width=208 valign=top style='width:155.9pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Listlevel1 style='margin-top:6.0pt'><img border=0 width=148
   height=99 src="Votubia-II-61%20EN%20PI%20clean_files/image026.jpg"></p>
   </td>
  </tr>
  <tr>
   <td width=414 valign=top style='width:310.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:
   -28.35pt'><b><span style='font-size:11.0pt'>Adding the dispersible tablets</span></b></p>
   <p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:
   -28.35pt'><span style='font-size:11.0pt'>&nbsp;</span></p>
   <p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:
   -28.35pt'><span style='font-size:11.0pt'>4.       Use scissors to open the
   blister along the dotted line. Remove the dispersible tablets from the
   blister.</span></p>
   </td>
   <td width=208 valign=top style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:21.25pt'>&nbsp;</p>
   </td>
  </tr>
  <tr style='height:68.85pt'>
   <td width=414 valign=top style='width:310.2pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:68.85pt'>
   <p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:
   -28.35pt'><span lang=EN-GB style='font-size:11.0pt'>5.       Add the
   dispersible tablets into the water</span><span style='font-size:11.0pt'>.</span></p>
   </td>
   <td width=208 valign=top style='width:155.9pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:68.85pt'>
   <p class=Listlevel1 style='margin:0in;text-indent:0in'><img border=0
   width=149 height=83 id="Picture 18"
   src="Votubia-II-61%20EN%20PI%20clean_files/image027.png"></p>
   </td>
  </tr>
  <tr>
   <td width=414 valign=top style='width:310.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:
   -28.35pt'><b><span lang=EN-GB style='font-size:11.0pt'>Mixing the medicine</span></b></p>
   <p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:
   -28.35pt'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
   <p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:
   -28.35pt'><span lang=EN-GB style='font-size:11.0pt'>6.       Wait for 3&nbsp;minutes
   until the dispersible tablets have completely broken apart.</span></p>
   </td>
   <td width=208 valign=top style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:21.25pt'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
   <p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:21.25pt'><span style='position:relative;z-index:251668480'><span
   style='left:0px;position:absolute;left:83px;top:-58571px;width:61px;
   height:1px'><img width=61 height=1
   src="Votubia-II-61%20EN%20PI%20clean_files/image028.png" alt="3 Min&#13;&#10;&#13;&#10;"></span></span><img
   border=0 width=149 height=83
   src="Votubia-II-61%20EN%20PI%20clean_files/image029.jpg"></p>
   <p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:21.25pt'><span lang=EN-GB>&nbsp;</span></p>
   </td>
  </tr>
  <tr>
   <td width=414 valign=top style='width:310.2pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:
   -28.35pt'><span lang=EN-GB style='font-size:11.0pt'>7.       Gently stir the
   contents of the glass with a spoon and then proceed immediately to step 8.</span></p>
   </td>
   <td width=208 valign=top style='width:155.9pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Listlevel1 style='margin:0in;text-indent:0in'><img border=0
   width=150 height=100 src="Votubia-II-61%20EN%20PI%20clean_files/image030.jpg"></p>
   <p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:21.25pt'><span lang=EN-GB>&nbsp;</span></p>
   </td>
  </tr>
  <tr>
   <td width=414 valign=top style='width:310.2pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:
   -28.35pt'><b><span lang=EN-GB style='font-size:11.0pt'>Taking the medicine</span></b></p>
   <p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:
   -28.35pt'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
   <p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:
   -28.35pt'><span lang=EN-GB style='font-size:11.0pt'>8.       The patient
   must immediately drink all of the oral suspension from the glass.</span><span
   style='font-size:11.0pt'> If the suspension is not used within
   60&nbsp;minutes, throw it away and prepare a new suspension.</span></p>
   </td>
   <td width=208 valign=top style='width:155.9pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:21.25pt'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
   <p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:21.25pt'><span style='font-size:11.0pt;font-family:"Verdana",sans-serif'><img
   border=0 width=148 height=85 id="Picture 21"
   src="Votubia-II-61%20EN%20PI%20clean_files/image031.jpg"></span></p>
   <p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:21.25pt'><span lang=EN-GB>&nbsp;</span></p>
   </td>
  </tr>
  <tr>
   <td width=414 valign=top style='width:310.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:
   -28.35pt'><b><span lang=EN-GB style='font-size:11.0pt'>Making sure all of
   the medicine has been taken</span></b></p>
   <p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:
   -28.35pt'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
   <p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:
   -28.35pt'><span lang=EN-GB style='font-size:11.0pt'>9.       Refill the
   glass with the same amount of water (about 25&nbsp;ml). Stir the contents
   with the spoon to remove any medicine left on the glass and spoon.</span></p>
   </td>
   <td width=208 valign=top style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:21.25pt'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
   <p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:21.25pt'><img border=0 width=150 height=99 id="Picture 1"
   src="Votubia-II-61%20EN%20PI%20clean_files/image032.jpg"></p>
   <p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:21.25pt'><span lang=EN-GB style='font-family:"Bookman Old Style",serif'>&nbsp;</span></p>
   </td>
  </tr>
  <tr>
   <td width=414 valign=top style='width:310.2pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB
   style='font-size:11.0pt'>10      The patient must drink all of the oral
   suspension from the glass.</span></p>
   <p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left'><b><span
   style='font-size:11.0pt'>If the total prescribed dose is more than 10&nbsp;mg
   </span></b><b><span style='font-size:11.0pt'>or has to be prepared using
   more than 5&nbsp;dispersible tablets</span></b><b><span style='font-size:
   11.0pt'>, repeat steps 2 to 10 to finish taking the dose.</span></b></p>
   </td>
   <td width=208 valign=top style='width:155.9pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:21.25pt'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
   <p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:21.25pt'><span style='font-size:11.0pt;font-family:"Verdana",sans-serif'><img
   border=0 width=149 height=85 id="Picture 23"
   src="Votubia-II-61%20EN%20PI%20clean_files/image033.jpg"></span></p>
   <p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:21.25pt'><b>&nbsp;</b></p>
   </td>
  </tr>
  <tr>
   <td width=414 valign=top style='width:310.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:
   -28.35pt'><b><span lang=EN-GB style='font-size:11.0pt'>Cleaning up</span></b></p>
   <p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:
   -28.35pt'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
   <p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:
   -28.35pt'><span lang=EN-GB style='font-size:11.0pt'>11.     Wash the glass
   and the spoon thoroughly with clean water. Wipe the glass and spoon with a
   clean paper towel. Store them in a dry and clean place until next time</span><span
   lang=EN-GB>.</span></p>
   </td>
   <td width=208 valign=top style='width:155.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:21.25pt'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
   <p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:21.25pt'><span style='font-size:11.0pt;font-family:"Verdana",sans-serif'><img
   border=0 width=149 height=88 id="Picture 24"
   src="Votubia-II-61%20EN%20PI%20clean_files/image034.jpg"></span></p>
   <p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:21.25pt'><span lang=EN-GB>&nbsp;</span></p>
   </td>
  </tr>
  <tr>
   <td width=414 valign=top style='width:310.2pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:
   -28.35pt'><span lang=EN-GB style='font-size:11.0pt'>12.     </span><span
   style='font-size:11.0pt'>Wash and dry your hands.</span></p>
   </td>
   <td width=208 valign=top style='width:155.9pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:21.25pt'>&nbsp;</p>
   </td>
  </tr>
 </thead>
</table>

<p class=NormalAgency style='margin-right:6.0pt;text-autospace:none'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

</div>

</body>

</html>
